 
 
 
 
 
 
 
 
 
 
 
 
 
 
C–Pulse® Implantable 
Counterpulsation Pump (ICP) 
A Heart Assist Device  
 
March 4, 2015  
 
Investigational Plan  
 
 
 
 
 
 
 
Confidential  
© Sunshine Heart  PRO 02291 –I 
This page is intentionally left blank.  
 
 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 3 of 150 
© Sunshine Heart  Confidential   
  
 
TABLE OF CONTENTS  
TRIAL  CONTACT  INFORMATION  ................................ ................................ ................................ ........................  7 
INTRODUCTION  ................................ ................................ ................................ ................................ ........................  8 
Purpose  ................................ ................................ ................................ ................................ ........................  8 
Study Size and Duration ................................ ................................ ................................ .............................  8 
Background  ................................ ................................ ................................ ................................ .................  9 
C-P ULSE  DEVICE  DESCRIPTION  ................................ ................................ ................................ ........................  13 
The Sunshine Heart C –Pulse® ICP System  ................................ ................................ ............................  13 
System  Features  ................................ ................................ ................................ ................................ ........  15 
Indications for Use and  Intended Use  ................................ ................................ ................................ ..... 15 
Summary of  Implant  procedure  ................................ ................................ ................................ ..............  15 
STUDY  DESCRIPTION  ................................ ................................ ................................ ................................ ............  17 
Design  ................................ ................................ ................................ ................................ .........................  17 
Objectives  ................................ ................................ ................................ ................................ ..................  18 
Primary  Objectives  ................................ ................................ ................................ ................................ . 18 
Secondary  Objectives  ................................ ................................ ................................ .............................  18 
Patient Selection  ................................ ................................ ................................ ................................ ........  20 
Inclusion Criteria  ................................ ................................ ................................ ................................ .... 20 
Exclusion Criteria ................................ ................................ ................................ ................................ ... 20 
Investigational  Center Information  ................................ ................................ ................................ .........  22 
Number of  Sites  ................................ ................................ ................................ ................................ ..... 22 
Investigator Agreement/Financial Disclosure  ................................ ................................ ........................  22 
Investigational  Review  Board  ................................ ................................ ................................ ................  22 
Access to Center and  Study  Materials  ................................ ................................ ................................ .... 22 
Confidentiality  ................................ ................................ ................................ ................................ ....... 23 
Attending Investigator Meetings or  Conference  Calls  ................................ ................................ ...........  23 
Required Equipment  ................................ ................................ ................................ ...............................  23 
Supply of Study Materials and  Device  Accountability  ................................ ................................ ..........  23 
Criteria for Early Termination  or Suspension  ................................ ................................ ........................  23 
Laboratory Accreditation and Normal Values  ................................ ................................ .......................  24 
Procedures  ................................ ................................ ................................ ................................ .................  24 
Screening and Patient  Informed  Consent  ................................ ................................ ...............................  24 
Patient Withdrawal or Loss  to Follow –Up ................................ ................................ .............................  25 
Data  Collection  Overview  ................................ ................................ ................................ ......................  25 
Summary of  Required  Testing  ................................ ................................ ................................ ...............  29 
Clinical Procedures – Implant  through  discharge  ................................ ................................ ..................  35 
Readmission  ................................ ................................ ................................ ................................ ...........  40 
Post-Implant Follow –up Testing and Data Collection  ................................ ................................ ...........  41 
Adverse  Event Reporting  ................................ ................................ ................................ .......................  41 
Patient  Deaths ................................ ................................ ................................ ................................ .........  47 
Explant Handling and Final  Device Dis position  ................................ ................................ ....................  48 
Patient Withdrawal and Study  Exit ................................ ................................ ................................ ........  48 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 4 of 150 
© Sunshine Heart  Confidential   
 STATISTICAL METHODS AND DATA ANALYSIS  ................................ ................................ ............................  49 
Justification  of Methodology  ................................ ................................ ................................ .................. 49 
Primary  Safety  Measures  ................................ ................................ ................................ ........................ 49 
Efficacy  measurements  ................................ ................................ ................................ ........................... 50 
Secondary  Objectives  ................................ ................................ ................................ .............................. 51 
RISK ANALYSIS  ................................ ................................ ................................ ................................ ........................  53 
Potential  Risks  ................................ ................................ ................................ ................................ ........ 53 
Risk Minimization  ................................ ................................ ................................ ................................ ..59 
C-Pulse® Potential Benefits  ................................ ................................ ................................ .................... 60 
Justification for  the Investigation  ................................ ................................ ................................ ............ 61 
STUDY OVERSIGHT  AND  INTEGRITY  ................................ ................................ ................................ ...............  65 
Designation of Sponsor, Data Manager,  and Auditor  ................................ ................................ ............ 65 
MONITORING  PROCEDURES  ................................ ................................ ................................ ...............................  66 
Summary of Monitoring Procedures  and Responsibilities  ................................ ................................ ....66 
Interim  Monitoring  Visits  ................................ ................................ ................................ ......................... 66 
Study Closure  ................................ ................................ ................................ ................................ ............. 67 
Name and Address of  Study  Monitors  ................................ ................................ ................................ .....67 
Study Safety  ................................ ................................ ................................ ................................ ............... 67 
TRAINING  PROCEDURES  ................................ ................................ ................................ ................................ ...... 69 
PROTOCOL  DEVIATIONS  ................................ ................................ ................................ ................................ ...... 70 
RECORDS  AND REPORTS  ................................ ................................ ................................ ................................ ...... 72 
Investigational  Records  ................................ ................................ ................................ ............................. 72 
Investigator  Reports  ................................ ................................ ................................ ................................ ..72 
Sponsor  Records  ................................ ................................ ................................ ................................ ........ 74 
Sponsor  Reports ................................ ................................ ................................ ................................ ......... 74 
PUBLICATION STRATEGY  ................................ ................................ ................................ ................................ .... 75 
Publication  Committee  ................................ ................................ ................................ .............................. 75 
Authorship  Selection  ................................ ................................ ................................ ................................ .75 
Review and  Communication Guidelines  ................................ ................................ ................................ ..76 
Ancillary Publications  ................................ ................................ ................................ ............................... 76 
APPENDIX A:  ABBREVIATIONS AND  ACRONYMS  ................................ ................................ ........................  77 
APPENDIX B:  NATIONAL  CO–PRINCIPAL  INVESTIGATORS  ................................ ................................ ..... 78 
APPENDIX C:  PARTICIPATING  INSTITUTIONS  ................................ ................................ .............................  79 
APPENDIX D:  IRB  LIST  ................................ ................................ ................................ ................................ ..........  80 
APPENDIX E:  SUMMARY OF  PREVIOUS STUDIES  ................................ ................................ ........................  81 
Intra –operative clinical  feasibility  study  ................................ ................................ ................................ .81 
Long –term extra –aortic balloon counterpulsation  in sheep  ................................ ................................ ..81 
Prospective  Observational Study  ................................ ................................ ................................ ............. 82 
APPENDIX F:  LA BELING AND OPERATOR MANUAL  ................................ ................................ ...................  84 
APPENDIX G:  SAMPLE HIPAA DISCLOSURE  ................................ ................................ ................................ .. 85 
APPENDIX H:  SAMPLE INFORMED CONSENT  ................................ ................................ ...............................  87 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 5 of 150 
© Sunshine Heart  Confidential   
 APPENDIX I:  REQUIRED  TESTS  ................................ ................................ ................................ .....................  1102 
APPENDIX J:  CORE  LABORATORIES  ................................ ................................ ................................ ...........  4105 
Cardiopulmonary  Exercise Testing  ................................ ................................ ................................ .... 4105 
Echocardiography  ................................ ................................ ................................ ..............................  4105 
CT Scan  ................................ ................................ ................................ ................................ ..............  4105 
APPENDIX K:  SAMPLE CASE  REPORT  FORMS  ................................ ................................ .........................  5106 
APPENDIX L: NEUROLOGICAL  TESTING  ................................ ................................ ................................ .... 6107 
NIH Stroke  Scale  ................................ ................................ ................................ ................................ .. 6107 
Modified  Rankin  ................................ ................................ ................................ ................................ ... 9110 
APPENDIX M:  HOME  DISCHARGE  CHECKLIST  ................................ ................................ .....................  10111 
APPENDIX N:  QUALITY OF  LIFE  QUESTIONNAIRES  ................................ ................................ ............  11112 
Minnesota Living With Heart  Failure  Questionnaire  ................................ ................................ ..... 11112 
Kansas City Cardiac Quality of Life Questionnaire  ................................ ................................ ........  13114 
APPENDIX O: HEART  FAILURE  ASSESSMENTS  ................................ ................................ .......................  17118 
NYHA  Classificati on ................................ ................................ ................................ .......................  17118 
ACC/AHA Stages of  Heart Failure  ................................ ................................ ................................ .. 17118 
APPENDIX P:  SIX MINUTE  HALL  WALK  ................................ ................................ ................................ ... 18119 
APPENDIX Q:  CARDIOPULMONARY EXERCISE  TESTING  OVERVIEW  ................................ ..........  20121 
APPENDIX R:  STUDY SUMMARY  ................................ ................................ ................................ .................  22123 
APPENDIX  S:  BIBLIOGRAPHY  ................................ ................................ ................................ ......................  30131 
APPENDIX T:  CLINICAL STUDY  AGREEMENT  TEMPLATE  ................................ ................................  33134 
APPENDIX U:  INF ECTION  CONTROL  GUIDELINES  ................................ ................................ ...............  34135 
APPENDIX V:  INVESTIGATIONAL  PLAN  REVISIONS  ................................ ................................ ............  41142 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 6 of 150 
© Sunshine Heart  Confidential   
  
LIST OF TABLES  
 
Table 1  C -Pulse® System Components  ................................ ................................ .........................  14 
Table 2.  Follow –up Windows  ................................ ................................ ................................ ....... 26 
Table 3.  Data  Collection  Summary  ................................ ................................ ...............................  27 
Table 4.  Neurological Testing  Collection  Schedule  ................................ ................................ ...... 32 
Table 5.  Unavoidable  Events  ................................ ................................ ................................ ..........  47 
Table 6.  Investigator  Reports  ................................ ................................ ................................ ........  73 
Table 7.  Sponsor  Reports  ................................ ................................ ................................ ..............  74 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 7 of 150 
© Sunshine Heart  Confidential   
  
 
Trial Contact Information  
 
Sponsor & Distributor  Sunshine Heart, Inc. 
12988 Valley View Rd  
Eden Prairie, Minnesota 55344 
Tel: 952 345 4200  
Fax: 952 224 0181  
www.sunshineheart.com  
Primary Contact: Aleela Baune  
Chief Executive Officer  Dave Rosa  
12988 Valley View Rd  
Eden Prairie, Minnesota 55344 
Tel: 952 345  4200  
Fax: 952 224  0181  
Dave.Rosa@sunshineheart.com  
Sponsor’s Medical Director  William Peters, MD 
CTSU  
Auckland City Hospital  
Park Rd, Grafton, New Zealand 
william.peters@sunshineheart.com  
National Co -Principal Investigator 
Cardiothoracic Surgeon  Patrick M. McCarthy, MD  
Chief, Division of Cardiothoracic Surgery 
Northwest ern University Feinberg School of Medicine  
pmccart@nmh.org  
National Co -Principal Investigator 
Heart Failure Cardiologist  William Abraham, MD  
Chief, Division of Cardiovascular Medicine  
Ohio State University 
William.Abraham@osumc.edu  
Manufacturer  Sunshine Heart, Inc. 
12988 Valley View Rd  
Eden Prairie, Minnesota 55344 
Tele: 952 345 4200  
Fax: 952 224 0181  
www.sunshineheart.com  
Clinical/Technical Support Hotline 
1-877-742-7857 (1 -877-SHCPULSE)  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 8 of 150 
© Sunshine Heart  Confidential   
  
 
INTRODUCTION  
 
PURPOSE  
 
 
Sunshine Heart Inc. is sponsoring a prospective, multi –center trial to assess the safety and 
provide indications for performance of the Sunshine Heart C -Pulse® System (“C -Pulse®”). 
The purpose of the study is to determine whether use of C -Pulse® as treatment for patients in 
moderate to severe heart failure (HF) is associated with reasonable assurance of safety and 
performance, such that the C -Pulse® merits Food and Drug Administration (FDA) approval 
for continuation into a pivotal study to examine the safety and efficacy of C -Pulse® for US 
market approval.  
 
STUDY SIZE AND DURATION  
 
 
This clinical study is expected to commence September 2008. The duration of the study  is 
expected to be 120 months. The primary study population will include 20 patients 
enrolled and implanted with C -Pulse® in up to 7 centers in the Uni ted States (US) and 
potentially some Outside the United States (OUS) centers. This expansion protocol will 
allow 40 patients to be enrolled and implanted in up to 9 centers. The first 40 patients that 
meet all eligibility criteria will proceed to implantat ion. Up to approximately 60 patients 
will be enrolled and consented for performing screening and testing required to confirm 
eligibility, such as Computed Tomography (CT) scan. All patients must be consented 
prior to performing any study related procedures . A patient is considered enrolled upon 
signing the informed consent. To minimize the burden to the patient, data collected as 
standard of care  and not for the specific reason for study eligibility may be used for 
baseline data points as outlined in the in formed consent. These tests will suffice for the 
baseline dataset if collected within the screening timeframe of 30 days prior to  implant.  
Only the patients who meet the eligibility criteria will proceed to implantation. All 
patients who do not meet the eligibility requirements will be promptly study exited. Study 
exit of these patients must be documented on the Study Exit form. The period of follow – 
up will be 6 months to assess the safety and performance before initiating the pivotal 
randomized clinical  trial. All patients will continue to be followed annually during long 
term follow –up to a minimum of five  years.  
The study will be conducted in accordance with Code of Federal Regulations (CFR) Parts 
11, 50, 54, 56 and 812. A progress report of the clinic al outcomes will be prepared by the 
Data and Safety Monitoring Board (DSMB) following enrollment of the first five (5) 
patients and at least twice per year thereafter. The recommendation(s) from the DSMB 
may be circulated to each of the Investigation Revie w Boards (IRB) participating in the 
study upon request.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 9 of 150 
© Sunshine Heart  Confidential   
  
 
BACKGROUND  
 
 
Heart Failure (HF) represents a major and growing public health concern in terms of 
incidence, prevalence, morbidity, mortality and economic cost. Chronic HF is 
predomina ntly the result of ischemic heart disease or idiopathic dilated cardiomyopathy.  
Chronic HF is conventionally treated with drugs. However there are many circumstances 
where drug therapy is insufficient or where the heart has become refractory to drug 
therap y. Cardiac Resynchronization Therapy (CRT) is indicated in patients with HF who 
have ventricular dyssynchrony, commonly evidenced by a widened QRS complex.  
Resynchronization therapy is suitable for approximately 30% of moderate HF [(New York 
Heart Associat ion (NYHA) Class III] patients, and has been shown to provide significant 
clinical improvement [as measured by NYHA Class, quality of life (QOL) score, 6 minute 
walk test, freedom from advanced heart failure treatments, etc.]1. However, as many as 
30% of p atients who have CRT implants do not have a satisfactory response (“non – 
responders”). Further, many patients initially have a good response but then develop more 
advanced symptoms.  
Heart transplantation is an effective therapy for end stage NYHA Class IV patients. 
However, the number of donor hearts falls short of meeting the needs of patients and 
many patients are excluded because of age (the upper limit for transplant being 
approximately 65 years)2. 
Left Ventricular Assist Devices (LVADs) have b een shown to offer the potential for the 
treatment of end stage NYHA Class IV HF patients. LVADs have been shown to improve 
survival in patients suffering severe HF and some LVADs have been approved as a bridge 
to transplant (BTT) and for destination thera py (DT). However, because of the blood – 
contacting nature, these devices have high associated risks such as bleeding, stroke, 
infection and device failure. Furthermore, despite prolonging life, patients spent more time 
in hospital due to these associated c omplications3. 
There is growing evidence that the unloading actions of LVADs can facilitate significant 
recovery and reverse remodeling of the heart4. However, there is a need for lower risk, 
lower cost devices that allow for long –term implant in less sick  patients. Such a device 
could provide for partial unloading of the heart such that the patient can be weaned and for 
the device to not necessarily be removed.  
It is well established that a mode of circulatory support, known as counterpulsation, works 
by reducing the load on the heart, augmenting heart pump function, and increasing both 
coronary artery and total body blood flow. Unlike LVADs, counterpulsation devices act to  
 
 
 
 
 
1 [Abraham 2002]  
2 [Demers 2003]  
3 [Rose 2002]  
4 [Reinlib 2003, Birks 2006]  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 10 of 150 
© Sunshine Heart  Confidential   
  
 
augment native heart function rather than to replace it. Whilst LVADs unload the heart, it 
is evident that they do not necessarily increase coronary artery blood flow5. 
Counterpulsation has 2 main benefits to heart function:  
• When the aortic valve is closed and the balloon is inflated, diastolic pressure  is 
increased (“diastolic augmentation”): there is augmentation of flow into the 
peripheral arteries from the aorta, and particularly to the coronary  arteries  
• Following the electrical ex citation of the left ventricle [electrocardiogram (ECG) 
QRS complex], the heart contracts and the balloon is deflated. The reduction in 
impedance reduces aortic pressure and thus the work load of the heart by reducing 
the pressure –head which the heart has to eject against. This is termed  "pre–systolic 
ventricular unloading" and allows the heart to contract more vigorously and with 
greater  efficiency.  
Counterpulsation has been widely used the past 30 years for short term (2 to 7 days) 
cardiac support in pati ents with hemodynamic compromise but in whom recovery can be 
expected, such as after heart surgery or after a major heart attack. These intra –aortic 
balloons (IABs) are widely used in hospitals. The IAB is inserted via a femoral artery and 
positioned in th e descending aorta. The IAB is attached to a bedside module that inflates 
and deflates the device based on the R wave of the ECG signal. When the condition of the 
heart has improved the IAB is removed. IAB counterpulsation a) increases coronary  blood 
flow,  b) reduces ventricular afterload to reduce the workload of the left ventricle, and c) 
increases cardiac output. 6 The level of counterpulsation may affect cardiac performance 
in the short –term: Cohen et al showed in a limited study of 20 patients a signif icantly 
higher velocity time integral across the Left Ventricle (LV) outflow tract resulted when 
counterpulsated at 1:1 versus 1:8. They did not show any difference with varying the 
balloon volume from 40 to 32 cubic centimeters  (cc)7. 
The beneficial effec t of counterpulsation in short term situations has stimulated interest in 
its potential effects when used in longer term situations. Long term counterpulsation may 
chronically reduce the load on the heart and augment the native heart blood pumping 
capacity . The devices can be turned on and off as required, particularly if the heart 
recovers its strength following months of support. Specific examples of investigational 
long term counterpulsation therapies include the CardioVAD device and a technique 
known as  Aortomyoplasty. Ambulatory IAB (positioned via a graft in the axillary artery) 
has also been used to support patients as a bridge to transplant8. 
The CardioVAD (LVAD Technology, Inc., Detroit, MI) comprises a pump sewn into the 
wall of the descending aort a, an access device to allow a gas tube to pass through the skin, 
and a driver unit worn by the patient to move air into and out of the pump. The 
CardioVAD has been implanted in a limited number of patients in Class IV heart failure in  
 
 
 
5 [Ootaki 2005]  
6 [Cochran 2002, Cheung 1996, Reichart 1993]  
7 [Cohen 1995]  
8 [Cochran 2002]  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 11 of 150 
© Sunshine Heart  Confidential   
  
 
an Investigational Device Exemption (IDE) Feasibility trial in the USA. Results of the 
trial to date have shown that the CardioVAD can significantly improve blood flow  through 
the body and reduce HF symptoms9, though there is a significant surgical risk due to the 
invasive nature o f the surgery.  
Aortomyoplasty involves surgically wrapping a muscle from a patient’s back around the 
outside of the aorta and electrically stimulating that muscle to contract in counterpulsation 
with the patient’s heart rhythm using a pacemaker –like device . The results of a series of 
15 patients have shown substantial benefits in heart pumping capacity compared to pre – 
operative measurements, improvement in patient well -being, and an excellent long –term 
(up to 8 years follow up) safety profile10. However, t his procedure is associated with a 
significant surgical risk and lengthy rehabilitation period since the back muscle must be 
trained over a period of at least 6 weeks before there is effective counterpulsation.  
The current need is for a counterpulsation de vice or method that is effective enough to 
make its application appealing as a long –term implant to a large number of patients and 
physicians. It must be simple and safe, with a straight –forward implant procedure, and 
with long –term measurable patient bene fits. Further, it would be advantageous for the 
counterpulsation device to be smaller, easier to insert, ambulatory, disconnectable, and not 
in the bloodstream. Such a device may be more readily adopted by a wider group of 
cardiologists and surgeons, and b e suitable for a wider group of people in NYHA Class III 
or IV heart failure. It is important to point out that a counterpulsation device is aimed to 
augment native heart function and is fundamentally different from total artificial hearts, 
left ventricula r assist devices and heart transplants which are meant to be a total 
replacement or an alternative to the native heart. Thus, the counterpulsation device is 
considered non –obligatory and not life –supporting.  
Sunshine Heart, Inc. has proposed C -Pulse®, a novel ambulatory, non –obligatory, non – 
blood contacting extra –ascending aortic counterpulsation system. The C -Pulse® System is 
designed to be implanted without the need for cardiopulmonary bypass or extensive 
dissection, to be able to be activated immediat ely, to augment heart function in a safe 
manner and to provide sustained relief from heart failure symptoms. It can be turned off 
safely, and similarly, in failure modes, is considered to have an associated low risk of 
death or disability, other than the r ecurrence of heart failure symptoms. C -Pulse® is not an 
alternative to the heart, it is an augmentation device, and it does not preclude the use of 
therapies that provide full circulatory support such as heart transplantation or LVADs.  
The C -Pulse® System consists of a counterpulsation Cuff secured around the outside of the 
ascending aorta, the main blood vessel out of the heart. The Cuff and a heart signal 
sensing wire are attached to an external driver. The external Driver inflates and deflates 
the Cuff i n sequence with the ECG signal to assist heart function and improve the 
pumping capacity of the heart. The Cuff deflects the aorta in a “thumb –printing” manner 
which has been optimized to minimize aortic wall strain and maximize blood volume 
displacement p er beat. The C –Pulse® System is non –blood contacting, simple to insert, 
and can be turned on and off as required; all natural blood pathways are maintained – there  
 
 
9 [Jeevananddam 2001]  
10 [Tranini 2002]  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 12 of 150 
© Sunshine Heart  Confidential   
  
 
is no exposure of foreign material to the bloodstream. See Appendix E for a summary of 
experience to date with C –Pulse®. 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 13 of 150 
© Sunshine Heart  Confidential   
  
 
C-P ULSE DEVICE  DESCRIPTION  
 
THE SUNSHINE HEART C–PULSE® ICP S YSTEM  
 
 
The C -Pulse® ICP utilizes an “extra –aortic” inflatable Cuff which is surgically implanted 
around the ascending aorta, thus a) avoiding blood contact, and b) allowing the device to 
be both ambulatory and non –obligatory, for long –term cardiac assistance. Furthermore, 
counterpulsation on the ascending aorta is more efficient t han the descending aorta 
position because 1) the blood displacement is “unidirectional,” and 2) diastolic and pre- 
systolic pulse wave propagations versus cardiac systole are better matched11 12. In 
addition, the ascending aorta is of a predictable helical  shape13 14, has a large capacitance, 
no branches and presents a minimal risk of disease15. The implanted Cuff is inflated by  the 
external battery powered pneumatic Driver and timing is coordinated to the R wave of the 
ECG. A standard implantable cardiac pacemaker lead is used with the system. A separate, 
exchangeable, wire –wound percutaneous interface lead (PIL) is implanted to connect the 
gas line of the Cuff and the ECG Sense Lead to the  Driver.  
The C -Pulse® ICP has been designed to have a simple, highly reliable implantable 
component (the Cuff) and external wearable components (the Drive Unit and Battery 
Carrier) which are connected by means of a Percutaneous Interface Lead (PIL). A standard 
epicardial pacemaker lead serves as the EC G Sense Lead. The Driver is programmable by 
a physician using a Programmer via infra –red (IR) connectivity.  
The modular design of the C -Pulse® is shown in Figure 1. For the IDE study, the patient 
will be provided with two (2) each of the Drive Unit and Ba ttery Carrier. The 
Percutaneous Lead is designed to facilitate simple surgical replacement of this  component, 
in the case of untreatable skin infections at the exit site or damage to the patient  connector.  
Figure 1 IDE C -Pulse System  
 
 
 
11 [Furman 1971]  
12 [Davies 2005]  
13 [Misfeld 2004]  
14 [Peters 2006]  
15 [Takasu 1992]  

PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 14 of 150 
© Sunshine Heart  Confidential   
  
 
Key components of the C -Pulse system are outlined in Table 1 Table 1 . 
Table 1 C -Pulse® System Components  
SHC implantable Cuff:  
• Simple, less invasive  surgery  
• No cardiopulmonary  bypass  
• 3 sizes to fit ascending aorta outside diameter 29 –40 millimeter  (mm)  
• Non–blood  contacting  
SHC Percutaneous Interface Lead:  
• 5 mm outside  diameter  
• Silicone with ECG wire  re-enforcements  
• Transmits air/ECG/heart  sounds  
• Patient connecto r (with water –tight cap) 
• Lead is  exchangeable  
• Home care package including supplies for dressing  changes  
SHC wearable/portable Drive Unit and Battery Carrier:  
• Detachable, approx. 2.5 kilogram (kg) (total weight, split between Driver  and 
Battery  Carrier)  
• Ergonomic  design  
□ wear in a vest or carry in a  bag 
□ simple patient interface – on/off button and battery  indicator  
□ visual and audible  alarms  
• 4 hour battery life; single battery – recharge separately or in Battery  Carrier  
• 1.4 meter (m) Driver cable with Isolation  Module  
• Physician  programmer  
□ Infra –red functionality  
□ Intuitive interface for setting counterpulsation  functions  
□ Discrete “verification” button on Driver to accept Programmer  changes  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 15 of 150 
© Sunshine Heart  Confidential   
  
 
SYSTEM FEATURES  
 
 
C–Pulse® Allows Ambulation  
It is vital for a device intended to restore a heart failure patient quality of life that the 
device can allow the patient to ambulate and to be discharged home. The C -Pulse® Driver 
and Battery Carrier can be worn on a belt as a harness – the Battery Carrier and Driver are 
of approximately equal weights which allows even and ergonomic distribution of weight. 
A single long -life battery is used and is easily exchanged and re –charged. The Driver and 
Battery Carrier can be alternatively placed  into one small carry –bag, for carrying over the 
shoulder. The Driver has a 1.4m cable that allows the Driver to be comfortably used in 
bed or when the patient is showering, and which can be coiled up and stored on the  Driver. 
To avoid twisting in the line , the cable can be disconnected to coil it  appropriately.  
Non–blood contacting  
The non –blood contacting feature of the C -Pulse® is unique for mechanical circulatory 
support devices.  No foreign body material is in the blood stream and thus the risk of 
blood clotting within the device mechanism is eliminated. There is no requirement for  use 
of anti –coagulants for C -Pulse® use. 
Non–obligatory  
The non –blood contacting feature of C -Pulse® also allows the device to be intermittently 
turned off as tolerated. This  allows the patient freedom for personal hygiene and 
convenience. The non -obligatory feature of C -Pulse® is essential in improving the 
patient’s quality of life and safety, however, the Device is expected to be used greater  than 
80% of the time during the trial period. During the trial period, patient must not 
disconnect for longer than 15 minute intervals for a maximum of 4 hours daily (80% 
usage). The Driver records  usage.  
 
INDICATIONS FOR USE AND INTENDED USE 
 
 
The C -Pulse® System is indicated for use in patients with moderate to severe heart failure 
[American College of Cardiology/American Heart Association (ACC/AHA) Stage C; 
NYHA Class III/IV], who are refractory to optimal medical therapy. The C -Pulse® 
System is intended to relieve the symptoms o f heart failure, improve quality of life and 
cardiac function. The C -Pulse® System is also indicated for use in patients who are non 
responders to CRT pacemaker therapy. It is intended for use in hospital and at home. It is 
not intended as a replacement fo r heart function; it is not life sustaining or  life–supporting 
therapy. It does not preclude the use of other heart failure therapies, such as valve 
surgery, heart transplantation or  LVAD.  
 
SUMMARY OF IMPLANT PROCEDURE  
 
 
The C -Pulse® Cuff and Sense Lead are implanted through a chest incision and without the 
use of cardiopulmonary bypass. Only a small pericardiotomy is required, limiting the  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 16 of 150 
© Sunshine Heart  Confidential   
  
 
potential for bleeding and for post –operative adhesions. The ascending aorta is isolated 
and it s circumference measured. The circumferential length is marked on the Cuff and the 
Cuff is wrapped around the aorta such that the inflating aspect of the Cuff is positioned on 
the outside curvature. The Cuff is then checked to fit the aorta conformably and  that the 
circumferential marks are appropriate prior to securing of the wrap with sutures.  
Interrupted ‘mattress’ sutures are recommended, placed with the Cuff ‘open’ and using  the 
circumferential marks as guidance, and such that the inflation chamber of the Cuff is 
always visualized. A bipolar ECG Sense Lead is placed on the heart and the gas line of 
the Cuff and ECG Sense Lead are attached to the intra –corporeal “Y – connector” end of 
the Percutaneous Lead.  The Percutaneous Lead is then tunneled out over  the abdomen, 
the extra –corporeal end of the Lead having a Patient Connector permanently  attached.  
Alternatively, the Percutaneous Lead may be tunneled retrograde and secondarily  attached 
to the gas line and sense lead. The Percutaneous Lead is designed to  be exchanged or 
removed if required, the latter eliminating the exit site. If removal occurs, the Cuff and 
Sense Lead will remain within the thorax with the gas line of the Cuff and the connector 
of the Sense Lead capped off and accessible with minimal su rgery in the subcutaneous 
tissue of the abdominal  area.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 17 of 150 
© Sunshine Heart  Confidential   
 
 
 
STUDY DESCRIPTION  
 
DESIGN  
 
 
The study is designed to assess the safety and potential benefit of the C -Pulse® System 
before initiating a wider randomized clinical trial to demonstrate safety and effectiveness. 
The effect of the C -Pulse® system in relieving heart failure symptoms in patients with 
ACC/AHA Stage C, NYHA Class III -ambulatory Class IV heart failure will be 
documented with this study.  
This Feasibility Study is mul ti-center study which is being expanded to include up to 9 
centers in the US and potentially some OUS centers. The study population will be 
expanded to include 40 patients enrolled and implanted with the C -Pulse® System. The 
period of follow -up for the ini tial 20 patients will be 6 months to assess the safety and 
performance before initiating the pivotal clinical trial. It is desired that the system be used 
all the time.  However, the System should not be “Off” for greater than one hour at any 
one time for a maximum of four hours total per day during the study period.  For the 
extent of the trial period (6 months), C -Pulse ®should be used at least 20 hours per day 
(i.e. device must be used greater than 80% of the time).  The patient must limit the 
duration o f disconnection to 15 minute intervals for a maximum of 4 hours total during  the 
trial period to ensure the device is used for 80% of the time. The Driver logs patient  usage 
automatically and stores into the system  files.  
Patients will be followed for up to 10 years or until the study is closed.  
If a patient undergoes anesthesia for the purpose of C -Pulse implantation but does not 
receive a C -Pulse System, the patient will be followed until 30 days or discharge 
whichever occurs first.  
 
 
Basel ine 
Inclusion/Exclusion  
≤ 30 Days   
Implant  1, 3, and 6 
month  
Follow -up Long term Follow -up 
12 and 18 month  – 
annually  thereafter  
 
 
Figure 1A. Study Design  
Patients will be enrolled into the trial upon providing informed consent. Procedures 
related directly to the study must not be performed prior to informed consent. Data 
collection will be noted prior to implantation of the device and at one, three, and six 
months following implant and then long term at 12 and 1 8 months followed by annually 
post–implant for five years. Adverse events will be collected throughout the study until 
study closure and will be adjudicated by the Clinical Event Committee (CEC).  
Progress reports of the clinical outcomes will be reviewed b y the DSMB after enrollment 
of five (5) patients and twice per year thereafter, unless slow enrollment does not  warrant 
this meeting  frequency.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 18 of 150 
© Sunshine Heart  Confidential   
  
 
Progression to the Pivotal study will be based on the assessment for safety of the device 
and indi cators of performance. Baseline and follow –up data will be used to assess any 
significant difference in quality of life and functional variables pre and post implant and to 
assess the effect of counterpulsation.  
Following successful completion of this Feas ibility Study, a pivotal study will be 
conducted to examine the safety and efficacy of the C -Pulse® system in patients in 
moderate to severe heart failure. The pivotal trial is expected to measure the same 
variables as the Feasibility Study.  
The total dura tion of the Feasibility Study is expected to be approximately 120 months or 
until the study is closed.  
 
OBJECTIVES  
 
 
Primary Objectives  
Following are the primary objectives for this study. The primary objective of the C -Pulse 
feasibility study is to asses s safety, while at the same time obtain performance data for 
evidence of efficacy to assist planning for a pivotal study. Refer to the section on 
Statistical Methods and Data Analysis for a detailed discussion of the definitions and 
methodology.  
The Clinic al Investigation shall:  
1. Assess the risks with regard to the performance of the device as defined by  the 
serious adverse event rates, under normal conditions of  use. 
2. Assess the potential benefits of C -Pulse as defined by improvements in Peak VO 2, 
hemodynamic measures, quality of life and HF  symptoms.  
Secondary Objectives  
Secondary objectives are intended to provide additional information on patient response 
and device performance and to allow planning for the pivotal study. The secondary 
objective s are as follows:  
1. Further assess the potential risks with regard to the performance of the device as 
defined by the device failure rate, adverse event rates, adverse event attribution,  re- 
hospitalization rates, duration of support, and length of time to h ospital  discharge.  
2. Further assess the potential benefits of C -Pulse as defined by improvements in 
quality of life, fatigue impact scales, hemodynamics, average distance walked  in 
the 6 minute hall walk test, and blood  tests.  
3. Assess the device  usage.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 19 of 150 
© Sunshine Heart  Confidential   
  
 
Together the primary and secondary objectives will:  
1. Allow refinement of clinical and physiological criteria for patient selection and 
refinement of protocols for the operative procedure and concomitant medical 
therapy and rehabilitation po st-operatively – the results of the Feasibility  Study 
will allow effective planning of a larger study to examine device  efficacy  
2. Develop predictors for adverse events and measures for minimizing the  frequency 
and/or severity of such  events  
3. Determine the parameters of implantation, patient recovery,  hospitalization, 
rehabilitation and home  discharge  
4. Determine the means to design a successful pivotal trial in regards to the 
anticipated randomization, feasibility of blinding, core lab procedures and  data 
collection  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 20 of 150 
© Sunshine Heart  Confidential   
  
 
PATIENT SELECTION  
 
 
Inclusion Criteria  
Patients of both genders who satisfy all inclusion and exclusion criteria are eligible for this 
clinical study. Patients must meet the following criteria:  
1. Patient has AC C/AHA Stage C heart failure and remains in NYHA Class III - 
ambulatory Class IV despite optimal medical therapy. Patients must have stable, 
evidence –based optimal medical therapy for heart failure as defined  below:  
• ACE inhibitor or ARB (Angiotensin Recepto r Blocks) at least 30  days 
preceding implant or nitrate/hydralazine at the investigators  discretion  
• Beta–blocker for at least 90 days and stable for 30 days preceding  implant  
Note: Stable is defined as no more than a 50% reduction or 100% increase in 
the m edications listed above. Transition within a therapeutic class is allowed if 
the dose is equivalent.  
2. Patient has left ventricular ejection fraction (LVEF) ≤ 35%  
3. Patient has had Cardiac Resynchronization Therapy (CRT) for at least 90  days 
prior to enrollment or is not indicated for a CRT  device  
4. Patient has had an implanted cardio –defibrillator (ICD) at least 30 days prior to 
enrollment or is not indicated for ICD  implantation.  
5. Patient is at least 18 years of age and not older than 75  years  
6. Patient s ix minute hall walk assessment between 100 –350 meters  
7. Patient understands the nature of the procedure, is willing to comply with 
associated follow –up evaluations, and provide written informed consent prior  to 
the procedure  
Exclusion Criteria  
Candidates mus t be excluded from the study if any of the following are met:  
1. Patient has any evidence  of: 
o Ascending aortic calcification on posterior –anterior or lateral chest x –ray at 
initial  screening  
OR 
o Atherosclerotic ascending aortic disease, specifically intimal  thickening 
greater than 3mm or mobile atheroma (moderate) or mural calcification 
(severe) as detected by CT scan or echocardiography (Echo)  16 
 
 
 
 
16 [Davila –Roman 1999]  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 21 of 150 
© Sunshine Heart  Confidential   
  
 
2. Patient has ascending aorto -coronary artery bypass grafts, history of aortic dissection, 
Marfans disease or other connective tissue disorder or has had an aortic root 
replacement  
3. Patient aorta not conforming to specified dimensional constraints defined by CT  scan, 
most specifically mid ascending aortic outside dia meter less than 29mm or greater 
than 40mm  
4. Patient has severe mitral valve incompetence, grade  4+ 
5. Patient has moderate to severe aortic valve incompetence, grade  2–4+ 
6. Patient has systolic blood pressure less than 90 or greater than 140  mmHg  
7. Patient has a Se rum Sodium less than 130 mEq/L  
8. Patient has an Estimated Glomerular Filtration Rate (GFR) less than 40  ml/min/1.73m2 
9. Patient has any two of three of Bilirubin, Aspartate Aminotransferase (AST),  Alanine 
Aminotransferase (ALT) greater than three times upper l imit of normal for each 
institution  
10. Patient has a serum Albumin less than 3.0 g/dL  
11. Patient has Body Mass Index (BMI) less than 18 or greater than 40  kg/m2 
12. Men with Peak Oxygen Uptake (VO 2) of greater than 18 ml/kg/min or less than  10 
ml/kg/min  
OR 
Women with Peak VO 2 of greater than 16 ml/kg/min or less than 9 ml/kg/min  
13. Patient has any active  infection  
14. Patient has had a myocardial infarction (MI), stroke, transient ischemic attack (TIA), 
cardiac or other major surgery, in the 90 days prior to study  enrollment  
15. Patient has severe Chronic Obstructive Pulmonary Disease (COPD) as evidenced  by 
Forces Expiratory Volume (FEV1) less than or equal to 0.9  L/min  
16. Patient requires a concomitant surgical procedure [i.e. coronary artery bypass  graft 
(CABG), Valve  repair]  
17. Patient is supported with a left ventricular assist device or intra –aortic balloon  pump  
18. Severe Right Heart Dysfunction with systemic venous congestion evidenced by 
clinical signs/symptoms such as Central Venous Pressure (CVP) ≥ 20 mmHg,  Cardiac 
Index  (CI) < 2.0 l/min./m2, elevated liver function tests beyond three time the upper 
limit of normal and presence of  ascites  
19. Patient has reversible causes of heart failure that may be remedied by  conventional 
surgery or other  intervention  
20. Patient is pregnant; Note: Negative pregnancy test required in all women of  child 
bearing  potential  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 22 of 150 
© Sunshine Heart  Confidential   
  
 
21. Patient has any other condition that, in the opinion of the investigators, would 
disqualify the patient for inclusion in the study, limits survival to less than one year,  or 
not permit valid  consideration  
22. Patient is currently enrolled or has participated in the last 30 days in another 
therapeutic or interventional clinical study that is likely to confound study results  or 
affect study  outcome  
23. Patient has symptomatic Carotid artery disease or asymptomatic disease with  a 
stenosis greater than 70% as determined by Carotid Doppler  Ultrasound  
 
INVESTIGATIONAL CENTER INFORMATION  
 
 
Number of Sites  
It is intended that up to 9 centers in the US and po tentially some OUS centers will 
participate in this clinical evaluation.  
Investigator Agreement/Financial Disclosure  
An Investigator Agreement along with a Financial Disclosure Form must be signed by the 
investigator and returned to Sunshine Heart, Inc. and/or designee before commencement 
of the study at a clinical site.  
Curriculum vitae including the investigator’s current position and title will also be 
required from each investigator and co –investigator(s) participating in this study.  
Investigatio nal Review Board  
Investigational Review Board approval of the clinical study must be received and the 
contents of the approval letter approved by Sunshine Heart before commencement of the 
study at a clinical site. Required contents are as follows:  
• Name of study  
• Name/address of IRB  
• Date of  approval  
• Sufficient identification of version/date of the Protocol, amendments and  Informed 
Consent  
• An IRB member list or ID number must be provided to Sunshine  Heart  
Access to Center and Study Materials  
The investigato r(s) or his/her delegate(s) and the study coordinator(s) must be accessible 
to the Sunshine Heart monitoring staff or designee and Clinical Team. This accessibility 
is of particular importance for completing and/or correcting the data provided. For the 
study monitors, access to the patient records for source data verification will need to be 
granted and prepared prior to the monitoring visit.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 23 of 150 
© Sunshine Heart  Confidential   
  
 
Confidentiality  
All information generated during the trial is considered highly confidential and must not 
be disclosed by any method to persons not directly involved in the trial without prior 
consent from the sponsor or sponsor designee.  
Attending Investigator Meetings or Conference Calls  
Investigator and/or study coordinator meeting s or conference calls may be held to discuss 
the study protocol, device training, study data or other aspects of trial progress and 
management. Interim meetings or teleconference calls will be organized as needed to 
discuss relevant study issues. The inves tigator must agree to attend these meetings and/or 
conference calls or send a co –investigator if they are unable to attend.  
Required Equipment  
The following study equipment will need to be available at each center to support the 
implant and follow –up of th e C-Pulse® System:  
• The C -Pulse® ICP System  
• Standard cardiac surgery required equipment and  facility  
• Echocardiography  equipment  
• CT Scanning  equipment  
• Cardiopulmonary Exercise  equipment  
Supply of Study Materials and Device Accountability  
All investigators will receive the investigation plan, case report forms, and study 
agreement documents.  
Sunshine Heart’s clinical affairs department will control the supply of investigation 
devices, software, and administrative forms necessary to conduct and administer the study. 
A limited amount of investigational product will be distributed to designated Sunshine 
Heart field personnel and to approved investigators. A site must be approved to store 
equipment at their center. Approval will require the center to have made provisions for 
strict control of the investigational devices.  
A Device & Equipment Disposition Log shall be maintained at each center to track 
investigation product information including, but not limited to, the model, serial number  
of each investigational product and the date used. Completed System Implant and  Implant 
Equipment Case Report Forms and Device & Equipment Disposition Logs will be 
reviewed as part of the device tracking and ongoing site monitoring. Based upon return 
and review of these forms, additional clinical product will be supplied to the respective 
investigators within prescribed study limits. Labeling is packaged with each  device.  
Criteria for Early Termination or Suspension  
Reasons for possible suspension of a cli nical investigator or a clinical center from 
enrollment of further patients may at the sponsor’s discretion include but are not limited to 
the following:  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 24 of 150 
© Sunshine Heart  Confidential   
  
 
• Failure to obtain informed  consent  
• Non–compliance to the inclusion/exclusion  criteria  
• Failure to follow through with Investigational Review Board (IRB) for approval  or 
continuation of the clinical  study  
• Inadequate device tracking or off –label investigator device  use 
• Failure to follow –up patients per scheduled  follow –ups 
• Failure to submit da ta in a timely  manner  
• Failure to follow –up with findings on a monitoring  report  
Note that any patients previously enrolled will continue to be to be followed at this 
institution by the investigator or a named co -investigator.  
 
Laboratory Accreditation and Normal Values  
Before initiation of the study, appropriate accreditation for all laboratories to be used in 
the study must be provided to the sponsor. Throughout the study, the Investigator must 
provide documentation of all renewals of acc reditation. The ranges of values considered 
normal for the laboratory tests being performed for the study must be provided to Sponsor 
in order to facilitate pooling of the data.  
 
PROCEDURES  
 
 
Screening and Patient Informed Consent  
Prior to enrolling patients, each investigational center IRB will be required to approve the 
study Investigation Plan, and the Patient Informed Consent. In addition, patients will be 
required to provide written informed consent for enrollment. A Screening Log is lo cated 
within the site Regulatory Binder and should be completed for all patients screened but 
not enrolled for the study.  
Patients will undergo a pre –implant baseline assessment to ensure they meet the inclusion 
and exclusion criteria no more than 30 Days prior to the implant date. Patient informed 
consent must be signed prior to conducting any screening or baseline testing procedure 
performed for study purposes. When a patient signs an informed consent for the  
study, he/she is considered enrolled in the s tudy and will be assigned a study 
identification number by the center. To minimize the burden to the patient, data 
collected as standard of care  and not for the specific reason for assessing study eligibility 
may be used for baseline data points as outline d in the informed consent. These tests will 
suffice for the respective portion of the baseline dataset if collected within the pre -implant 
evaluation timeframe of 30 days prior to implant. Upon completion of screening, all 
patients that do not satisfy the eligibility criteria will be promptly study exited without 
proceeding to implantation. Study Exit of these patients must be documented on the Study 
Exit Form. Any patient whom undergoes anesthesia for the purpose of C -Pulse 
implantation but does not receiv e the device will be monitored for adverse events  as 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 25 of 150 
© Sunshine Heart  Confidential   
  
 
defined by the protocol for 30 days or discharge whichever occurs first. Any Sunshine 
Heart field personnel or designee present for the implant procedure should review the 
informed consen t prior to the procedure to ensure compliance.  
In accordance with the ethical principles that have their origin in the Declaration of 
Helsinki, each patient must be informed about the study and the patient or legal 
representative must sign and date an agreement acknowledging that participation in the 
study is voluntary. The Patient Informed Consent Form will be provided to the patient in 
the language he/she is able to read and understand. (Refer to Appendix H for the sample 
Consent Form). The original s igned Informed Consent will be retained in the individual 
Participant Study folders, and copies of the signed Informed Consent Form will be 
provided to the patient and to the hospital medical records of the patient.  
Patients shall be consented for follow –up to 10 years.  
Patient Withdrawal or Loss to Follow –Up 
In the event a patient chooses to withdraw from the clinical study, the investigational site 
should attempt to ensure that any adverse events are resolved and documented as such. A 
Study Exit/Death For m must be completed and the patient will no longer be followed in 
the clinical study.  
In the event the patient becomes lost to follow -up, the investigational site should make 
two documented attempts to contact the patient. A Study Exit/Death Form must be 
completed and the patient will no longer be followed in the clinical study.  
Data Collection Overview  
A review of patient files is required to determine preliminary eligibility according to 
patient inclusion and exclusion criteria. Baseline data including al l imaging and 
functional test must be collected no more than 30 days prior to the implant date.  
Follow –up data will be collected at the time of implant, hospital discharge, at planned 
follow –ups (1 -month, 3 -month, 6 -month, 12 -month, 18 -month and annually f rom the 
implant date thereafter), and “unscheduled” follow –ups (device testing, patient symptoms 
requiring re -hospitalization, etc.). All adverse events will be collected throughout the 
study until closure.  
Data will be collected via electronic data captur e (EDC) screens referred to as e -case 
report forms (eCRFs). Echocardiogram tapes, and digital storage media must be 
documented in the patient medical record for source documentation.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 26 of 150 
© Sunshine Heart  Confidential   
  
 
The table below outlines the data collection with the app ropriate time windows.  
 
Table 2.  Follow –up Windows  
Evaluation  Time  Window  
 
Pre–Implant  Evaluation  No more than 30 days prior to  implant 
Implant  Day 0 – Implant  
Pre-Discharge  Within 36 hours prior to  discharge  
1–month  follow –up Days 30 ± 7 Post–Implant 
3–month  follow –up Days 90 + 14 Post –Implant 
6–month  follow –up Days 180 ± 30  Post–Implant 
12-month  follow -up Day 365 ± 60 Post -Implant 
18-month  follow -up Day 540 ± 60  Post-Implant  
Annually  Post-Implant  Years 2, 3, 4, 5, 6, 7, 8, 9 and 10 Pos t Implant  
(± 60 days of anniversary)  
 
Testing should be conducted at the investigational site. The data collection criteria are 
summarized in Table 3.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 27 of 150 
© Sunshine Heart  Confidential   
  
 
 
Table 3.  Data Collection Summary  
 
Follow -up Requirements Baseline to 6 months Post Implant  
 Pre- 
Implant  Implant  Pre- 
Discharge7 1 mo  3 mo  6 mo  
A. PATIENT ELIGIBILITY  X      
B. GENERAL        
Demographic Data  X      
Medical History  X      
General Physical Examination  X X X X X X 
Concurrent Medications  X X X X X X 
Pregnancy test (if applicable)  X      
C. VITAL PARAMETERS        
Weight  X  X X X X 
Heart rate  
(ECG pre -implant)  X  X X X X 
Blood pressure  X  X X X X 
Respiratory rate  X  X X X X 
D. CARDIOPULMONARY        
CT aorta  X     X 
CXR  X    X X 
ECHO  X X2  X X X 
Right heart catheterization  
(CVP, PAP, CI, PCWP,SVR, PVR)  X     X 
Peak O2 uptake  X     X 
E. QUALITY OF LIFE        
NYHA Classification  X   X X X 
MLHF Score/ KCCQ  X   X X X 
Fatigue Impact Scales  X  X X X X 
Six Minute Walk  X   X X X 
F. HEMATOLOGY        
Hemoglobin  X  X X X X 
Hematocrit  X  X X X X 
Plasma free hemoglobin  X  X X X X 
Platelet count  X  X X X X 
White cell count  X  X X X X 
APTT  X  X X X X 
INR X  X X X X 
Fibrinogen  X  X X X X 
G. BIOCHEMISTRY        
Serum sodium  X  X X X X 
Serum potassium  X  X X X X 
Serum creatinine/ GFR3 X  X X X X 
BUN  X  X X X X 
Serum albumin  X  X X X X 
Serum bilirubin  X  X X X X 
Serum ALT  X  X X X X 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 28 of 150 
© Sunshine Heart  Confidential   
  
 
Follow -up Requirements Baseline to 6 months Post Implant  
 Pre- 
Implant  Implant  Pre- 
Discharge7 1 mo  3 mo  6 mo  
Serum AST  X  X X X X 
Serum BNP  X     X 
H. NEUROLOGICAL 
ASSESSMENT        
Neurological testing (NIHSS)4 X  X X X X 
Modified Rankin 4 X  X X X X 
Head CT 5 X      
Neurological Consultation  X  X6    
I. IMPLANT DETAILS   X     
J. DEVICE LOG   X  X X X 
K. DISCHARGE 
CHECKLIST    X    
1 Annually  post-implant  
2 Epi-aortic Echo at  implant  
3 Estimated GFR at Baseline and within one week post CT to evaluate contrast induced  nephropathy.  
4 Post Neurological Dysfunction AE – 30, 60 and 90 days post  event  
5 At Baseline only or as clinically indicated with any Neurological Dysfunction AE – Head CT should be completed only after clearance 
for implantation  
6 Required at 5 -7 days post ICU discharge or at hospital disch arge whichever occurs first and at the time of any suspected Neuro 
Dysfunction  AE 
7 At Discharge - within 36 hours prior and as close to discharge as possible (see Appendix  M) 
 
 
Long -term Post Implant Follow -Up Requirements  
 12 month  18 month  Annually  
Year  2-10 
A. PATIENT ELIGIBILITY     
B. GENERAL     
General Physical Examination  X X X 
Concurrent Medications  X X X 
Pregnancy test (if applicable)     
C. VITAL PARAMETERS     
Weight  X X X 
Heart rate  
(ECG pre -implant)  X X X 
Blood pressure  X X X 
Respiratory rate  X X X 
D. CARDIOPULMONARY     
ECHO  X X X 
E. QUALITY OF LIFE     
NYHA Classification  X X X 
MLHF Score/ KCCQ  X X X 
Fatigue Impact Scales  X X X 
Six Minute Walk  X X X 
F. HEMATOLOGY     
Hemoglobin  X X X 
Hematocrit  X X X 
Plasma free hemoglobin  X X X 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 29 of 150 
© Sunshine Heart  Confidential   
  
 
Long -term Post Implant Follow -Up Requirements  
 12 month  18 month  Annually  
Year  2-10 
Platelet count  X X X 
White cell count  X X X 
APTT  X X X 
INR X X X 
Fibrinogen  X X X 
G. BIOCHEMISTRY     
Serum sodium  X X X 
Serum potassium  X X X 
Serum creatinine/ GFR3 X X X 
BUN  X X X 
Serum albumin  X X X 
Serum bilirubin  X X X 
Serum ALT  X X X 
Serum AST  X X X 
J. DEVICE LOG  X X X 
K. DISCHARGE CHECKLIST7    
 
Summary of Required Testing  
Testing information will be recorded on the appropriate eCRF (Appendix K). Required testing 
includes:  
Device Performance Parameters – (at all follow –up visits)  
Device performance parameters shall be retrieved after optimization following 
implantati on on Day 0, at all follow –up periods and whenever there is an unscheduled 
visit accompanied by a change to any device parameters. Parameters to be recorded 
include:  
• Counterpulsation  mode  
• Counterpulsation  volume  
• Inflation slew  rate 
• Deflation slew  rate 
• Inflation hold  pressure  
• Device usage log (patient should use device for a minimum of approximately  20 
hours per  day) 
• Other Events (i.e. alarms and/or events logged into the driver system  file) 
• Heart  rate 
• Non-invasive sitting blood pressure must be recorded  at the time of the  device 
check.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 30 of 150 
© Sunshine Heart  Confidential   
  
 
Data will be downloaded from the driver. Data will be recorded on the Follow -up eCRFs 
and stored electronically.  
Echocardiographic Testing - (Baseline, 1, 3, 6, 12, 18 month, and annual follow –up visits)  
A transthoracic echocardiography test will be performed at Baseline and at the 1, 3, 6, 12, 
18 month and annual follow -up visits. A recording of the echocardiogram must be 
collected and sent to the Echo Core Lab for analysis. The Echocardiography 
measurement s will include:  
• Left ventricular end -diastolic and end -systolic dimensions (diameters, areas  and 
volumes)  
• Assessment of mitral, tricuspid and aortic valve function (regurgitation  and 
gradient)  
• Right ventricular systolic pressure (with estimation of  CVP)  
• Ejection Fraction and Myocardial  Mass  
• LV diastolic  function  
Data will be recorded on the Baseline and Follow -up eCRF.  
Epi-Aortic Surface Echo - (collected at implant)  
A surface ultrasound interrogation will be performed on the ascending aorta to confirm the 
absence of significant aortic disease. Confirmation of the absence will be recorded on the 
Implant eCRF.  
Right Heart Catheterization - (Baseline and 6 month follow –up visits)  
A right heart catheterization will be performed at Baseline and 6 mon th visit. The right 
heart catheterization should be performed using the thermal dilution method if possible 
with access via the subclavian or internal jugular (i.e. swan ganz). Data required from the 
procedure include: central venous pressure (CVP), systol ic/diastolic/mean pulmonary 
artery pressure (PAP), Cardiac Index (CI), pulmonary capillary wedge pressure (PCWP), 
pulmonary artery pressure (PAP), systemic vascular resistance (SVR) and pulmonary 
vascular resistance (PVR).  
Data will be completed on the Bas eline and Follow -up eCRFs – Appendix K.  
CT Scan - (Baseline and 6 month follow –up visits)  
An ECG gated 1 –2 mm slice thoracic CT scan is required at Baseline, and at the 6 month 
visit. A recording of the CT Scan must be collected and sent to the CT Scan Core Lab for 
analysis of the Baseline and 6 month assessment. A contrast study should be completed 
for Baseline testing. A minimum contrast injection rate of 4 cc/sec is recommended.  
(Note: Protection of renal function is important. Please minimize the vol ume of 
contrast, ensure prehydration and use acetylcysteine.)  
A contrast study is not required for follow –up tests unless there is a concern there is 
extravasation of blood from the aorta.  
Data required from the procedure include:  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 31 of 150 
© Sunshine Heart  Confidential   
  
 
• Sagittal and coronal images shall be reconstructed at mid –systole and mid –diastole 
to measure narrowest mid ascending aortic luminal dimensions (i.e. with Cuff 
inflated and  deflated).  
Assessment will be made of the intima for the degree of atherosclerotic ascending  aortic 
disease, specifically: Nil, Mild (intimal thickening less than or equal to 3 mm), Moderate 
(intimal thickening greater than 3mm or mobile atheroma) or Severe (mural 
calcification)17. The CT Scan Core Lab will assess the outcome of the test for 
acceptability. Data will be completed on the Baseline and Follow -up eCRFs.  
NOTE: Contrast -induced nephropathy must be evaluated within one week post -baseline 
CT scan. Patients with an increase in Creatinine ≥ 0.5 mg/dL or a greater than 20% 
reduction in GFR mu st be followed until resolution of the decrease in renal function. This 
will be tracked as an observation via the follow -up form and should not be reported as an 
adverse event.  
Neurological Assessment - (pre-implant, pre -discharge, 1, 3 and 6 month follow -ups) 
A series of tests/assessments are required to assess for the presence of neurological 
dysfunction. Outlined below is the required assessment tool and specific required interval 
for collection:  
 
NIH Stroke Scale and Modified Rankin  
NIH Stroke Scale (NIHSS) is the standardized assessment tool for screening for any 
unobserved neurological dysfunction. The Modified Rankin is a standardized 
assessment tool for scoring disability status and/or ability to function. The NIHSS and 
Modified Rankin are r equired at pre -implant, at pre -discharge, 1, 3 and 6 months post 
implant. In the case of a neurological dysfunction adverse event, the NIHSS and 
Modified Rankin are required at 30 and 60 days post event in addition to the regular 
follow -up schedule. Clinic ians performing the NIHSS and Modified Rankin are 
required to be trained. Clinicians performing NIHSS must also be certified prior to 
performing the assessment. Access to required training and certification tools will be 
provided in the study activation tr aining for the study personnel designated for 
collecting the NIHSS. A neurological consultation is also required if an increase of 2 
or more is noted on the NIHSS.  
 
Head CT Scan  
A standard CT scan of the head is required at pre -implant as a baseline measur e 
immediately prior to device implant (but after study enrollment). In the case of a 
neurological dysfunction adverse event a CT scan of the head is also required as 
clinically indicated at the time of the adverse event. The scheduled baseline CT scan 
of the head should be completed only after the scheduled CT of the aorta – if the aorta 
does not meet inclusion criteria then he/she is not exposed to a further CT scan.  
 
 
 
 
 
 
17 [Davila –Roman 1999]  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 32 of 150 
© Sunshine Heart  Confidential   
  
 
Standard Neurologic Consultation  
A neurological consultation is required within days 5 -7 post ICU discharge or at 
hospital discharge whichever occurs first. A neurological consultation is also required 
if an increase of 2 or more is noted on the NIHSS and at the time of a neurological 
dysfu nction adverse event. The neurologist must record the outcome from the 
consultation into the medical record per institutional requirements for source 
documentation and on the Neurological Exam eCRFs (see Table 4 below).  
 
Data will be completed on the NIHSS , Neurological Exam, Baseline and Follow -up eCRF. 
The table below highlights the neurological testing follow -up data collection:  
Table 4. Neurological Testing Collection Schedule  
 
Item  Pre- 
Implant  Post-ICU 
Discharge  Neuro  
AE 5 Post- Neuro 
AE Day 30,  
60, 905 PID 
30 PID 
90 PID 
180 
Neurological 
Exam 1 X X X     
Head CT2 X  X     
NIHSS3 X X X X X X X 
Modified 
Rankin4 X X X X X X X 
1- Performed by a neurologist after study enrolment and prior to implant. Collected on Neuro Exam  eCRF.  
2- After study enrolment and prior to implant. Result collected on Neurological Exam eCRF and Neuro Dysfunction eCRF. 
3-Collected on the NIHSS  eCRF.  
4- Collected on the Modified Rankin  eCRF.  
5- Neuro  Assessment  and testing  expected  within  7 days post AE, between days  23-37 days post AE, between days  53-67 and  between 
days 83 -97 post  AE. 
 
Laboratory Parameters and Hemodynamics - (Baseline, Pre -Discharge, 1, 3, 6, 12, 18 month and 
annual follow –up visits)  
A full listing of all required lab tests and hemodynamic measureme nts is included in Table 
3 above.  
Measurements must be done at Baseline, Pre -Discharge, 1, 3, 6, 12, 18 month visits and 
annually thereafter.  
Data will be completed on the Baseline, Pre -Discharge, and Follow -up eCRFs.  
Six Minute Hall Walk Test - (Baseline,  1, 3, 6, 12, 18 month, and annual follow –up visits)  
The patient must perform a six –minute hall walk test (6MHW) at Baseline, and at 1, 3, 6, 
12, 18 month visits and annually thereafter with the C -Pulse™. Detailed information is 
included in Appendix P.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 33 of 150 
© Sunshine Heart  Confidential   
  
 
A familiarization test is required, but may have been performed in the previous one –year 
prior to implant. Instructions for conducting a six -minute walk test are located in 
Appendix P.  
Data will be completed on the Baseline and follow -up eCRFs.  
Quality of Life Assessment - (Baseline, 1, 3, 6, 12, 18 month and annual follow –up visits)  
The patient must complete the Minnesota Living with Heart Failure Questionnaire 
(MLWHF) and the Kansas City Questionnaire (KCCQ) at Baseline, 1, 3, 6, 12, 18 month 
and annual visits.  
Copies of the questionnaires are included for reference in Appendix N. 
Data will be completed on the Baseline and Follow -up eCRFs.  
Fatigue Impact Scales - (Baseline, Pre -Discharge, 1, 3, 6, 12, 18 month and annual follow –up 
visits)  
The patient must complete the Fatigue Impact Scale and the Daily Fatigue Impact Scale at 
Baseline, Pre -Discharge, 1, 3, 6, 12, 18 month and annual visits.  
Data will be completed on the Fatigue Impact and Daily Fatigue Impact  eCRFs.  
NYHA Class Assessment - (Baseline, 1, 3, 6, 12, 18 month and annual follow –up visits)  
A clinician at each site shall complete the NYHA Classification at Baseline, 1, 3 6, 12, 18 
month and annual visits.  
Data will be completed on the Baseline and follow -up eCRFs. Refer to Appendix O for 
detailed description of the assessment.  
Concomitant Medications (Baseline, 1, 3, 6, 12, 18 month and annual follow –up visits)  
All medications will be recorded on the Medication eCRF. Doses are required for all 
cardiac medications including d iuretics. Heart Failure medications such as ACE inhibitors 
and Beta Blockers must remain stable through the six month study period. Upward 
titration is not permitted beyond the baseline equivalent  dose.  
Cardiopulmonary (CPX) Testing - (Baseline and 6 month  follow –up visits)  
Two CPX tests may be required pre –operatively:  
1) a familiarization test to allow the patient to become familiar with walking on  a 
treadmill and with the breathing apparatus in his/her mouth  and 
2) a baseline  test. 
During the familiarization, the patient should exercise to his/her symptomatic maximum. 
If the patient reaches his/her maximum, this test will be considered the baseline test.  
The first test should be conducted prior to implant for baseline assessment. If a second 
test is required it should be conducted greater than 24 hours after the first. Note: If a 
patient has a documented CPX test within the past 6 months prior to implant, then this  test 
will be considered the familiarization test. A baseline test will still be r equired prior to 
implant if not conducted within the past 30 days, but the familiarization can be  skipped.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 34 of 150 
© Sunshine Heart  Confidential   
  
 
Follow up measurements must be taken at the 6 month visit.  
Please refer to Appendix Q for additional information on the testing proce dure. A blinded 
independent core lab will evaluate the CPX test results. A recording of the CPX must be 
collected and sent to the CPX Core Lab for analysis.  
Data will be completed on the eCRF and via the electronic data stored on disk.  
Pre-implant Preparat ion 
When a patient signs the informed consent for the study, he/she is considered enrolled into 
the study. The patient informed consent must be signed prior to conducting any 
procedure/testing performed for study purposes. Any patient that does not meet th e 
eligibility requirements will be promptly study exited.  
Pre-Implant Baseline Testing and Data Collection Summary  
The following pre –implant baseline data will be obtained 30 days prior to implant. These 
data will be used by the center to confirm inclusion  and exclusion criteria are met. A 
complete reference list of tests and hemodynamics to measure is included in Table 3.  
• Inclusion and Exclusion  Verified  
• Informed Consent  Obtained  
• Medical History and Physical  Exam  
• Echocardiogram  
• Chest X –ray 
• ECG  
• Right Heart  Catheterization  
• Cardiopulmonary Exercise  Testing  
• Six Minute Hall  Walk  
• Fatigue Impact  Scales  
• Cardiovascular Medications  Documented  
• Cardiovascular Medical History  Documented  
• CT Scans – Aorta and Head  Documentation  
• Neurologic Assessment (Neurology Consu lt, NIHSS and Modified  Rankin)  
• Quality of Life Questionnaires (MLWHF and  KCCQ)  
• Baseline Hemodynamics  
• Serum  Labs  
• NYHA  Classification  
• Medications  
• All adverse events reported  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 35 of 150 
© Sunshine Heart  Confidential   
  
 
Clinical Procedures – Implant through discharge  
The System Implant eCRF will be used to collect implant data.  
The hospitalization phase is divided into three major parts: (i) Prior to implant, (ii) Implant 
procedures, and (iii) Post –implant to discharge.  
Pre–Implant Considerations  
Medication  Therapy  
Prescribed dru gs are to be maintained until the time of surgery unless instructed  otherwise 
by the anesthetist. Prophylactic anti –coagulation should be stopped. Premed given per 
institutional  protocol.  
Cardiac Resynchronization Therapy (CRT)  
Per the eligibility criteria  a patient should not be enrolled earlier than 90 days following 
CRT implant. Patients enrolled with a CRT device must have the Cardiac 
Resynchronization Therapy continued during the follow up period. ICD Therapy should 
remain activated except during the s urgical implantation.  
Planning for Device and Percutaneous Tube Positioning  
Have the patient try on the Vest and bag to determine the best exit site. The goal is to 
minimize trauma to the exit site and to maximize patient comfort. Pay particular attention 
to the costal margins, belt line, and impact of sitting and standing and lying, and the exit 
site when wearing the Driver. The distance of the exit site from the costal margin should 
be considered in relation to the thickness of subcutaneous tissue, in ord er to prevent the 
percutaneous tube from rubbing against the costal margin. Also consider patients who 
inject insulin into the abdominal area. Mark the exit site.  
Antisepsis Prophylaxis  
Administer prophylactic antisepsis coverage. Recommended prophylaxis:  
• Vancomycin 15mg/kg IV one hour pre -op given over 30 minutes and with 
minimum 5 minute interval blood pressure monitoring or arterial line monitoring  – 
note that Vancomycin can cause hypotension in this patient population and should 
not be given unsupervise d pre -operatively on the ward. Follow –up doses Q12 –24 
hr post -operatively for 48 hrs, guided by serum Vancomycin trough  levels.  
• Keflex 1g IV one hour pre –op then Q8 –12hr for 48  hrs 
• Rifampicin 600 mg PO 2hrs pre –op then daily for 2 days – stop if liver function 
tests become deranged greater than two times  baseline  
• Nasal Bactroban application day prior to  surgery  
Note: Record all drugs and doses on the Medication eCRF.  
Prepare and shave the patient: Pre -operative scrub with antiseptic (Septisol or 
Chlorhe xidine) on the night prior to surgery then again the morning of the surgery, and 
clip and shave the surgical area prior to transport to the operating room.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 36 of 150 
© Sunshine Heart  Confidential   
  
 
Observe Operating Room precautions – particularly, limit the number of people in the  
room, and traffic in and out of the room.  
 
Baseline Procedures  
Baseline investigational procedures as above should have been completed and data 
collected into the System Implant and Medication eCRFs.  
 
Implant Procedure  
Note: Refer to the Instructions for Use (IFU) for the C -Pulse® Cuff, Percutaneous 
Interface Lead and C -Pulse® System, which outline device preparation, implantation, and 
operation. The IFUs may be found in Appendix F.  
 
Procedure Summary  
1. Establish intra -venous and intra-arterial lines (if not already established  above). 
Insert central venous sheath and position right heart catheter (may be done 
following general anesthesia), and connect surface  ECG.  
2. Induce general anesthesia: intubate with endotracheal tube and vent ilate per 
routine. Blood gases, Hb, and Hct are monitored during surgery per  routine.  
3. Recommended three –step approach to skin  preparation:  
a. antiseptic scrub (Septisol or  Chlorhexidine)  
b. alcohol, which is then allowed to  dry 
c. Betadine gel, which is allowed to  dry. 
Note: combination alcohol/Betadine preparation may be used  
4. Drape patient with steri -drapes (e.g. Ioban), over exposed prepared  skin.  
5. Perform chest incision.  
6. Incise pericardium up onto ascending aorta, mobilize ascending aorta  from 
pulmonary  artery.  
7. Using umbilical tape, measure mid -ascending aortic circumference and record  on 
System Implant  eCRF.  
8. Use CT scan to select Cuff size per mid –ascending aortic outside  diameter.  
9. Delay opening sterile packaging for the C -Pulse® Cuff, ECG lead and PIL until 
they are ready to be implanted. See IFU for details regarding opening and 
implanting the C –Pulse® Cuff and PIL, including Warnings and  Precautions.  
10. Evacuate air from C -Pulse Cuff and mark circumferential lines for  suturing.  
11. Massage antibiotic solution* into the flocking anchors and into the wrap. 
(*Gentamicin and normal saline 160g/L, or Vancomycin and normal saline  2g/L)  
12. Implant device about the aorta and secure according to the  IFU. 
13. Open ECG lead sterile packaging when  required.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 37 of 150 
© Sunshine Heart  Confidential   
  
 
14. Attach a bipolar epicardial ECG sensing lead to the RV or LV per  IFU. 
15. Create exit site by excising skin button that is approximately 80% of the  tube 
outside  diameter.  
16. Secure Cuff and Lead and attach to intracorporeal aspect of PIL per IFU and track 
out under the costal margin through a curvilinear pathway, either superior or 
inferior to the umbilicus as it suits best, to the desired pre –determined exit site. A 
separate small incision may be needed to allow further tunneling of the Lead and 
gas-line to th e intended exit site. The PIL may alternatively be tunneled from  “out– 
to–in” and connected to the Cuff gas -line and ECG lead  secondarily.  
17. The PIL at the exit site should be oriented horizontally or slightly downward  to 
allow good natural drainage of the exit  site. 
18. The flocking of the PIL should be positioned to be subcutaneous, approximately  2 
cm from the exit  site. 
19. Verify device  function:  
a. Test for adequate sensing of the R wave by the Driver with respect  to 
beginning of LV systole per IFU.  
b. Optimize inflation/deflation and displacement volume. Gas inflation  hold 
pressure should not exceed 50mmHg above the mean arterial pressure. 
See IFU C –Pulse® System (LBL  01918).  
20. Fill chest with saline, massage any trapped air from under the Cuff, and obser ve to 
ensure no air -leaks are  visible.  
21. Inflate lungs fully to check percutaneous lines – gas–line and ECG lead may  be 
immobilized at 1 –2 other locations e.g. right anterior mediastinum, sub –costal 
incision.  
22. Check for hemostasis, irrigate with antibiotic  solution.  
23. Insert mediastinal and any other drains as required, and close all  wounds.  
24. Apply occlusive surgical dressings to all wounds and to immobilize  the 
percutaneous  tube.  
Post–Implant Considerations (prior to discharge)  
1. Patient taken to ICU – driver may be disconnected for  transport.  
2. Ensure both Drivers are configured with the same settings and verify function of both  as 
above.  
3. Extubate patient, when appropriate – move to the telemetry ward when  appropriate.  
4. Chest and other drains should be removed as soon as practical, at the discretion of  the 
surgeon, and typically within 48 hours, depending on  drainage.  
5. Recommended atrial arrhythmia treatment for new atrial fibrillation with rate greater  than 
110 beats per min: IV or oral amioderone loadin g and oral amioderone  maintenance.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 38 of 150 
© Sunshine Heart  Confidential   
  
 
6.  Heart rates should be maintained below 120 bpm and MAP below 100 mmHg to  allow 
optimal counterpulsation and minimize alarms from the  Driver.  
7. Commence over –night naso -gastric feeding post -operatively if di et not re –established  at 
day 2 or if serum Albumin below 3.3  g/dL.  
8. Blood sugars: An Insulin infusion, titrated to Q1 –4hr blood sugar measurement will be 
established in patients with diabetes or other glucose intolerance until a regular diet  and 
normal diab etic therapy can be  re–introduced.  
9. Active deep vein thrombosis management includes TED stockings, subcutaneous  Clexane 
or similar and bed leg  exercises.  
10. Early mobilization and graduated physiotherapy is to be conducted as tolerated from  day 
1, but the driver should not be used in a wearable configuration in the first week or until 
the chest incision is stable and comfortable. Use of the driver with the vest should be 
gradually built up and used with assistance from physiotherapy or other hospital  staff.  
11. The C –Pulse® can be de –activated intermittently for patients that are considered 
symptomatically stable per physician discretion (e.g. acceptable degree of shortness of 
breath and absence of dizziness), initially for short intervals (less t han 5 minutes) once  or 
twice a day, and this may be built up after 7 –10 days post –operatively such that de - 
activation periods provide an opportunity for the patient to be free of the Driver for 15 
minute intervals during the day or night. The Driver shoul d not be ‘Off’ for greater than 
30 minutes at any one time and not be ‘Off’ for a maximum of four hours total per day. 
For the extent of the trial, the device should be used at least 20 hours per day (i.e. 
device must be used greater than 80% of the  time).  
12. Heart failure medications should be re –started cautiously and drug doses titrated to 
clinical effect. It is recommended that the following regime be used as a guideline  for 
post–operative  medications:  
• Dopamine or Dobutamine for first 1 –7 days, weaned  down  
• Diuretics at pre –op dose or higher (including IV infusion as required)  from 
day 1: Diuretics may be weaned as indicated later in the post –operative 
period  
• ACE inhibitors from day 2 –3 – aim to titrate to then maintain at  pre-op 
dose for duration of the stu dy follow -up 
• Beta blocker from day 5 –7, as tolerated – aim to titrate to then maintain  at 
pre-op dose for duration of the study  follow -up 
13. Strict hygiene/hand washing must be practiced for all staff handling patient and lines. 
Remove all indwelling catheters as soon as possible. Change other lines regularly (at  least 
every 4 –7 days) as per hospital  policy.  
14. The exit –site dressing should be changed as frequently as required post –operatively while 
ensuring that the percutaneous lead is immobi lized – this may be up to 2 –3 times per day 
in the first 1 –2 weeks. If wounds are healing well and there is no discharge, then go to 
daily or second -daily dry dressings. Exit -site dressings must be limited to the least  number 
of clinical personnel, and pre ferably done by the patient or care -giver as much as  possible  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 39 of 150 
© Sunshine Heart  Confidential   
  
 
after the early post -operative phase, to limit exposure to micro -organisms and to limit 
cross -contamination.  
15. Antibiotics IV peri-operatively as described above. Ongoing oral broad spectrum/gram 
negative cover is recommended for 10 days or until chest drains are removed and the exit – 
site has dried sufficient for once daily dressing  only.  
16. Ongoing education to patient and care –givers on general hygiene e.g. regular hand 
washing and to treat percutaneous line gently and to avoid undue pulling, pushing  or 
torsion.  
17. Maintain a routine dressing change and observe for signs of infection (refer to  Appendix 
U for detailed infection control  procedures):  
• Always wash hands and apply alcohol  hand rub and use sterile gloves  when 
handling the exit  site. 
• Exit site should be examined and managed once per day (or more 
frequently if there is excessive moisture) by one person, specifically  the 
wound should not be disturbed or inspected at any other  time.  
• Irrigate wound site gently with Chlorhexidine solution and use sterile  gauze  
to lift off any debris. Dry with clean sterile gauze. Keep the exit site dry 
between dressings. Use 2 –3 small square gauzes or similar (e.g. Softwik), 
alternately split, to securely surround the percutaneous lead, and secure 
with tape or  similar.  
• Wound de terioration is usually caused by excess moisture. Increase 
dressings per day until this resolves – also consider oral broad  spectrum 
antibiotic or  similar.  
• If wounds not responding to increased dressings, change wound irrigation 
solution (examples include 2% Chlorhexidine gluconate in normal saline, 
or Vancomycin in normal saline  2g/L)  
• Swabs for culture should only be taken of copious or purulent discharge. 
Blood cultures should be done if the patient is to be treated with  antibiotics 
or if there is  evidence of  sepsis.  
18. Showering: If the patient is symptomatically stable while disconnected from the device, 
then the interface can be capped off, allowing the patient to shower. Leave the dressing 
intact during showering – cover the exit site and capped o ff connector with a 4x4 gauze 
sealed with an occlusive adhesive plastic dressing such as Tegaderm. It is  recommended 
that the patient be sitting on a stool or chair initially to avoid the risk of vasodilation 
hypotension. The dressing should be changed, pe r above, following  showering.  
19. Instruct patient to avoid sleeping on abdomen to avoid gas tube  complications.  
20. Educate patient and care –giver on how to operate the drivers, per the Patient  Handbook. 
Training of the patient and/or caregiver will be  documented . 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 40 of 150 
© Sunshine Heart  Confidential   
  
 
Hospital Discharge  
Preparation  
Educate patient and care –giver on how to operate the Driver. Provide the Patient with the 
C–Pulse® System Patient Manual and contact details for clinical personnel at the clinical 
site hospital. Refer to App endix M for discharge checklist.  
Discharge Criteria  
Discharge should be based on the following criteria, which are based upon initial clinical 
experience in the ANZ pilot study.  
• Healing wounds, and with no signs of infection or  sepsis  
• Oxygen saturation greater than or equal to age –predicted O 2 saturation on room  air 
• Sinus rhythm or atrial arrhythmia with ventricular rates < 120  bpm 
• Patient can walk 30 meters with the device without stopping due to shortness  of 
breath/muscle fatigue/unsteady  gait/pain  
• Caregiver or patient demonstrates aseptic technique in changing exit site  dressing  
• Patient and caregiver independently demonstrate connection and disconnection  of 
the Drivers, changing and recharging batteries, and to understand and respond to 
the Driver alerts and  alarms  
• Home assessment visit prior to discharge may be completed to  assess 
environmental  conditions  
• All scheduled follow -up testing is  completed  
The patient should not be discharged if any of the following issues are present:  
o Unresolved system  malfunction  
o Back -up equipment is not  available  
o Unresolved adverse event that threatens patient  safety  
o Patient requires any treatment for disease, illness, mental or  physical 
disability that cannot be provided outside the  hospital  
Readmission  
Should the patient be re -hospitalized at any time post index hospitalization, the Unscheduled 
Follow -up Form should be completed. While hospitalized, the Follow -up Forms will continue to 
capture data and adverse events should be documented on t he adverse event forms should they 
occur. When the patient is discharged again, the patient should be assessed per the discharge 
criteria to ensure they continue to meet the criteria.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 41 of 150 
© Sunshine Heart  Confidential   
  
 
Post-Implant Follow –up Testing and Data Collection  
Post–Implant Testing and Data Collection Summary  
The complete reference list of post –implant testing and data collection that will be 
performed at each time point is included in Table 3.  
Unscheduled Follow –up Visits  
If patients are seen between protocol –schedul ed visits because of clinical symptoms 
requiring readmission, device reprogramming, etc. a follow –up form must be completed 
with all appropriate sections. In addition, all adverse events must be documented 
throughout the study.  
System Modifications  
Immediately contact Sunshine Heart clinical support team if a need is suspected for 
system modification (component or system replacement). In the event that the C -Pulse® 
System requires modification (e.g. Cuff or PIL) a System Modification Form should be 
completed along with an adverse event form. Modifications should be done only in 
communication with Sunshine Heart Service personnel, unless the modification is a 
medical emergency. In which case, Sunshine Heart personnel should be notified as soon  as 
possi ble. In addition, the System Modification Form should be completed documenting 
the removal of the existing device or component. The C -Pulse® component(s) should be 
processed according to the Explant Handling Instructions and returned to Sunshine Heart 
or designee.  
In the event of a system modification, including component removal, reposition or 
replacement of the entire C -Pulse® system, the follow –up schedule for the patient will 
remain unchanged (i.e. the patient should continue to be seen for follow –up an d associated 
forms should be completed based on the original follow –up schedule). All adverse events 
should be reported and classified by the investigator. Additionally the CEC will provide 
further classification of adverse events.  
Adverse Event Reporting  
Overview  
Information on adverse events (AE) will be collected throughout the study. Upon 
identification, the investigator completes the adverse event information via the Adverse 
Event eCRF. Sunshine Heart clinical personnel or designee may request further 
information from the investigator if necessary for review of the event with the Clinical 
Event Committee (CEC).  
The following information will be collected in the database: the date of event onset, 
seriousness of the event, the relationship of the event to  the implant procedure, device, 
concomitant medications, patient management, other actions taken as a result of the event, 
and the outcome of the event.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 42 of 150 
© Sunshine Heart  Confidential   
  
 
Adverse Event Definitions  
Definitions are listed below for anticipated adverse events. The definitions are consistent 
with Version 2.2 adverse event definitions for the Intermacs® registry with the exception 
of Major Bleeding which does not have a minimum standard of transfusion. A ortic 
Disruption has been added in addition to the Intermacs® registry definitions as an 
additional screening for safety with respect to the C -Pulse unique application.  
Major Bleeding  
An episode of internal or external bleeding that results in death, the n eed for re -operation 
or hospitalization; or necessitates transfusion of red blood cells.  
NOTE: Hemorrhagic stroke is considered a neurological event and not as a separate 
bleeding event.  
Cardiac Arrhythmias  
Any documented arrhythmia that results in clinical compromise (e.g., oliguria, pre - 
syncope or syncope) that requires hospitalization or occurs during a hospital stay. Cardiac 
arrhythmias are classified as 1 of 2 types:  
1) Sustained ventricular arrhythmia requiring defibrillation or  cardioversion.  
2) Sustained supraventricular arrhythmia requiring drug treatment  or 
cardioversion.  
Pericardial Fluid Collection  
Accumulation of fluid or clot in the pericardial space that requires surgical intervention or 
percutaneous catheter drainage. This event will be sub divided into those with clinical 
signs of tamponade (e.g. increased central venous pressure and decreased cardiac output) 
and those without signs of tamponade.  
Aortic disruption  
Disruption to the intima of the ascending aorta. Disruption may be partial or complete  (i.e. 
transmural), and the latter may result in contained or free rupture. Typically this would  be 
documented initially by CT scan with contrast or by trans -esophageal  echocardiography.  
Device Malfunction  
Device malfunction denotes a failure of on e or more of the components of the MCSD 
system which either directly causes or could potentially induce a state of inadequate 
circulatory support (low cardiac output state) or death. The manufacturer must confirm 
device failure. A failure that was iatrogen ic or recipient -induced will be classified as an 
Iatrogenic/Recipient -Induced Failure.  
Device failure should be classified according to which components fails as follows:  
1) Pump failure (implanted components of pump and any motor or other pump 
actuating mech anism that is housed with the implanted components). In the 
special situation of pump thrombosis, thrombus is documented to be  present 
within the device or its conduits that result in or could potentially induce 
circulatory  failure.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 43 of 150 
© Sunshine Heart  Confidential   
  
 
2) Non-pump failure (e.g., external pneumatic drive unit, electric power  supply 
unit, batteries, controller, interconnect cable, compliance  chamber).  
Hemolysis  
A plasma -free hemoglobin value that is greater than 40 mg/dl, in association with clinical 
signs as sociated with hemolysis (e.g., anemia, low hematocrit, hyperbilirubinemia) 
occurring after the first 72 hours post -implant. Hemolysis related to documented non - 
device -related causes (e.g. transfusion or drug) is excluded from this definition.  
Hepatic Dysf unction  
An increase in any two of the following hepatic laboratory values (total bilirubin,  aspartate 
aminotransferase/ AST and alanine aminotranferease/ ALT ) to a level greater than three 
times the upper limit of normal for the hospital, beyond 14 days post -implant  (or if 
hepatic dysfunction is the primary cause of  death).  
Hypertension  
New onset blood pressure elevation greater than or equal to 140 mm Hg systolic or 90 
mm Hg diastolic (pulsatile pump) or 110 mm Hg mean pressure (rotary pump).  
Major Infectio n 
A clinical infection accompanied by pain, fever, drainage and/or leukocytosis that is 
treated by anti -microbial agents (non -prophylactic). A positive culture from the infected 
site or organ should be present unless strong clinical evidence indicates the need for 
treatment despite negative cultures. The general categories of infection are listed below:  
Localized Non -Device Infection  
Infection localized to any organ system or region (e.g. ) without evidence of 
systemic involvement (see sepsis definition), a scertained by standard clinical 
methods and either associated with evidence of bacterial, viral, fungal or protozoal 
infection, and/or requiring empirical treatment.  
Percutaneous Site and/or Pocket Infection  
A positive culture from the skin and/or tissue s urrounding the drive line or from 
the tissue surrounding the external housing of a pump implanted within the body, 
coupled with the need to treat with antimicrobial therapy, when there is clinical 
evidence of infection such as pain, fever, drainage, or leu kocytosis.  
Internal Pump Component, Inflow or Outflow Tract Infection  
Infection of the implanted C -Pulse Cuff documented by positive site culture.  
Sepsis  
Evidence of systemic involvement by infection, manifested by positive blood 
cultures and/or hypotension.  
Myocardial Infarction  
Two categories of myocardial infarction will be identified:  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 44 of 150 
© Sunshine Heart  Confidential   
  
 
Peri-Operative Myocardial Infarction  
The clinical suspicion of myocardial infarction together with CK -MB or Troponin  
> 10 times the local hospita l upper limits of normal, found within 7 days following 
implant together with ECG findings consistent with acute myocardial infarction.  
Non-Perioperative Myocardial Infarction  
The presence at > 7 days post -implant of two of the following three criteria:  
a) Chest pain which is characteristic of myocardial  ischemia,  
b) ECG with a pattern or changes consistent with a myocardial  infarction, 
and 
c) Troponin or CK (measured by standard clinical pathology/laboratory 
medicine methods) greater than the normal range for the local hospital 
with positive MB fraction (≥ 3% total CK). This should be  accompanied 
by a new regional LV or RV wall motion abnormality on a myocardial 
imaging  study.  
Neurological Dysfunction  
Any new, temporary or permanent, focal or g lobal neurological deficit ascertained by a 
standard neurological examination (administered by a neurologist or other qualified 
physician and documented with appropriate diagnostic tests and consultation note). The 
examining physician will distinguish betw een a transient ischemic attack (TIA), which is 
fully reversible within 24 hours (and without evidence of infarction), and a stroke, which 
lasts longer than 24 hours (or less than 24 hours if there is evidence of infarction). The 
NIH Stroke Scale and Modif ied Rankin (for patients > 5 years old) must be re - 
administered at 30, 60 and 90 days following the event to document the presence and 
severity of neurological deficits. Each neurological event must be subcategorized as:  
1) Transient Ischemic Attack (acute e vent that resolves completely within  24 
hours with no evidence of  infarction)  
2) Ischemic or Hemorrhagic Cardiovascular Accident/CVA (event that persists 
beyond 24 hours or less than 24 hours associated with infarction on an imaging 
study)  
Psychiatric Episode  
Disturbance in thinking, emotion or behavior that causes substantial impairment in 
functioning or marked subjective distress requiring intervention. Intervention is the 
addition of new psychiatric medication, hospitalization, or referral to a mental healt h 
professional for treatment. Suicide is included in this definition.  
Renal Dysfunction  
Two categories of renal dysfunction will be identified:  
Acute Renal Dysfunction  
Abnormal kidney function requiring dialysis (including hemofiltration) in patients 
who d id not require this procedure prior to implant, or a rise in serum creatinine of  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 45 of 150 
© Sunshine Heart  Confidential   
  
 
greater than 3 times baseline or greater than 5 mg/dL (in children, creatinine 
greater than 3 times upper limit of normal for age) sustained for over 48 hours.  
Chronic Renal Dysfunction  
An increase in serum creatinine of 2 mg/dl or greater above baseline, or 
requirement for hemodialysis sustained for at least 90 days.  
NOTE: Contrast -induced nephropathy must be evaluated within one week post -baseline 
CT scan. Patients with an increase in Creatinine ≥ 0.5 mg/dL or a greater than 20% 
reduction in GFR must be followed until resolution of the decrease in renal function. This 
will be tracked as an observation via the follow -up form and should not be reported a s an 
adverse event.  
Respiratory Failure  
Impairment of respiratory function requiring reintubation, tracheostomy or (for patients 
older than age 5 years) the inability to discontinue ventilatory support within six days (144 
hours) post -implant. This exclude s intubation for re -operation or temporary intubation for 
diagnostic or therapeutic procedures.  
Right Heart Failure  
Symptoms and signs of persistent right ventricular dysfunction [central venous pressure 
(CVP) > 18 mmHg with a cardiac index <2.0 L/min/m2 i n the absence of elevated left 
atrial/pulmonary capillary wedge pressure (greater than 18 mmHg), tamponade, 
ventricular arrhythmias or pneumothorax] requiring RVAD implantation; or requiring 
inhaled nitric oxide or inotropic therapy for a duration of more than 1 week at any time 
after implantation.  
Arterial Non -CNS Thromboembolism  
An acute systemic arterial perfusion deficit in any non -cerebrovascular organ system due 
to thromboembolism confirmed by one or more of the following:  
1) standard clinical and laboratory  testing  
2) operative  findings  
3) autopsy  findings  
This definition excludes neurological events.  
Venous Thromboembolism Event  
Evidence of venous thromboembolic event (e.g. deep vein thrombosis, pulmonary 
embolism) by standard clinical and laboratory te sting.  
Wound Dehiscence  
Disruption of the apposed surfaces of a surgical incision, excluding infectious etiology, 
and requiring surgical repair.  
Other  
An event that causes clinically relevant changes in the patient’s health (e.g. cancer).  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 46 of 150 
© Sunshine Heart  Confidential   
  
 
Adverse Event Classification  
All reported adverse events will be classified by the investigator, based on the following 
categories:  
• Relatedness (i.e. device, procedure, concomitant medication, or  patient 
management);  
• Timing (i.e. pre –implant, implant or  post–implant);  
• Serious events (i.e., result in death, are life -threatening, require  surgical 
intervention, result in permanent disability, require hospitalization or 
hospitalization is unduly  prolonged).  
• Status (i.e. ongoing or  resolved)  
Device Related  
An adverse event will be considered device related if it is a direct result of, or is affected 
by the presence, or operation (intended or otherwise) of the investigational device.  
Procedure Related  
An adverse event will be considered procedure rela ted if it is a direct result of the 
implantation procedure, which cannot be directly attributed to any particular device or 
implant tool.  
Patient Management Related  
An adverse event will be considered related to patient management if it is a direct result of 
the medical complexities of managing the co –morbidities of heart failure.  
Concomitant Medication Related  
An adverse event will be considered related to concomitant medication when it is 
reasonable to believe that the event is directly associated with medications used in 
conjunction with the investigational device and it is not otherwise specific to the device, 
procedure or patient management.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 47 of 150 
© Sunshine Heart  Confidential   
  
 
Unavoidable Events  
The events listed in Table 5 are considered minor and if the onset occu rs within the 
timeframe specified, are not subject to adverse event reporting.  
Table 5. Unavoidable Events  
Event  Description  Timeframe 
(post –implant)  
Anesthesia  related  nausea/vomiting  24 hours  
 
Low–grade fever (<102  degrees F)  48 hours  
Minor incision/exit  site pain 72 hours  
 
Minor, localized tenderness, swelling, oozing, etc. at incision  
sites 72 hours  
Early post –operative pain associated with endotracheal tube  
placement and  mechanical  ventilation  72 hours  
Electrolyte imbalance without  clinical  sequelae  72 hours 
Systolic and diastolic blood pressure changes that do not  require  
treatment  or intervention  On–going  
Chest tube drainage or blood loss not requiring intervention and  
hematocrit remaining  above  25% 72 hours  
Sinus bradyca rdia and tachycardia that does not require  
intervention  On–going  
Adverse Event Reporting to IRB and Regulatory Agencies for Unanticipated Device Events  
The investigator must report any unanticipated adverse device effects (UADE) to the 
Sponsor (Sunshine H eart) and IRB within 10 days after the investigator first learns of the 
event. The Sponsor must report any UADE to the regulatory agencies, IRBs, and all 
investigators within 10 days of receipt of notice of the event.  
An unanticipated adverse device effect is defined as:  
Any serious  adverse effect on health or safety or any life -threatening problem or death 
caused by, or associated with, the device, if that effect, problem or death was not 
previously identified in nature, severity, or degree of incidence in the protocol or 
applicatio n (including a supplementary plan or application), or any other unanticipated 
serious problem associated with a device that related to the rights, safety, or welfare of 
subjects. [21 CRF 812.3 (s)]  
Patient Deaths  
All patient deaths must be documented on th e Study Exit/Death Form. If the patient dies 
during the study, notify the Sunshine Heart field support personnel as soon as possible 
upon first learning of the death. Follow any IRB requirements for reporting of deaths or 
adverse events.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 48 of 150 
© Sunshine Heart  Confidential   
  
 
In the event of a patient death, efforts should be made to retrieve the implanted device and 
to obtain an autopsy in order to assess the state of the heart and aorta. A sample of the 
aorta beneath the C -Pulse® Cuff should be collected for analysis. Please ca ll Sunshine 
Heart Clinical Support for more instruction. For patients who do not undergo autopsy, 
written documentation from the investigator will be required regarding circumstances as to 
why an autopsy was not performed. The device will be analyzed by lo cal staff and 
Sunshine Heart clinical support personnel according to a standardized device retrieval 
protocol.  
A death summary and an autopsy report are required, please send upon completion to 
Sunshine Heart to provide to the adjudication committee.  
Expla nt Handling and Final Device Disposition  
Promptly call Sunshine Heart Clinical Support for instruction regarding Explant Handling. 
Cultures should be taken from the device implantation site along with visual analysis and 
photographs when possible. Explante d products should be returned to Sunshine Heart for 
analysis.  
Complete the Study Exit/Death Form. Report all associated adverse events. Update the 
Device & Equipment Disposition Log with all products. If the device is not returned to 
Sunshine Heart, justif ication must be provided in the log.  
Patient Withdrawal and Study Exit  
A Study Exit/Death Form shall be completed if patient is unable to or refuses to continue 
participation in the study. Notify the Sunshine Heart clinical support team as soon as 
possible  upon learning of a patient withdrawal/study exit.  
If the patient fails to comply with follow –up visits, the study center must make repeated 
attempts to contact the patient. Each attempt to contact the patient must be documented in 
the patient’s records an d on the Study Exit/Death form.  
If the patient officially withdraws from the study, the investigator will document the 
reason for withdrawal and indicate any relationship of the withdrawal to the study or the 
device on the Study Exit/Death form.  
If a patient withdraws from the study at any time, there will be no penalty or loss of future 
medical care.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 49 of 150 
© Sunshine Heart  Confidential   
  
 
STATISTICAL METHODS AND DATA ANALYSIS  
 
This feasibility study intends to examine the effect of C -Pulse® on long -term heart failure, and t o 
look for trends in performance indicators. This study is not powered to detect statistical 
significance. As such, clinical judgment is required to assess device safety and potential efficacy 
from data collected during this study. This clinical judgment w ill be provided by the DSMB.  
Justification of Methodology  
This study is designed as an open -label single -arm study to develop a further understanding of 
the C -Pulse®. It will provide safety and efficacy information for patients in whom C -Pulse® is 
implante d and maintain counterpulsation for six months or longer.  
At six months post -procedure, the patients will provide an adverse event profile related to 
surgical placement of the C -Pulse® and six months employment of C -Pulse® counterpulsation. 
After six month s of the study there will be additional information related to the adverse event 
profile. The patients will provide an adverse event profile for patients in whom C -Pulse® is 
placed and maintain counterpulsation for greater than six months.  
Similarly, these  patients will provide an efficacy profile. At six months post -procedure, the 
patients will provide information on how well a patient improves since baseline through six 
months of counterpulsation. After six months these patients provide additional efficac y 
information related to how well a patient improves since baseline through greater than six 
months of  counterpulsation.  
Primary Safety  Measures  
The safety of the C - Pulse® will be evaluated by reviewing a composite of the device -related 
adverse events through six months, as classified by the CEC. The composite device -related 
adverse event rate will be the percent of patients who experience at least one of the following 
adverse events as adjudicated by the CEC as device -related out of the total nu mber of patients:  
• Death  
• Neurological  Dysfunction  
• Aortic  Disruption  
• Myocardial  Infarction  
• Major Infection  
• Any other device -related adverse event (as adjudicated by the  CEC)  
The definitions for these adverse events are provided in the Adverse Event Definitions section.  
Performance Requirements  
Safety will be represented in the composite device -related adverse event rate which will be 
reported with its 95% two -sided exact confidence interval. The composite device -related 
adverse event rate will be ass umed to follow the Binomial Distribution. The DSMB will 
decide the clinical acceptability of this observed event rate in assessing trial success.  
Additionally each event will be presented with its respective rate and confidence interval. 
Death will be sepa rated into deaths that occur before 30 -days post -procedure and those 
that occur between 30 -days post -procedure and 6 months.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 50 of 150 
© Sunshine Heart  Confidential   
  
 
Efficacy measurements  
The efficacy of C -Pulse® will be evaluated by assessing the change of the efficacy 
variables from baseline to 6 months post -implant. The following measurements will be 
taken at baseline and 6 -months.  
• Peak  VO 2 
• Quality  of Life as measured  by the Minnesota  Living  with Heart Failure  (MLWHF)  
• HF Symptoms as measured by  NYHA  
• Six Minute Hall Walk  Test  
Performance Requirement  
Trial success will be evaluated by analyzing each patient’s response to the four efficacy 
variables. A responder analysis will for each patient will performed assessing the 
response to each of the four efficacy variables. Each effic acy variable will be assessed  for 
clinical improvement (“responder”), decline (“non -responder”) or no change 
(“indeterminant”).  
Clinical improvement will be defined for each efficacy variable as:  
• 1.2 ml/kg/min improvement in peak  VO 2 
• 7 point improvement in  MLWHF  score  
• 1 class improvement in  NYHA  
• 50 meter improvement in the Six Minute Hall  Walk  
Clinical decline will be defined for each efficacy variable as:  
• 1.2 ml/kg/min decrease in peak  VO 2 
• 7 point decrease in MLWHF  score  
• 1 class decrease in  NYHA  
• 50 meter decrease in the Six Minute Hall  Walk  
A patient that shows no improvement or decline in a particular endpoint will be labeled as  
“indeterminate” for that endpoint.  
The overall percentage of responders, non -responders and indeterminates for each effica cy 
variable along with the respective 95% two -sided exact confidence interval will be 
presented. Additionally the point estimate for the average change and its respective 
standard deviation will be presented for peak VO 2, MLWHF, and the Six Minute Hall 
Walk. The improvement in NYHA will be presented by a cross -tabulation summary. The 
DSMB will decide the clinical acceptability of this responder analysis in assessing trial 
success.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 51 of 150 
© Sunshine Heart  Confidential   
  
 
Secondary Objectives  
The secondary objectives are descriptive  in nature and will be evaluated in order to gain 
additional information regarding the C -Pulse® system. There are no specified 
performance criteria for these objectives. For continuous measures the mean, standard 
deviation, minimum and maximum values will be presented. For categorical variables  the 
frequency and percent will be  presented.  
Endpoints consistent with the primary safety and efficacy objectives will be evaluated at 
all additional time points.  
1. The adverse event rate will be presented at 3, 6, 12 and 18 months post - 
procedure, and annually for years 2 -5 post-procedure.  
2. The change from baseline to follow -up will be evaluated for peak VO 2, Six 
Minute Hall Walk, MLWHF, Fatigue Impact Scales and heart failure  symptoms 
from  NYHA.  
The device failure rate will be quantified. Failure will be defined as both failure of the 
device, and failure of the device to be programmed to the treatment.  
Additional ly, the adverse  event  rate for each of the adverse  events  described  in the Adverse 
Event Definitions section – pages 36 -40 – will be provided. Exact 95% two -sided 
confidence intervals with an underlying Binomial Distribution will be provided for each 
event . Adverse  events  will also be tabulated  by attribution  (seriousness,  device -relatedness, 
and procedure -relatedness) according to the  CEC.  
The following additional efficacy measures will be analyzed at each time point to evaluate 
the efficacy of the C - Pulse® System. For these measures the averages and the average 
change from baseline to each follow -up period will be presented along with the trend over 
time:  
• Hemodynamic measures are from right heart catheterization (RHC): Cardiac 
Index (CI), Pulmonary Ar tery Pressure (PAP), Pulmonary Capillary Wedge 
Pressure (PCWP), and Cardiac Output  (CO).  
• Quality of  Life 
• Kansas City  Questionnaire.  
• Blood tests (e.g. Serum sodium, serum creatinine, serum bilirubin, hemoglobin, 
ALT and AST).  
• Concomitant cardiovascular  medications 
The following measures will also be  summarized:  
• Re-hospitalization (HF -related and  all-cause)  
• Duration of support/survival  duration.  
• Length of time to ICU and hospital  discharge  
• Device evaluation – Device log and C -Pulse® User lo g will be evaluated and 
summarized. Average daily device use will be provided for each time  period.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 52 of 150 
© Sunshine Heart  Confidential   
  
 
Sample Size Determination  
This is a single -arm study designed to determine the safety of the C -Pulse® as well as give 
an insight into the efficacy of counterpulsation.  
Because estimates from this study will be used to power the pivotal study, this study  must 
be able to provide such  estimates. A sample size of 20 implanted patients is considered 
clinically sufficient to give indications of both safety and potential efficacy. With this 
sample size, we feel we can decide whether to proceed to a pivotal study, determine 
endpoints for su ch a study, and design the study to answer the proposed hypotheses. Up 
to approximately 10 additional subjects may be enrolled to account for subjects who do 
not meet inclusion/exclusion criteria involving non -standard clinical  practices.  
Subjects for Anal ysis 
Patients will be included in two analyses. The primary analysis will be an “as - treated” 
analysis, wherein only subjects in whom the device is placed are analyzed. The secondary 
analysis will be an “intention to treat” analysis, wherein all followed -up subjects will be 
analyzed.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 53 of 150 
© Sunshine Heart  Confidential   
  
 
RISK ANALYSIS  
 
SHC has evaluated the potential risks and benefits (listed below) associated with the C -Pulse® 
and its appropriateness for therapy for symptomatic Stage C HF patients with NYHA Class III – 
ambulatory Class IV symptoms. Evaluation is based on the preclinical and clinical experiences 
to date. The adverse event definitions in the previous sections highl ight and expose a standard 
level of expected risks. Any unanticipated risks and associated events will be captured through 
the adverse event reporting.  
Potential Risks  
Risks Related to the Implantation Procedure  
Surgical risks along with mitigations specif ic to the C -Pulse® system include:  
• Damage to Cuff on implantation not  detected  
• Misplacement of ECG lead – not able to sense ‘R’ wave  appropriately  
Implantation is an invasive procedure requiring a median sternotomy and the use of 
general anesthesia and mec hanical respiratory support. The potential risks associated with 
the implant procedure also include those associated with any cardiothoracic surgery, 
including implantation of devices and include the following:  
• Bleeding  
• Infection  
• Neurological  Dysfunction  
• Renal Dysfunction  
• Cardiac  Arrhythmias  
• Pericardial Fluid Collection  
• Aortic  disruption  
• Device  Malfunction  
• Hemolysis  
• Hepatic  Dysfunction  
• Hypertension  
• Myocardial  Infarction  
• Psychiatric  Episode  
• Respiratory  Failure  
• Right Heart  Failure  
• Arterial Non –CNS Thromboembolism  
• Wound  Dehiscence  
• Death  
There may be other unforeseen risks.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 54 of 150 
© Sunshine Heart  Confidential   
  
 
Risk Related to the Investigational Device  
The C -Pulse ICP is designed to allow implantation with a satisfactorily low hospital 
mortality risk and to allow intermit tent use to augment native cardiac function as well as 
to improve the quality of life in patients in Stage C, Class III/IV heart failure. Avoiding  or 
minimizing surgical risk factors such as blood contact, anti -coagulation, bleeding, 
thromboembolism, prolo nged operating time, and device -dependent circulation are 
important when considering the design of C -Pulse®, the operative mortality risk associated 
with implanting the device and the potential for long -term benefit to a patient’s quality of 
life and heart  function. C -Pulse® has undergone extensive component and system testing. 
Potential failure modes that Sunshine Heart was not able to mitigate through testing have 
undergone individual risk analysis. Key risks associated with the device and how they 
have b een minimized or mitigated are detailed as follows.  
Lack of effect – insufficient relief from heart failure symptoms  
Given the natural toroidal shape of the ascending aorta, the greatest opportunity for 
displacement of blood from the ascending aorta with the least amount of aortic wall strain 
is for inward displacement of the outer curvature of the ascending aorta – a so-called 
“thumb -printing” action that results in a rolling back and forth of the outer aortic wall.  
The C -Pulse Cuff actuator is positioned on the outer curvature of the aorta, pre -shaped like 
a cap when deflated – the inflation/deflation port is positioned radially in the central 
aspect of the outer part of the balloon. A circumferential Dacron wrap holds the actuator 
in place. As the actuator inflates, the outer ascending aortic wall is pushed toward the 
posterior inner arc of the ascending aorta.  The wrap stays circumferential, and the 
actuator takes on a ‘lens’ shape as it fills, and displaces blood in the ascending aorta. The 
ascending aorta provides for a relatively large volume of blood displacement, which is key 
to effective  counterpulsation.  
Counterpulsation is proven to be more effective the closer this occurs to the aortic 
valve.18,19,20 The pre -systolic unloading action a t the level of the ascending aorta is more 
direct on the left ventricle. In the descending aorta, there are diffusive losses, with 
multiple branches, bi -directional blood volume displacement, and less precision of timing 
to aortic valve opening and closing . Diastolic counterpulsation on the ascending aorta, 
against the closed aortic valve, may also contribute more directly to forward cardiac 
output by creating unidirectional flow.  
The C -Pulse Cuff has a maximum target volume setting of 20 –30cc, dependent on  Cuff 
size. The degree of efficiency of counterpulsation on the ascending aorta is of the order of 
2–3 times compared to the descending aorta. As such, a displacement volume in the 
ascending aorta of 16 –20 ml might be comparable to a 40 ml descending thora cic aortic 
IAB. Although not proven by FDA, aortomyoplasty displacement volume may be as little 
as 15 ml, and counterpulsation is run at 1:2 and has good clinical effect. In addition, the 
Kantrowitz counterpulsation device is positioned in the descending a orta and has a  
 
 
18 [Furman 1970]  
19 [Gitter 1998]  
20 [Davies 2002]  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 55 of 150 
© Sunshine Heart  Confidential   
  
 
maximum capacity of 60 ml but operates clinically at a maximum of 50 –55 ml at 1:1 
counterpulsation, with good clinical effect.  
The dimensions of the ascending aorta were d etermined by literature review, and by 
cadaveric, intra -operative, and radiology studies. The cuff dimensions were based on 
these measurements; to allow a certain inflation profile that would fit most aortas, but if 
over-inflated would not allow the intima l surfaces to touch, and to at least match an 
equivalent counterpulsation volume to those achieved in humans with predicate devices 
with clinically significant results.21 The C -Pulse Cuff is thus supplied in three sizes 
designed to fit to a range of aortic  dimensions and to minimize absolute strains and rates 
of change of strains in the Cuff and aorta during inflation and deflation, whilst allowing 
significant blood volume displacement in the aorta.  
The ascending aorta was selected over the descending thoracic aorta because of:  
• surgical  access  
• counterpulsation on ascending aorta is unidirectional and more  efficient  
• ascending aortic diameter is greater than the descending thoracic therefore  less 
wall movement is required for a given volume  displacement  
• no side branches such as intercostal and spinal  arteries  
• uniform ascending aortic  anatomy  
• low incidence of atheromatous disease in the ascending  aorta  
The wrap design allows for minimal axisymetric expansion of the aorta during systole yet 
containment of the actuator ensures the proper inward inflation profile for effective 
diastolic counterpulsation.  
R wave detection by the Driver is highly specific and sensitive to ensure the Driver is able 
to deflate the balloon effectively in relation to  the onset of systole and to not remain 
inflated during any systolic event, including from ventricular premature beats, paced beats 
or other arrhythmias. The gas line is designed for high air flow rates, thus ensuring rapid 
balloon inflation and deflation.  These features are key in ensuring the C -Pulse system is 
able to effectively counterpulsate.  
If the left ventricular failure is severe, counterpulsation may not prove adequate to  support 
the patient in the short or long term. The device is not intended to  fully support the 
systemic circulation. The C -Pulse is not indicated in Class IVb heart failure patients; 
those that are not ambulatory, are inotrope dependent or have severe multi –organ  failure.  
Improving left heart function may reduce the load on the ri ght heart, however if the right 
heart failure is severe, or is secondary to primary pulmonary hypertension, then there 
exists a risk that C -Pulse counterpulsation will not be as effective.  
 
 
 
 
 
21 [Legget 2005]  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 56 of 150 
© Sunshine Heart  Confidential   
  
 
Device Failure  
The pre-shaped extra -aortic non -blood contacting design of the Cuff significantly reduces 
any consequence of device failure.  
The Cuff actuator has been designed for maximal durability by designing to minimize 
strain in the flexing membrane. Finite element anal ysis (FEA) of the current design was 
iterated using ABAQUS FEA software to reduce the strain to an acceptable level. The 
greatest area of strain is around the moving membrane. Key elements of strain related to 
the thickness of the membrane and to its edge radius. Varying aortic wall thickness 
between 1.5 – 2 mm had no significant effect. Membrane material thickness and the edge 
radius are most critical in minimizing strain in the C -Pulse Cuff.  
The membrane edge radius gets compressed to less than its molded  edge radius when 
assembled on the aorta and assumes the wall tension of the pressurized aorta. It does not 
crease. The rolling edge design has the further advantage of allowing the Cuff better 
conformation to the slight variations in individual aortic dim ensions.  
The Cuff needs to comply to the natural shape of the ascending aorta to not cause local 
pressure. The wrap is designed to maintain the actuator in position on the aorta, and to 
ensure it deflects inward. A pre -shaped wrap made of woven Dacron, and  with some 
strain relief feature in the top and bottom edges of the cuff to better transition from the 
cuffed aorta to the non -cuffed aorta has been used. Woven Dacron has proven long -term 
use clinically as both a peri -vascular wrap and as a graft replacem ent, and has only 5% 
stretch long -term in vivo . It is secured to itself using standard suturing.  
The inflation fluid is filtered room air. Accelerated over -pressure device testing indicates 
that the balloon is very unlikely to fail within the first four ye ars of continuous use.  
Premature failure may occur if the inflation membrane of the Cuff migrates under the 
wrap and causes a crease line and counterpulsation is continued. The expected 
consequences of a persistent leaking balloon may include surgical emph ysema or 
pneumothorax. Leakage of non –sterile air may also predispose to mediastinal infection. 
There is negligible risk of air embolism if the aorta is not compromised.  
There is a risk of a needle puncture hole being made intra -operatively. Surgeons are 
required to undergo multiple implantations of the cuff on a mock inflated ascending aorta 
prior to their first implantation, and there is an intra -operative check -list to reduce the 
chance of making an inadvertent needle -hole, and to check for and discover any such hole 
and thus replace the cuff.  
The Driver is designed to detect air leaks and trigger an alarm and to stop. The Driver is 
designed to detect air leaks and will immediately alarm and stop if a major leak occurs.  
The electronic system is also used to detect impending malfunctions by performing 
diagnostic tests on the system. Safety features built into the Driver are designed to protect 
the patient in the event of system failure, as well as to protect the integrity of the system. 
Safety features incl ude protection against current leakage, defibrillating voltages, failure 
of the microprocessor and power supply and over -inflation of the Cuff.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 57 of 150 
© Sunshine Heart  Confidential   
  
 
Device stoppage for any reason is not immediately dangerous to the patient, but the 
symptoms of heart failure may return. The device is engineered to resume a deflated state 
if there is a power loss or malfunction, thus the natural blood pathways of the heart and 
vasculature are preserved.  
Emboli arising from ascending aorta and risk of n eurological damage  
The device does not contact blood thus in normal use there is no foreign surfaces in 
contact with the blood. Thromboembolism may result from ascending aortic disease or 
left ventricular mural thrombus. There is a risk such emboli may cause cerebral ischemia. 
If there is a breach of the intimal lining caused by the cuff then mural thrombus may 
develop and embolize . 
Significant contraindications for implanting the C -Pulse include pre -existing ascending 
aortic atheroma, particularly intim al thickening greater than 3mm or any mural thrombus 
or mobile atheroma or calcific or aneurysmal disease of the ascending aorta. Patient 
eligibility in this regard may be determined accurately by CT scan and/or 
echocardiography: CT specificity (as compare d to epi -aortic scanning at surgery) has been 
reported at 98%. 22 
The incidence of atherosclerosis increases with age, the presence of coronary artery 
disease, and distance from the aortic valve. The ascending aorta is one of the areas least 
affected by at herosclerosis because there are no branches to create turbulence and the flow 
is vortical in nature given the natural shape of the ascending aorta.23 
In the pilot intra -operative clinical study to confirm safety and performance of a gas - 
driven C -Pulse Cuf f in patients with normal ventricles undergoing OPCAB24, the Cuff fit 
all patients and counterpulsation was effective with approximately 50 –70% compression 
of the aortic lumen. No patient that consented for the study was later excluded for aortic 
disease, and no complications arose. The right common carotid artery was monitored  over 
20 minutes intervals with the device both on and off – there was no significant difference 
in the rate of high intensity transient signals (HITS) detected and there were no post - 
operative neurological  events.  
The frequency of HITS has been studied in relation to various types of prosthetic aortic 
heart valves and LVADs. Most studies have measured HITS in the middle cerebral artery. 
Mechanical valves appear to have higher HITS ra tes25, but most appear to be harmless 
epiphenomena26. Thrombo -embolic events are prevalent in LVAD patients, and there may 
be a significant relationship between HITS and thrombo -embolic events; this may be  
 
 
 
 
 
 
22 [Davila –Roman 1999]  
23 [Leuprecht 2002]  
24 [Leggett 2005]  
25 [Laas 2003]  
26 [Nadareishvili 2002]  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 58 of 150 
© Sunshine Heart  Confidential   
  
 
influenced in part by increased hemostatic activity despite aggressive anticoagulant 
therapy and in part by the type of LVAD in situ.27,28,29 
Aortic Rupture  
There are  several examples of extra -aortic banding or counterpulsating, using different 
materials, and in different species. In humans, Dacron wraps have been used to support 
primary ascending aortic aneurysm repair as described in a number of clinical series, with  
10 year follow -up.30,31,32 Note that patients requiring an aorto -coronary graft had it placed 
via a hole cut in the Dacron wrap. There has been no reported instance of aortic dilation 
above or below the wrap. However, a poorly fitted or not well secured w rap may migrate 
and this may cause aortic erosion and subsequent false aneurysm formation.33 
The pre -shaped C -Pulse Cuff is designed to minimize the risk of migration – it is 
anatomically designed to conformally fit the toroidal ascending aorta between the  
sinotubular junction and the brachiocephalic artery. The Cuff cannot fully occlude the 
aorta, thus there is negligible risk of any abrasion of aortic wall surfaces.  
An infected Cuff may cause aortitis. If the infection is aggressive or left untreated, 
subsequent erosion of the aortic wall resulting in contained or free aortic rupture may 
result (see below).  
Device –related Infection – Intra -thoracic and Exit -site 
There exists the risk of mediastinal infection involving the implanted Cuff. This may 
occur as a result of inoculation at the time of implantation, or arise at long –term follow – 
up; the latter may be due to seeding of circulating microbes or from infection ascending 
from the exit –site. 
Perforation of the Cuff at the time of surgery is of concern as the air used to inflate the 
cuff is filtered but not sterile. There is no risk of air -leak and thus no risk of infection if 
the Cuff is not damaged. Cuffs are 100% checked during the assembly process and 
following complete assembly to confirm integrity. Bench testing of the Cuffs has 
demonstrated very high confidence of reliability beyond 6 years of cycling at significantly 
higher pressures than required clinically. However, there remains the r isk that a leak  could 
be made at the time of implant and this may potentially cause mediastinal infection. Thus 
diligence is required to ensure a needle -hole is not made at the time of surgery and if it is, 
that it be recognized and the cuff replaced prior to closing the chest. To this end, the 
methodology to implant the Cuff has been revised to allow visualization of the balloon at 
all times when placing sutures into the wrap, and intra -operative testing is a  mandatory  
 
 
27 [Nabavi 2003]  
28 [Kofidis 2002]  
29 [Wilhelm 1999]  
30 [Barnett MG 1995]  
31 [Carel 1991]  
32 [Rubiscsek 1994]  
33 [Bauer 2003]  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 59 of 150 
© Sunshine Heart  Confidential   
  
 
part of the procedure. Furthermore, bench and in vivo models have been developed to 
provide surgeon training prior to implantation.  
Infection of the cuff may lead to erosion of the aorta, with subsequent risk of septic 
thromboemboli and poses a significant problem. Early recognition of an infected Cuff and 
aggressive treatment will likely limit potential complications. Chest pain and/or fever of 
unknown origin should be thoroughly investigated. Removal of the Cuff is an option, 
which allows also surgical debridement and drainage as well as long -term antibiotic 
therapy. Other methods of cardiac support may be required in the interim.  
Infec tion risk may be reduced by careful selection of patients: excluding non -ambulatory 
patients or those in hospital on intravenous ionotropic support, those who are severely 
cachetic or have severe chronic renal failure may improve early healing post -surgery  and 
reduce the risk of early device infection. Similarly, optimal implant techniques, 
appropriate use of antibiotics and avoiding nosocomial infections in indwelling catheters 
peri-operatively will minimize implant infection rates. The protocol is specifi c to 
reducing the risk of peri -operative infection.  
The presence of a percutaneous line creates a risk of long -term infection at the exit -site 
and specific guidelines are given to care -givers and patients for managing this wound site 
long-term. The percuta neous lead has been specifically designed to reduce the risk of 
infection – the outside diameter is approximately 5 mm, the material is Silicone, and the 
tubing is soft and flexible. Flockings exist subcutaneously to anchor the Lead in a manner 
similar to Tenkhoff and Hickman catheters.34 There is no device ‘pocket’ created.  
The Cuff and ECG lead can be terminated subcutaneously and sealed if the Percutaneous 
Lead is chronically infected or otherwise damaged and needs removal.  
Risks Related to the Study Conduct  
The methods for data collection involve only standard, well -established methods and do 
not differ from normal mechanical circulatory support device implantation and heart 
failure management follow -up practice. Therefore, the clinical study re quirements of C – 
Pulse® pose no additional risk to the patient.  
Risk Minimization  
Sunshine Heart has attempted to minimize the risk of implanting the C -Pulse® through 
careful design and pre -clinical testing. Preclinical testing includes bench and animal 
testing to verify performance, software validation testing, destructive analysis and shock 
tests, and packaging qualifications.  
Risks normally associated with cardiac devices and their implantation will be minimized 
by selecting investigators who are experie nced in the diagnosis and treatment of patients 
with end -stage heart failure. In addition, investigators will be trained on the device 
operation and protocol prior to participating in the study. Product labeling is also 
provided which further addresses ris k mitigation.  
 
 
 
 
34 [Ash 1990]  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 60 of 150 
© Sunshine Heart  Confidential   
  
 
Prior to implant patients should go through a complete cardiac evaluation. After 
implantation, patients will be followed at regular intervals to confirm that the device 
parameters are appropriate and to monitor the status of the C -Pulse® system. Frequent 
follow -up will promote faster identification and resolution of adverse events. The severity 
of system related events will be minimized by restricting use of the C -Pulse® to hospitals 
equipped with redunda nt systems and staffed by qualified, trained personnel.  
C-Pulse® Potential Benefits  
Anticipated benefits of the C -Pulse® may include:  
• Relief of  symptoms  
• Improved  QOL  
• Enhanced  mobility  
• Home  discharge  
• Freedom to disconnect from the external driver for short periods of time  before 
noticing return of symptoms, particularly shortness of  breath  
• Anti–coagulants not  required  
• Increased diastolic coronary artery blood  flow 
• Reduced systolic pulmonary artery pressures and mitral  regurgitation  
• Increased cardiac  index 
• Straightforward implant surgery  
• No cardio –pulmonary  bypass  
• Avoid risk of lung and right heart complications associated with cardiopulmonary 
bypass – critical in patients with  HF 
• Preserved pericardial sac around  ventricles  
• Modular  design  
• Implanted device is very  small  
• There is no ‘pocket’  created  
• Device can be removed and infection treated if  necessary  
• Subcutaneous line is long, and multiple flocking anchors are  provided  
• Line exiting skin is made of biostable and biocompatible materials, is soft  and 
flexible, and can be removed and/or  replaced  
Overall advancement of medical and scientific knowledge that may benefit future patients 
may also be realized from this study.  
There may also be other benefits that are unforeseen at this time.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 61 of 150 
© Sunshine Heart  Confidential   
  
 
Justification for the Investigation  
The ethical conduct of a clinical trial of a new therapy relies on the promise the therapy 
has some benefit, but its efficacy to achieve this benefit is unknown and the new therapy 
always carries so me risk (clinical equipoise) .35  A careful and complete presentation of 
the scientific merit for the trial, including evidence both for and against the  investigational 
treatment, forms the ethical basis for the study design and  conduct.  
Clinical Need  
Ther e are over 1.4M people in the USA in Class III and IV heart failure. Biventricular 
pacemakers are indicated in patients with a wide QRS – approximately 30% of this 
population. Approximately 2200 heart transplants are done per year. A similar number 
might r eceive an LVAD as either a bridge to transplant or as destination therapy.  
There remain a very large number of people that may benefit from an improvement in 
their clinical status from NYHA Class III/IV to Class I/II. The targeted Patient population 
is defined by the expected natural history of heart failure. Figure 2 Figure 2  highlights the 
trend of heart failure, and the relationship of severity of heart failure with repeat 
hospitalization and with mortality.  
Figure 2. Annual survival rate and frequency of hospitalizations versus NYHA 
Classification  
It can be seen from the figure that repeat hospitalizations, on a logarithmic scale on the 
right hand side, changes at a much greater rate compared to the mortality curve, with any 
change in the NYHA Class. In the patient group indicated for C -Pulse® i.e. NYHA Class 
III–IV, patie nts are characterized as beginning to have more frequent admissions to 
hospital or increasing length of stays, with significant cost burden, but remain ambulatory. 
Patients in late Class IV have a more rapidly escalating mortality rate, and are generally 
not ambulatory at all.  
 
 
 
 
 
35 [Warner –Stevens]  

PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 62 of 150 
© Sunshine Heart  Confidential   
  
 
As the severity of disease increases, there is greater certainty regarding imminent death, 
and less certainty is required regarding the device performance and patient outcome after 
implantatio n. However, generally, increasing disease severity also increases the risk of 
adverse outcomes attributable more to the patient than the device. At lesser grades of 
severity, when death is not imminent, details regarding the expected function and quality 
of life with mechanical circulatory support become more critical. Patient preference for 
quality of life versus survival shows remarkable variation at every level of disease 
severity.  
From a practical standpoint, apart from those with high predicted in -hosp ital mortality (i.e. 
Cardiogenic Shock or Class IV with risk factors such as multi -organ failure) many patients 
exhibit a dynamic state that fluctuates over months, with exacerbations related to dietary 
indiscretion, seasonal viral infections, and other ex ogenous factors.  
Ambulatory heart failure patients on oral therapy are generally not as sick, but experience 
discomfort during any physical activity and may have discomfort while at rest. The 
hypothesis is that a mechanical circulatory support device will provide such patients with 
an improved physiologic and functional quality of life. The probability of survival at a 
specific time is not well established. End -points of interest include quality of life, all – 
cause and cardiac -related mortality, and morbidi ty, whereby a sustained improvement in 
quality of life and significantly less morbidity may be considered a significant benefit 
even if survival is equivalent. For ambulatory heart failure patients, a large component of 
the decision to receive investigatio nal therapy is the degree to which the current clinical 
status is unacceptable.  
The objective of the C -Pulse® system is to provide an effective, low risk and low cost 
mechanical heart assist device for use in patients in NHYA Class III –IV. Basic safety has  
been demonstrated on a very sick group of patients (NYHA Class III –IV) in a Pilot Study 
in Australia and New Zealand. Significantly, there was no surgical -related mortality and 
while there were very good indicators for device performance in relation to he art failure 
symptoms and cardiac function, there was an incidence of early infection. The method of 
training, the Cuff itself, the percutaneous line, and the inclusion and exclusion criteria 
have all been modified to reduce this infection risk. Furthermore , the need for a back -up 
ECG sense lead in a subcutaneous pocket has been eliminated.  
The focus of the IDE Feasibility Clinical Investigation will be on safety but also on 
examining the dose –effect of counterpulsation, much like a Phase II drug trial.  
Meas urements including Peak VO 2, Quality of Life scores, LV function and blood tests 
will be made to allow planning for a pivotal study design. Assessment will be made of all 
adverse events.  
Study Design – Control Groups  
The IDE Study will be conducted in two phases: Feasibility is an open -label, single arm 
study to determine the safety of the device as well as examine the effect of different levels 
of counterpulsation. For the Pivotal trial, an expanded randomized double -blind crossover 
study is anticipated.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 63 of 150 
© Sunshine Heart  Confidential   
  
 
The template of the double -blind, randomized control trial has emerged as the gold 
standard for evaluating new pharmacological therapies. Multiple large, randomized, 
placebo -controlled trials established angiotension -converting enzyme inhibitors as the 
cornerstone of therapy36, and more lately beta -adrenergic blocking agents have shown 
longer -term improved hemodynamics and survival in recent large trials of mild -moderate 
heart failure37. Chronic use of int ravenous inotropic drugs has not provided sustained 
hemodynamic improvements and mortality is increased. End points of survival, clinical 
status, cardiovascular function and cost -effectiveness can be evaluated using this template 
without either physician o r patient knowing who has received the new therapy being 
tested.  
The inability to provide comparable placebo therapy (e.g. sham operations), strong patient 
preferences regarding invasive procedures, and the front -loaded risk of LVAD studies 
have complicate d the evaluation of new mechanical circulatory support devices for 
advanced heart failure using a randomized control trial template. The impact of the  device 
is more transparent than that of a drug, in part because the most obvious risks are front - 
loaded compared with those from new drugs. The combination of debilitating disease and 
unblinded therapy raises ethical issues – patients consenting to new trials are likely to be 
already biased toward the procedure and thus may perceive randomization to the cont rol 
arm as a loss of hope, with potentially deleterious impacts on individual outcomes.38 
Furthermore, patient preference for specific therapies perceived to be life –saving may 
limit enrollment into the randomization  process.  
Resynchronization therapy has,  because of the nature of the device, allowed use of a 
randomized, double -blinded trial structure to evaluate its safety and efficacy. The device 
requires surgery for implantation, thus exposing front –loaded risk to all patients, but it can 
be tuned to opt imize bi -ventricular timing or used in a simple pacing mode.  
C-Pulse acts to a) increase coronary blood flow, b) reduce ventricular afterload to reduce 
the workload of the left ventricle, and c) increase cardiac output. C -Pulse® offers the 
unique situation  whereby the level of counterpulsation can be adjusted without the patient 
being cognizant of how much benefit he/she is receiving from the device. Cohen et al 
showed in a limited study of 20 patients a significantly higher velocity time integral  across 
the LV outflow tract resulted when counterpulsated at 1:1 versus at 1:8. They did not 
show any difference with varying the balloon volume from 40 to 32  cc.39 
 
 
 
 
 
 
 
 
 
 
36 [Davis 1979]  
37  [Packer  2001]  
38  [Neaton  2007]  
39 [Cohen 1995]  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 64 of 150 
© Sunshine Heart  Confidential   
  
 
Trial End –Points  
The End Points for a Clinical Trial are chosen according to the severity of disease in the 
population selected. The target population for this trial has been defined widely to  include 
patients with the best natural history compatible with the degree of certainty that the 
device will provide an improvement. This will help maximize the generalization of the 
results. The primary endpoint should be clinically relevant and sensitive to the 
hypothesized effect of the treatment. End -points should be obtainable in all patients and 
be inexpensive to measure. Endpoints may include clinical outcomes such as death or 
morbid events such as repeat hospitalizations, or measures of quality of li fe such as 
NYHA Class or QOL scores. Surrogate measures of heart failure for heart assist devices 
have not been established but may strengthen a trial by showing correlation with clinically 
relevant findings. Composite endpoints may include clinical outcom es and surrogates,  but 
should avoid combining safety and efficacy outcomes; composite structure has the 
advantage of reducing sample size, though selection of composites requires that the 
treatment has similar affect for all endpoints  selected.  
The C -Pulse® is targeted at Class III –IV patients, where mortality is difficult to predict, 
but the quality of life of patients is poor enough to consider the need for an implantable 
heart assist device. The primary endpoint in this Feasibility study is safety, and w ill be 
assessed by showing the device is not associated with an unacceptable mortality or 
morbidity profile in the selected patient population, as judged by the DSMB.  Performance 
variables will allow statistical planning of the Pivotal study and selection of appropriate 
endpoints and study  design.  
Studies regarding NYHA Class III and IV patients also are useful to identify boundaries of 
expected changes in endpoints.  
Summary  
The objective of the feasibility clinical investigation shall be related to establi shing or 
verifying the safety, and identify trends of efficacy and performance of the device, when 
used for its intended purpose and according to the documented instructions. The study 
may be expanded to a pivotal randomized double -blinded trial after taki ng into account  the 
serious adverse event profile and anticipated levels of performance and efficacy as 
compared to other circulatory support  devices.  
The primary objective of the feasibility study is to demonstrate reasonable safety in 
patients in Class I II–IV heart failure. Placing C -Pulse® in suitable patients in ACC/AHA 
Stage C; NYHA Class III –IV HF with the objective of improving the patient’s quality of 
life and cardiac performance is justifiable based on the results of testing of the C -Pulse® 
device to date, and on the efficacy of clinical performance and safety data of similar 
devices, such as biventricular pacemakers, other forms of chronic counterpulsation, and 
LVADs.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 65 of 150 
© Sunshine Heart  Confidential   
  
 
STUDY OVERSIGHT AND INTEGRITY  
 
DESIGNATION OF SPONSOR , DATA MANAGER , AND AUDITOR  
 
 
 
Role  Organization  Address  Contact  Numbers  
 
 
Sponsor  Sunshine Heart, Inc. 12988 Valley View Rd 
Eden Prairie 
Minnesota  55344  Primary Contact: 
Aleela  Baune  
 
952.345.4200  
 
 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 66 of 150 
© Sunshine Heart  Confidential   
  
 
MONITORING PROCEDURES  
 
The Sunshine Heart C -Pulse™ study will be monitored according to the guideline 
summarized below.  
 
SUMMARY OF MONITORING PROCEDURES AND RESPONSIBILITIES  
 
 
It is the responsibility of the study sponsor (Sunshine Heart Inc.) to ensure that proper 
monitoring of the investigation is conducted and that IRB review and approval of the 
investigation is obtained. Monitoring visits will occur based on implant volume at the 
center or at least annually. Adequately trained Sunshine Heart or  delegates appointed by 
the study sponsor will do study monitoring in order to ensure that the investigation is 
conducted, recorded and reported in accordance with:  
• The signed Investigator  Agreement  
• The Investigational Plan  
• Applicable laws and regulations.  
Monitoring will be planned at the study site to assure compliance with the study protocol. 
The sponsor (or appropriate designee) must therefore be allowed access to the patients’ 
files as per the informed consent at the investigator’s site when so requested.  
 
INTERIM MONITORING VISITS  
 
 
Routine monitoring visits are made periodically to assess the Investigator’s adherence to 
the Investigational Plan, IRB review of the progress (if appropriate), maintenance of the 
records and reports and selection r eview of source documents for accuracy, completeness, 
legibility and omissions. The following factors will be taken into account when 
determining the frequency of the monitoring visits: patient accrual at each center, total 
number of patient enrolled at ea ch center, and protocol compliance at each center. Each 
participating institution will be monitored once per year, at a minimum.  
The monitors will acquire information to assess the progress of the study (toward meeting 
study objectives) and identify any co ncerns that stem from observation of device 
performance and/or review of the investigator’s patient records, study management 
documents, device tracking and Patient Informed Consent documents. Resolution of 
concerns and completion of assigned tasks may be documented by the monitors. Source 
data verification and review of any ongoing finding may occur during monitoring visits.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 67 of 150 
© Sunshine Heart  Confidential   
  
 
STUDY CLOSURE  
 
 
Study closure is defined as a specific date that is determined when Sunshine Heart 
regulatory requir ements have been satisfied per the Investigational Plan (IP) and/or by a 
decision of the business leaders for Sunshine Heart. Study closure visits will be conducted 
at all clinical sites in order to review record retention requirements, device disposition 
requirements, etc. with site personnel. A telephone contact may take the place of a study 
closure visit if appropriate (e.g. low patient enrollment, recent monitoring visit, etc.)  
 
NAME AND ADDRESS OF STUDY MONITORS  
 
 
Sunshine Heart will monitor investigational sites to ensure that the study is conducted, 
recorded and reported in accordance with the protocol, standard operating procedures 
(SOPs) and applicable regulatory requirements.  
Monitoring visits will be conducted by trained Sunshine Heart or designated 
representatives. A Monitoring Plan will be completed for the study and will identify the 
frequency of monitoring and further identifies the names of monitors.  
 
STUDY SAFETY  
 
 
Clinical Events Committee (CEC)  
A CEC will be established by  Sunshine Heart or designee to assess, review, and classify 
all adverse events and deaths during the clinical study. Classification will include device - 
relatedness, seriousness, and procedure -relatedness. The committee will consist of a 
minimum of three p hysicians including a chairperson appointed by Sunshine Heart or the 
CEC committee. The CEC will regularly review and adjudicate reported adverse events 
including deaths.  
At the onset of the study, the CEC, along with support from Sunshine Heart will estab lish 
a charter outlining the minimum data required and the algorithm followed in order to 
classify an event. This charter will be approved by the committee during the first round of 
meetings. Members will be provided data summaries from the clinical study in a blinded 
fashion without site, patient or physician identification.  
Data and Safety and Monitoring Board (DSMB)  
A DSMB will convene, composed of a least one heart failure cardiologist, cardiac 
surgeon, medical doctor of associated disciplines and a bio statistician who are not directly 
involved in the trial. The DSMB will review the study data after enrollment of the first 
five patients. Enrollment of further patients will occur as the DSMB reviews the data.  
The DSMB will provide a report following the r eview and may recommend to Sunshine 
Heart to continue, modify or stop the trial based on their findings. The DSMB will 
provide further evaluation at least twice per year and after the first five patients are 
enrolled. If slow enrollment is experienced, the  DSMB may meet less frequently.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 68 of 150 
© Sunshine Heart  Confidential   
  
 
Based on the data, the DSMB may recommend to Sunshine Heart to modify or stop the 
trial. All final decisions, however, regarding the trial modifications, rest with Sunshine 
Heart and the Medical Advisory Boar d. 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 69 of 150 
© Sunshine Heart  Confidential   
  
 
TRAINING PROCEDURES  
 
Site training is required at all investigational sites. Each study site will be trained on all aspects of 
the protocol, device implantation and operation, as well as patient training in preparation for 
discharge. At the end of the training course, all participants should be competent in ensuring 
optimum care of the patient. In addition, each site will have identified a local expert user to 
provide continuing training to team members.  
The training program  will be conducted according the Sunshine Heart standard operating 
procedures and quality system requirements. A summary of the contents and audience are 
included in the table below.  
 
 
Training component  Audience  Format required  
Surgical training  • Surgeon  • Cuff mock implant  training  
• Observe Surgery, if  possible  
• Mentor support at  implant  
Expert users training  • Cardiologists  
• Clinical  coordinator  
• Surgeon  • Product  overview  
• Protocol  overview  
• System/Programmer  training  
Site Initiation /protocol 
training  • All investigators  
• Study  coordinator  
• Back -up study coordinator must be 
trained on protocol, ICH/GCP and 
investigator responsibilities  • Self directed review of 
presentation by ALL 
Investigators and self  assessment 
with optional independent 
education by Clinical trial  staff 
 
AND  
 • Meeting with key 
investigators/personnel & 
clinical coordinator to discuss 
recruitment, logistics for 
equipment storage,  monitoring 
schedule  
Clinical /support staff  • Emergency,  • Product  overview  
• Implant  overview  
• Protocol  overview  
• Practical “get to  know”  
equipment session  training (as appropriate)  • Intensive  care 
 • Coronary  care 
 • Cardiothoracic surgical ward  
 • Cardiac  ward  
 • Operating Room  
 • Physiotherapy  
 • Nutrition  
 • Occupational  Therapy  
 • Infectious  Diseases  
 • Patients Local  EMT  
 • Patients Primary  Caregivers  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 70 of 150 
© Sunshine Heart  Confidential   
  
 
PROTOCOL DEVIATIONS  
 
A Protocol Deviation is defined as an event where the clinical investigator or site 
personnel did not conduct the study according to the investigational plan, protocol or the 
investigator agreement.  
Prior notification to the study manager is expected in those situations in which the 
investigator anticipates, contemplates, or makes a conscious decision to depart from the 
procedure specified in the Investigation Plan, except when necessary to protect the life or 
the physical well -being of a patient in an emergency. Prior notification is required in 
situations where the unforeseen circumstances are beyond the control of the Investigator 
(e.g. i nadvertent mistakes, equipment failure, patient ill and unable to perform testing, 
etc.).  
Protocol deviations must be recorded on the Protocol Deviation eCRF. Include a 
description of the deviation, justification for the deviation, corrective action and wh ether 
the clinical manager was notified prior to the deviation.  
Deviations will be reported to the clinical manager regardless of whether medically 
justifiable, pre -approved by the clinical manager or taken to protect the patient in an 
emergency. Protocol deviations should be reported as soon as possible upon notification 
of the deviation. Study deviations may be discovered through variety of sources, such as 
during the data review, telephone conversations, and site monitoring. Report protocol 
deviations to  your IRB in accordance with IRB policies and/or local laws.  
FDA regulations require the investigators to notify the sponsor and reviewing IRB  within 
5 working days for the following  deviations:  
Deviation from the investigational plan to protect the life o r physical well – 
being of a patient in an  emergency.  
“An investigator shall notify the sponsor and the reviewing IRB (see 56.108(a)(3) 
and (4) of any deviation from the investigational plan to protect the life or physical 
well–being of a patient in an emergency. Such notice shall be given as soon as 
possible, but in no event later than 5 working days after the emergency occurred.” 
812.150(a)(4)  
No informed consent prior to device use.  
“If an investigator uses a device without obtaining informed consent,  the 
investigator shall report such use to the sponsor and the reviewing IRB within 5 
working days after the use occurs” (21 CFR 812.150(a)(5))  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 71 of 150 
© Sunshine Heart  Confidential   
  
 
A Protocol Deviation eCRF is to be completed for each study protocol deviation, 
including but no t limited to:  
• Failure to obtain informed  consent  
• Incorrect version of informed consent document  used 
• Patient did not meet inclusion/exclusion  criteria  
• Missed follow –up visit 
• Follow –up visit out of  window  
• Failure to adhere to protocol required  testing  
• IRB a pproval not obtained prior to  implant  
• Implant occurring during IRB lapse of approval 
The following will not be considered protocol  deviations:  
• Minor titration of cardiovascular medication regimen  including:  
• Any downward titration of medications less than 50% of initial  dose 
• Any upward titration of medication greater than 100% of initial  dose 
• ACE/ARB may be added after implantation if  tolerated  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 72 of 150 
© Sunshine Heart  Confidential   
  
 
RECORDS AND REPORTS  
 
INVESTIGATIONAL RECORDS  
 
 
The investigator is responsible for the preparation (review and signature) and retention of 
all records cited below. All of the below records, with the exception of case history 
records, should be kept in the Investigator Site File, i.e., the study binder provided to the 
investigator. The follow ing records are subject to inspection and must be retained for a 
period of two year (or longer as local law requires) after the study closure.  
• All correspondence that pertains to the  investigation.  
• Patient’s case history records, including the signed patient informed consent  form; 
all relevant observations; observations of adverse events; medical history; implant 
and follow –up data; documentation of the dates and reasons for any deviations 
from the  protocol.  
• Device & Equipment Disposition Logs, contain ing Site delivery dates of  devices, 
implant dates and returned to Sponsor dates, quantities and serial numbers of 
devices delivered at the site, quantities and serial numbers of devices returned to 
Sponsor, expiration dates and patient IDs of the patients  implanted.  
• Signed Clinical Trial Agreement and current curriculum  vitae.  
• IRB documentation and  correspondence.  
• Center personnel training documentation  forms.  
 
INVESTIGATOR REPORTS  
 
 
The investigator is responsible for the preparation (review and signature) and submission 
to the sponsor of all eCRFs, all death and adverse events (except unavoidable adverse 
events) and any deviations from the investigational plan; other reports are list ed in Table  
6Table 6 . All reports are subject to inspection and to the retention requirements described 
above for the investigator  records.  
If an IRB takes any action as a result of this study, copies of all pertinent  documentation 
must be forwarded to the  sponsor.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 73 of 150 
© Sunshine Heart  Confidential   
  
 
Table 6.  Investigator Reports  
 
Report  Submit to:  Description  
Unanticipated Adverse  Sponsor and IRB  If an unforeseen complication  
Device Effect   is determined to be related to  
  the device, this information  
  must be reported to FDA, IRB,  
  and Sponsor.  
Withdrawal of IRB  Sponsor  The investigator must report a  
Approval   withdrawal of the reviewing  
  IRB approval within 5 working  
  days.  
Progress Report  Sponsor and IRB  The investigator must submit  
  this report if the study lasts  
  more than one year on an  
  annual basis.  
Deviation from the  Sponsor and IRB  The IRB and sponsor must be  
Investigational Plan   notified within 5 working days  
  of the event of an emergency  
  deviation from the IP to protect  
  the life or physical well –being  
  of a patient. Except for the  
  deviations under emergencies,  
  prior notification must be  
  submitted to Sunshine Heart.  
Failure to Obtain Informed  Sponsor and IRB  The investigator must make  
Consent   notification within 5 working  
  days after device use.  The 
  report must include a brief  
  description of the  
  circumstances justifying the  
  failure to obtain informed  
  consent and include written  
  concurrence by a licensed  
  physician not involved in the  
  investigation.  
Final Report  Sponsor and IRB  A final report must be  
  submitted within 3 months  
  after termination or completion  
  of the study.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 74 of 150 
© Sunshine Heart  Confidential   
  
 
SPONSOR RECORDS  
 
 
Sunshine Heart will retain the following records:  
• All correspondence which pertains to the  investigation.  
• Device disposition records containing site delivery date of device, implant  device 
serial numbers, expiration dates, quantities of devices shipped and  returned.  
• Signed Clinical Trial Agreemen ts, financial disclosure forms, and recent CV  of 
investigators.  
• All adverse events (except unavoidable adverse events), deaths and  complaints.  
• All eCRFs that are submitted, samples of the informed consents,  investigational 
plans, and report of prior  investigations.  
 
SPONSOR REPORTS  
 
 
 Table 7.  Sponsor Reports  
Report  Submit to:  Description  
Unanticipated  FDA, all IRBs and  Sunshine Heart will report any and all unanticipated  
Adverse Event – all Investigators  device -related adverse event evaluation within 10  
Device Related   working days of receipt of notice.  
Withdrawal of IRB  FDA, all IRBs and  Notification will be made within 5 days.  
Approval  all Investigators   
Withdrawal of FDA  All IRBs and  Notification will be made within 5 working days.  
Approval  Investigators   
Current Investigator  FDA  Sunshine Heart will submit a list of names and  
List  addresses of all participating investigators at 6 - 
  month intervals (starting at 6 -month after FDA  
  approval).  
Progress Report  FDA, all IRBs and  A progress report will be submitted at least yearly.  
 all Investigators   
Recall and  FDA, all IRBs and  Notification will be made within 30 working days  
Disposition  all Investigators  and will include the reasons for any request that an  
  investigator return, repair or otherwise dispose of  
  any devices.  
Final Report  FDA, all IRBs and  Sunshine Heart will notify FDA within 30 working  
 all Investigators  days of the completion or termination of the  
  investigation. A final report will be submitted  
  within 6 months after completion or termination.  
Failure to Obtain  FDA/IRB  A copy of the investigator’s report will be submitted  
Informed Consent   within 5 working days of the notification.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 75 of 150 
© Sunshine Heart  Confidential   
  
 
PUBLICATION STRATEGY  
 
Sunshine Heart will form a publication committee that includes participating investigators. 
The committee will finalize a publication plan. The scientific validity and timing of 
publications will be evaluated in order to maximize the benefits der ived from the 
publication of the North American clinical data of the study. In general, publications 
utilizing worldwide data will be managed as described below.  
 
PUBLICATION COMMITTEE  
 
 
The publication committee will be defined by the time enrollment for the primary 
objective is completed. Sunshine Heart will form a publication committee that includes 
participating investigators, the VP of Clinical Studies, and other Sunshine Heart 
personnel.  
The publication committee is responsible for over seeing the development of case reports, 
manuscripts, and abstracts according to the Publication Strategy, identifying and 
appointing the manuscripts/abstracts first author(s)/writer(s) and identifying Sunshine 
Heart personnel responsible for assisting the first author. The publication committee will 
meet approximately annually to refine the publication strategy.  
The publication committee reviews not only the main publications, but also ancillary 
publications. If necessary, specified authorship criteria may be applied for ancillary 
publications. The Committee may decide that no case reports, publications or abstracts 
will be prepared prior to the end of the study, or not on individual center data.  
Being a member of the subcommittee gives no privileges for aut horship selection.  
Centers will be appraised of the objectives of the Publication Committee. Participating 
centers will agree that publication of the aggregate data from this multi -center trial takes 
precedence over results from an individual center.  
 
AUTH ORSHIP SELECTION  
 
 
The first author will be selected on the basis of the following:  
• A significant contribution to the design of the study and/or development of  the 
product;  
• A significant contribution to patient enrollment into the  study;  
• High procedure volume and high quality of data as determined by the  clinical 
study  requirements;  
• Demonstration of a high level of interest in the performance of the product and/or 
the unique product features, applications, and the ability to write, review, edit , and 
present the  publication;  
• A demonstration of a good publication  history;  
• A willingness to contribute to the  publication;  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 76 of 150 
© Sunshine Heart  Confidential   
  
 
Appropriate geographic representation if a geographic region enrolls a significant number 
of patients. The Publication Committee recommends the number of authors per region.  
Appropriate Sunshine Heart personnel or representatives (e.g. clinical study personnel, 
statistician, and field personnel) are considered based on substantive contributions to the 
study or publication effort.  
All investigators not listed as co -authors will be acknowledged as the “Sunshine Heart 
C-Pulse® Investigators” and will be individually listed according to the applicable 
scientific journal.  
 
REVIEW AND COMMUNICATION GUIDELINES  
 
 
Investigators will receive a communication regarding the authorship selection, the 
publication co -authors and to which scientific platform the publication will be submitted.  
Prior to the submission of a publication (abstracts and manuscripts), the Sunshine  Heart 
study team, publication committee and all co -authors will review and approve the  contents 
and scientific platform. No individual center or individual investigator publications will 
be permitted for the Sunshine Heart C -Pulse® study unless agreed upo n by the Publication 
Committee, to ensure consistency of methods, data integrity, and appropriate publication 
timing.  
Investigators who contribute patient data will be provided a copy of the final 
manuscript/abstract.  
For publication of investigator’s own data, Sunshine Heart will limit its review to a 
determination of whether or not confidential information is disclosed or if technically 
incorrect statements are made and will not attempt to censor the data or conclusions.  
 
ANCILLARY PUBLICATIONS  
 
 
The pub lication committee will review ancillary requests. Ancillary publications include 
those reporting on a subset of the patient population or reporting a specific aspect of the 
study.  
Requests for publications using regional data beyond the North American res ults will be 
evaluated for scientific validity and the ability of Sunshine Heart to provide resources. 
The publication committee must approve requests and will need to ensure that requests  do 
not present conflicts with other geographical regions. If multip le geographies contribute 
to data, co -authorship will be representative, using the guideline for authorship selection 
described  above.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 77 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX A: ABBREVIATIONS AND ACRONYMS  
 
 
 
CEC  Clinical Events  Committee  
MAB  Medical Advisory  Board  
AE Adverse  Events  
DSMB  Data Safety and Monitoring  Board  
HF Heart  Failure  
ECG  Electrocardiogram  
BTT  Bridge to  transplant  
VAD  Ventricular Assist  Device  
TTE  Transthoracic  echocardiography  
FDA  Food and Drug  Administration  
TEE  Transesophageal  echocardiography  
CRT  Cardiac Resynchronization  Therapy  
NYHA  New York Heart Association  
QOL  Quality of  Life 
LVAD  Left Ventricular Assist  Device  
DT Destination  Therapy  
IAB Intra Aortic  Balloon  
IDE Investigational Device  Exemption  
ICP Implantable Counterpulsation  Pump  
PIL Percutaneous Interface  Lead  
IR Infra –red 
CPX  Cardiopulmonary Exercise  Testing  
IRB Investigational Review  Board  
MLWHF  Minnesota Living With Heart  Failure  
KCCQ  Kansas City Cardiac Quality of Life  Questionnaire  
CXR  Chest Xray  
ECHO  Echocardiogram  
eCRF  Electronic Case Report Form Template  
ICU Intensive Care  Unit 
IV Intra –venous  
PRBC  Packed Red Blood  Cells  
 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 78 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX B: NATIONAL CO –PRINCIPAL INVESTIGATORS  
 
 
The following physician –investigators have been designated as Principal Investigators for this 
study:  
 
William T. Abraham, M.D.  
Chief of Cardiovascular Medicine 
Ohio State University  
Division of Cardiovascular Medicine 
Room 110P DHLRI  
473 W. 12th Ave.  
Columbus, OH  43210 –1252  Patrick McCarthy, M.D.  
Chief, Divisio n of Cardiothoracic 
Surgery  
Co–Director, Bluhm  Cardiovascular 
Institute  
Heller –Sacks Professor of Surgery  
Northwestern University Feinberg 
School of Medicine  
201 East Huron Street, Galter 11 –140 
Chicago, IL 60611 –2968  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 79 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX C: PARTICIPATING INSTITUTIONS  
 
Up to 9 centers in the US and potentially some OUS centers will participate in the study. The 
following table represents the centers proposed for investigational sites.  
 
Site Name/Co -Principal & Principal 
Investigators  Investigator Contact Info  
Ohio State University Medical Center  
Principal Investigator: 
Garrie Haas, MD (HFC)  Ohio State Heart Center  
473 West 12th Ave, Suite 200 DHLRI 
Columbus, OH 43210 -1252  
 Ph (614) 293 -4967  
Fax (614) 247 -7789  
Northwestern University  
Feinberg School of Medicine 
Principal Investigator:  
Edward C. McGee, Jr.MD (CTS)  Northwestern University Feinberg School of Medicine 
Bluhm Cardiovascular Institute  
201 East Huron Street, Galter 11 -120 
Chicago, Illinois 60611 -2968  
Ph (312) 695 -3121  
Fax: (312) 695 -1903  
Penn State Hershey Medical Center  
Principal Investigator: 
Walter Pae, MD (CTS)  Penn State Milton S. Hershey Medical Center 
Division of Cardiology, H047  
500 University Drive, Room H1511 
Hershey, PA 17033 -0850  
 Ph (717) 531 -8329  
Fax: (717) 531 -8521  
University of Alabama at Birmingham  
Principal Investigator:  
Salpy Pamboukian, MD (HFC)  Division of Cardiothoracic Surgery 
University of Alabama at Birmingham 
760 THT, 1900 University Blvd.  
Birmingham, AL 35294  
 Ph: (205) 934 -5486/ (205) 934 -3368  
Fax: (205) 975 -2553  
University of Louisville Jewish 
Hospital  
Principal Investigator: 
Sumanth Prabhu, MD (HFC)  University of Louisville -Jewish Hospital 
201 Abraham Flexner Way, Suite 1200  
Louisville, KY 40202  
Ph (502) 629-2555  
Fax (502) -629-2551  
United Heart and Vascular Clinic 
Principal Investigator:  
Alan Bank, MD (HFC)  Allina Hospital and Clinics 
2925 Chicago Ave  
Minneapolis, MN 55407  
Saint Luke’s Hospital – Mid America 
Heart Institute  
Principal Investigator: 
Sanjeev Aggarwal, MD  (CTS)  Saint Luke’s Hospital of Kansas City  
4401 Wornall Road 
Kansas City, MO 64111  
To be determined – will provide in 
Progress Report once IRB approval 
received  To be determined  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 80 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX D: IRB LIST  
 
A list of the IRB contacts for each participating investigational center is included below.  
 
Site Name/Principal Investigator  Institutional Review Board  IRB Chairperson  
Northwestern University 
Feinberg School of Medicine  
Principal Investigator:  
Edward C. McGee, MD (CTS)  Northwestern University  
Office for the Protection of Research Subjects 
750 North Lake Shore Drive, Suite 700 
Chicago, Illinois 60611  Darren R. Gitelman, MD  
Ohio State University Medical 
Center  
 
Principal Investigator: 
Garrie Haas, MD (HFC)  Western Institutional Board (WIRB) 
3535 7th Avenue SW  
Olympia, WA 98502 -5010  Theodore D. Schultz, J.D.  
Penn State -Milton S. Hershey 
Medical Center  
 
Principal Investigator: 
Walter Pae, MD (CTS)  Penn State College of Medicine  
Penn State Milton S. Hershey Medical Center 
Human Subjects Protection Office, 
Institutional Review Board  
Room ASB 1140  
600 Centerview Drive, PO Box 855 Hershey, 
Pennsylvania 17033 -0855  Kevin Gleeson, MD  
University of Louisville 
Jewish Hospital  
Principal Investigator: 
Sumanth Prabhu, MD (HFC)  University of Louisville 
MedCenter One, Suite 200 
501 E. Broadway  
Louisville, KY 40202 -1798  Laura L. Clark, MD  
University of Alabama at 
Birmingham  
 
Principal Investigator:  
Salpy Pamboukian, MD (HFC)  Western Institutional Board (WIRB) 
3535 7th Avenue SW  
Olympia, WA 98502 -5010  Theodore D. Schultz, J.D.  
United Heart and Vascular Clinic  
 
Principal Investigator: 
Alan Bank, MD (HFC)  Allina Hospital and Clinics IRB 
2925 Chicago Ave  
Minneapolis, MN 55407  Thomas Ducker, MD  
Saint Luke’s Hospital – Mid 
America Heart Institute  
Principal Investigator: 
Sanjeev Aggarwal, MD  (CTS)  Saint Luke’s Hospital of Kansas City  
4401 Wornall Road 
Kansas City, MO 64111  Alan Forker, MD  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 81 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX E: SUMMARY OF PREVIOUS STUDIES  
 
Experience to date by Sunshine Heart provides evidence of safety and performance. These 
include:  
 
INTRA –OPERATIVE CLINICAL FEASIBILITY STUDY  
 
 
The aim of this study was to determine the safety and performance of a new method  of 
non blood contacting counterpulsation utilizing an inflatable cuff (C -Pulse) around the 
ascending  aorta.  
In 6 patients undergoing first time off pump coronary bypass surge ry via sternotomy, the 
C-Pulse was secured around the ascending aorta and attached to a standard 
counterpulsation console. At baseline, and with 1:2 and 1:1 augmentation, hemodynamic 
and echocardiographic parameters of ventricular function and coronary flo w were 
measured. High intensity transient signals (HITS) were measured using transcutaneous 
Doppler over the right common carotid artery.  
No complications occurred.  
With C -Pulse there was no significant change in heart rate and blood pressure, and no 
increase in HITS. There was a 67% increase in diastolic coronary blood flow (mean left 
main diastolic velocity time integral 15.3 cm unassisted vs 25.1 cm assisted, p<0.05).  
Measurements with transesophageal echocardiography, at baseline and with 1:1 
count erpulsation, demonstrated a 6% reduction in end diastolic area (p = NS), 16% 
reduction in end systolic area (p < 0.01), 31% reduction in LV wall stress (p < 0.05), and a 
13 % improvement in fractional area change (p < 0.005). It was concluded that C -Pulse 
counterpulsation augments coronary flow and reduces left ventricular afterload.  
 
LONG–TERM EXTRA –AORTIC BALLOON COUNTERPULSATION IN SHEEP  
 
 
This study was undertaken to examine the effect of chronic counterpulsation with C -Pulse 
on the integrity of the as cending aorta in sheep at 5 and 10 months.  
A pre -shaped cuff, consisting of a polyurethane balloon and polyester wrap, was 
implanted around the ascending aorta via a left mini -thoracotomy in 11 adult sheep. An 
endocardial ECG sensing lead was implanted via  the right external jugular vein. The 
balloon’s gas line and the sensing lead were brought out percutaneously over the back and 
connected to a Datascope 90 IABP console.  
Sheep were counterpulsated for approximately five and ten months. Prior to post -mortem , 
intra-aortic ultrasound examination was completed to examine balloon function.  
Following euthanasia, an autopsy was conducted in all sheep; particular attention was paid 
to the heart, brain and kidneys. Detailed histology was completed on the heart and g reat 
vessels with the attached device, from each sheep.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 82 of 150 
© Sunshine Heart  Confidential   
  
 
Intra -aortic ultrasound showed each cuff to be inflating and deflating in a normal pattern 
following 5 and 10 months operation. Sheep were terminated at five months (6) and 10 
months ( 5). 
One sheep was euthanized at 5 months because it became ill over several days; at autopsy 
it was found to have a bacterial infection involving the cuff and the aorta resulting in a 
contained aortic rupture. In two other sheep (at 5 and 10 months, respec tively) non - 
disruptive aortitis was noted at post -mortem and this was confirmed by microscopic 
pathology.  
Hence the thoracic aorta was assessed microscopically in 8 sheep; 4 at 5 months and 4 at 
10 months. Histology of the aortic wall at the root and arch appeared normal. Sections 
through the mid -ascending aortas revealed the peri -aortic implants were well incorporated 
by the adventitial peri -aortic tissues and that there was no disruption to the endothelial 
surfaces. Histology demonstrated that for ea ch of the 8 sheep the intima and inner half of 
the media, measuring 0.6 –0.9 mm thick, appeared normal. Findings in the outer one third 
to one half of the aortic wall included muscular atrophy, thin -walled blood vessels, 
petechial haemorrhages, small focal strips of coagulative necrosis (0.1 –0.3 mm thick) and 
viable reparative tissue responses. Those at 10 months, displayed a recognizable 
reparative microvascular (arterial and venular) pattern with less necrosis than at 5 months. 
The changes were circumferen tial. While the cuffed aortic wall was thinner than the 
normal wall, there was no evidence of progressive damage to the inner media and intima 
when comparing results from sheep at 5 months to those at 10  months.  
In conclusion, the structural integrity of b oth the counterpulsation cuff and the inner wall 
of the ascending aorta enclosed by the cuff remained intact for 10 months. Intermittent 
ongoing focal areas of damage and repair in the outer media were related to the device. 
Infection was an important comp lication leading to aortic disruption in one case. The 
anatomical intimacy between aorta and pulmonary artery in the sheep is closer than that 
observed in humans, and the aorta is more friable. Also, in this sheep study the cuff was 
inflated to transmural pressure at least twice that considered for humans.  
 
PROSPECTIVE OBSERVATIONAL STUDY  
 
 
Following preclinical studies and the intra -operative clinical study, a prospective 
observational study of the C -Pulse in NYHA Class III –IV end -stage heart failure patients 
was undertaken. Endpoints were safety, quality of life and cardiac performance. Five 
patients aged 54 –73 years underwent implantation.  
There were no hospital deaths. All patients were discharged to rehabilitation and/or home. 
All patients were able to tolerate the device being turned off for short periods.  
There was a mean improvement of one NYHA class at one month. The cardiac index was 
increased and systolic pulmonary artery pressure reduced. One patient died of progressive 
multi -organ fa ilure at 3 months, and two required device removal at 5 & 7 weeks 
respectively due to mediastinitis – one subsequently died from persistent intrathoracic 
infection . One patient was successfully transplanted at one month and one was 
symptomatically and hemo dynamically improved on the device at 6 months follow -up. 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 83 of 150 
© Sunshine Heart  Confidential   
  
 
This latter patient developed an exit -site infection with Pseudomonas and died at 7 months 
of sepsis -related multi -organ failure.  
In this first human long -term experience, the C -Pulse was safely implanted and was able 
to be turned off for brief periods. C -Pulse provided important relief of heart failure 
symptoms and improved cardiac performance. Early infection is likely related to the 
implant procedure. The device, training, implant procedure and peri -operative care 
procedures have been modified to reduce infection risk. An expanded feasibility study is 
warranted.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 84 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX F: LABELING AND OPERATOR MANUAL  
 
 
 
 
 
 
 
 
Not related to this change – not resubmitted.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 85 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX G: SAMPLE HIPAA DISCLOSURE  
 
Authorization for the Use and Disclosure of Protected Health Information (HIPAA) 
C-Pulse® Implantable Counterpulsation Pump (ICP) US Feasibility Study  
Sponsor:  
 
 
Principal Investigator:  
 
Phone Number:  
 
 
This section is asking you to authorize the use and disclosure of your health information for the 
C–Pulse® Implantable Counterpulsation Pump (ICP) which is a Heart Assist Device Study. To do 
that you need to know:  
• The kind of health information a bout you that the study will collect and use;  this 
information  includes:  
- medical chart  review  
- and laboratory test  results;  
• The reasons that we are doing this study, which have been described to you earlier, can  be 
found in the Informed Consent section “Why Is This Study Being Done?”  
- Dr. < insert site PI, or whoever may replace this doctor > and the research staff  are 
responsible for collecting this information here at < insert institution  name >. 
- This clinical site will send your information on a fo rm to the sponsor, which 
maintains of the database for the  study.  
- Investigators for study, including representatives from the sponsor, will use your 
information to better understand how the C –Pulse® improves or does not improve 
life for heart failure patients, but they will not use your name or social security 
number.  
- The investigator and sponsor who make sure that your rights and safety are 
protected and that study findings are accurate may also need to see  information 
about you in your  record s. 
• This authorization will end at the end of this study when all the information has  been 
evaluated.  
• You can stop the use of your information in this research study by sending a  written 
request to Dr. ( insert name of PI ). If you decide to withdraw your  authorization:  
- No more information will be collected from you or your records for the  research 
study from the time the written request is  received;  
- The study will only use the information it has already collected from you  before 
you sent the written  request.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 86 of 150 
© Sunshine Heart  Confidential   
  
 
• When you sign this document and authorize the use and disclosure of your health 
information for this research, the information disclosed may no longer be protected by  the 
federal privacy regulations found at 45 CFR Part 164. But, t he researchers for this study 
can only use or disclose your health information for purposes that are approved by an 
Institutional Review Board or as required by law or  regulation.  
 
 
Note: This consent form with the original signatures MUST be retained on file by the 
principal investigator. A copy must be given to the volunteer. A copy should be placed in the 
volunteer’s medical record, if applicable.  
Date  
 PI or Designee Signature  
 PI or Designee Name (print)  
PI or Designee’s Statement:  
I have reviewed the authorization for the use and disclosure of protected health information 
with the patient. To the best of my knowledge, she understands the meaning of this 
authorization.  
Date  
 Witness Signature  
 Witness Name (print)  
Date  
 Participant Signature  
 Participant Name (print)  
STATEMENT OF CONSENT  
(NOTE: This is only a suggested signature format. Sites may use their own signature page .) 
The details of this authorization have been explained to you and you have been given the 
oppo rtunity to ask any questions you wish.  
If you voluntarily agree to allow the researchers to use and disclose your health information 
for the purpose of this study, please print and sign your name below.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 87 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX H: SAMPLE INFORMED CONSENT  
 
SAMPLE OF INFORMED CONSENT 
FOR INVESTIGATIONAL RESEARCH  STUDY  
 
PROTOCOL  TITLE:  C-Pulse® Implantable Counterpulsation Pump (ICP)  US 
Feasibility Study  
 
PROTOCOL NUMBER:  
 
INSTITUTION:  [Institution]  
 
INVESTIGATOR:  [Investigator]  
 
 
 
Introduction  
Your  physician  has recommended  that you consider  undergoing  a surgical  procedure  to receive  the 
C-Pulse® heart  assist  device  to treat your heart  failure.  The C-Pulse  device  works  to assist  the heart 
to pump blood, rather than “replacing” the heart function, and can be safely turned on or off as 
required.  
 
Currently,  heart  transplantation  is the only widely  accepted  treatment  option  for patients  with heart 
failure resistant to standard medications. Mechanical heart assist devices, pumps that do all the 
work of the heart to pump blood around the body, are used in some patients as a bridge -to- 
transplant, and in other patients who are not suitable for heart transplant, as a long -term implant 
(otherwise known as “destination t herapy”). Such blood -contacting heart pumps require extensive 
surgery to implant, and cannot be turned off without the risk of permanent injury to the patient or 
death. The C -Pulse ® device is a new heart -assist device that allows you to remain active and does 
NOT  contact  the blood,  therefore,  the device  does not require  the use of blood  thinning  medications.  
 
Purpose  
The purpose  of this consent  form  is to provide  you with information  to decide  whether  to participate 
in this study.  Before  you consent,  study  procedures  will be explained  to you, as well as the possible 
risks and benefits associated with the study. You understand that you are being asked to take part 
in a clinical research trial. If you sign this form, you agree to participate in this study.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 88 of 150 
© Sunshine Heart  Confidential   
  
 
The purpose of this research study is to evaluate a new heart assistance device, known as C -Pulse 
device to assist your failing heart. The C -Pulse is an experimental device and is not approved by 
the Federal and Drug Administrat ion (FDA) in the United States. The C -Pulse device is being 
studied  to evaluate  its safety  and ability  to provide  your body  with improved  blood  flow.  This means 
that the sponsor is conducting this study in order to verify that the new C -Pulse device can safely 
and effectively improve heart function in people with ongoing heart failure and who are resistant to 
medications. If you agree and you are suitable fo r the study, your surgeon will perform an operation 
on you to connect the cuff of the device to the aorta (largest artery in your body that comes from 
your heart and supplies your body with blood), thread a lead from the outside of your heart  and 
tunnel  it through  your skin over your abdomen  and to the outside  driver  unit-that controls the 
operation of the system and is attached to a vest or carry bag that you will  wear.  
It is important that you read and understand this consent form. It may contain words th at you do 
not understand. Please ask your doctor to explain any words or information that you do not 
understand.  Do not sign this consent  form  unless  you have  received  answers  to all of your questions.  
 
There will be up to 40 patients enrolled and implanted in this study in the United States and up to 
9 centers in the US and potentially some OUS centers. Your part in the study and follow -up visits 
are expected to last up to 8 years.  
 
Device Description  
The C -Pulse device is a new heart -assist device  that allows you to remain active and does NOT 
contact the blood, therefore, you will not need blood thinning medications. The C -Pulse device 
works  to assist  the heart  to pump  blood,  rather  than “replacing”  the heart  function,  and can be safely 
turned on o r off as  required.  
The C-Pulse  Cuff is positioned  around  the ascending  aorta,  the main  artery  coming  out of the heart 
that delivers blood to the body. The Cuff deflates just before the heart pumps blood, reducing the 
workload of the heart  (Fig 1A), and the Cuff is timed to re -inflate in between heart beats, once the 
heart has finished ejecting blood and the aortic valve closes. During this latter period, as the heart 
is re-filling,  the Cuff inflation  acts like a second  heart  beat,  producin g a second  surge  of blood  flow 
to the heart muscle and around the body (Fig 1B). Reducing the load on the heart and increasing 
the blood flow to the heart muscle are very important in assisting the heart to pump blood around 
the body. Keeping the device ou t of the bloodstream limits the difficulty of implantation of the 
device and allows the device to be turned on and off for short periods of  time.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 89 of 150 
© Sunshine Heart  Confidential   
  
 
 
  
 
The C-Pulse  device  is intended  as a permanent  implant  and for the duration  of the study  to be used 
for at least 20 hours per day. It is considered safe to turn the device off for short periods (up to 15 
minutes)  though  you may experience  return  of symptoms  of heart  failure  such as shortness  of breath 
or dizziness  during the period the device is  off. 
The implanted  C-Pulse  Cuff is intended  to have  an operational  life of at least four years.  The Driver 
is designed  to detect  any Cuff failure  and alarm  and stop pumping.  The Cuff is expected  to be able 
to be replaced if this is  indicated.  
Screening Evaluation, Tests, and Procedures  
You are being asked to participate in some screening tests and procedures determine if you are 
eligible for the study. If you meet criteria based upon these evaluations, you may be eligible to 
participate in the study. If you do not meet these criteria, you will not qualify to participate in the 
study. Once you sign this consent form you will begin your screening tests and procedures.  
If, after discussing the screening test procedures with your doctor, you agree to participate in the 
screening,  your doctor  will need  to get  information  from you  to determine  if you have  any medical 
condition  that could  exclude  you from  the study,  increase  your risks  of surgery  or interfere  with the 
therapy. Your evaluation may include the  following;  
• Medical  history  
• General physical  exam  
• Recording of weight, heart rate/rhythm, blood pressure, respiratory  rate 
• Documentation of  medications  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1A: C -Pulse Cuff deflates as the 
heart ejects blood, unloading the heart.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1B: C -Pulse Cuff inflates as the heart 
refills with blood, giving a secondary pulse of 
blood to the body and heart muscle.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 90 of 150 
© Sunshine Heart  Confidential   
  
 
You will be asked to have a c hest x -ray to determine the condition of your aorta (the largest artery 
in your body  that comes  from  your heart  and supplies  your body  with blood)  and lungs  to see if you 
have  any hardened  areas  in your aorta  or any lung problems  that may be a risk to you if you receive 
the C-Pulse  Cuff. If  your chest  x-ray indicates you  have  hardened  areas  in your aorta  or your  lungs 
are not clear,  you will not need  to go on with any further  screening  tests and procedures  as you will 
not be able to participate in the  study.  
If the chest  x-ray indicates  you have  no hardened  areas  in your  aorta  and your lungs  are clear, your 
doctor will ask you to have a more extensive procedure to determine the condition of your aorta 
called a computed tomography (CT) scan or CAT scan. This test is used to show by imaging in 
detail, sections of your aorta to determine if disease is present. This scan will be performed in the 
hospital or out -patient image center. You will be asked to lie on a narrow table  that slides into the 
center of the scanner while x -ray beams rotate around your chest. You may be asked to hold your 
breath during image capture. You may need some medication to help you relax. You will also be 
given some medication as part of the test to  make the images more clear. Your doctor will  monitor 
your kidneys after the CT scan to check for any damage from the medication. If the CT scan 
indicates  you have  aortic  disease,  it may be a risk to you if you receive  the C-Pulse  Cuff,  therefore, 
you will  not need to go on with any further testing and will not participate in the  study.  
Once the condition of your aorta has been determined to be suitable for the study by chest x-ray 
and the CT scan; you may go on to obtain more tests to determine if you are eligible for the  study. 
If at any time during the testing you are not eligible for the study, your doctor will stop any 
further testing and you will not participate in the study. The following is a remaining list of 
procedures that you will be tested for t o determine if you are eligible for the  study.  
• CT scan of your head will follow the CT scan of your aorta. It is exactly like the CT 
scan of your aorta only the x -ray beams will rotate around your  head.  
• Right heart catheterization is the passing of a thin tube (catheter) into the right side of 
the heart.  The procedure  is done  to see blood  movement  through  the heart  and to monitor 
your heart’s function. An X -ray image will help the doctor see where the catheter is 
placed. The test can be done in the hos pital or outpatient procedure center depending 
upon your hospitals requirements. The physician who will perform the catheterization 
will go over the risks with you before it is  done.  
• Transthoracic echocardiogram, (ECHO of your chest and heart) a painless p rocedure 
where gel is placed on a transducer which is then goes on your chest to measure your 
heart chambers and function including the valves of your  heart.  
• Complete  two questionnaires  relating  to your quality  of life (MLHF  Score,  KCCQ)  and 
a questionnaire about how you feel (Fatigue Impact  Scales)  
• A Neurological test called the National Institute of Health Stroke Score (NIHSS) and a 
test called the Modified Rankin will be done to assess your neurologic  state 
• Complete two assessments (NYHA Clas sification, Six Minute Walk - to measure how 
far you can walk in 6  minutes)  
• Pregnancy test (if  applicable)  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 91 of 150 
© Sunshine Heart  Confidential   
  
 
• Cardiopulmonary  test shows  the maximum  amount  of oxygen  your heart  can provide  to 
your muscles during constant activity. Doctors cons ider this a true measure of your 
heart’s ability to keep you going. This test requires special equipment so it is usually 
done in a special clinic or hospital. You will be asked to blow into a tube connected to 
a lung doctor’s machine first. They you will have small adhesive electrodes stuck to 
your chest and sides like for an EKG. The wires will attached to the electrodes will 
connect you to a heart monitor. You will stand on a treadmill or exercise bike and your 
blood pressure will be taken with a cuff. A  padded clothespin is clamped over your 
nostrils so you cannot breathe except through your mouth. The treadmill starts slowly 
and speed will slowly increase until it is as fast as you can manage and you are not 
talking “comfortable”. This is a test where t hey want to push you hard. You will be 
monitored during the exercise closely. The test continues until you are unable to go  on. 
• Blood  tests  
 
Study Procedures  
If you meet all screening criteria for the study and after discussing the study with your doctor, you 
decide to participate in the study, you will be scheduled and prepared to undergo surgery.  
The following are a list of procedures you can expect during and after the surgery: 
During the implant procedure (2 hours)  
During surgery, a sternotomy ( your breast bone will be cut open) will be performed and a cuff that  
has been  correctly  sized  to your aorta  will be wrapped  around  your aorta  and activated  to help assist 
the heart in pumping  blood.  
The ascending aorta (the main blood vessel which carries blood ejected from the heart) is freed up.  
The pre -shaped inflatable C -Pulse® Cuff is wrapped around the aorta and a lead to sense the ECG 
(the electrical signals of the heart) is attached to your heart.  
The gas line and sensing lead are connected to a sin gle tube that is tunneled under the skin and 
brought out through the skin over the abdomen. This tube has a connector that allows it to be 
connected  to a Driver  (Fig 1). The Driver  is activated  during  surgery  to ensure  the device  performs 
as expected.  
During the surgery, examination of your heart and aorta with an ultrasound  probe 
Monitoring of arterial blood  pressure  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 92 of 150 
© Sunshine Heart  Confidential   
  
 
 
After the procedure and before you leave the hospital:  
All patients in the study will receive the device and it will be turned ON for the duration of the 
study.  
Following the surgery, the expected stay in Intensive Care is 2 -3 days to ensure the device is 
functioning in time with the heart and there are no heart rhythm disturbances and that the blood 
pressures are stable. The stay on the ward is 7 -14 days and discharge from the hospital will be 
judged on your medical condition, your ability to walk without aid for short distances and you and 
your care -giver being able to handle the Driver and look after the exit site dressings. Your will 
continue to take anti -heart failure medication under the guidance of the investigators and your 
cardiologist. Rehabilitation following surgery is important to ensure a  good recovery and this will 
also involve a program of physical and nutritional guidance.  
Your doctor and medical team may teach you to disconnect from your device for short periods  of 
time (no more than 15 minutes at a time). You will need to discuss this  with your  doctor.  
You will not leave the hospital until your doctor has decided that you are ready. Before you  leave, 
your doctor will do the  following:  
• Echocardiogram, (ECHO of your chest and heart) a painless procedure where jell  is 
placed on a transducer which is then goes on your chest to measure your heart 
chambers and function including the valves of your  heart.  
• A neurological consultation from a specialist that will assess your brain and  reaction 
functions.  
Be sure that you understand the co mplete device information and personal care that you need to 
do at home.  
Fig 2: C -Pulse device with wearable driver unit.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 93 of 150 
© Sunshine Heart  Confidential   
  
 
1- Month Follow -up Visits  
• General physical examination (including blood  tests)  
• Documentation of  medications  
• Recording of weight, heart rate, blood pressure, respiratory  rate 
• (ECHO of your chest and  heart)  
• Complete Six Minute Hall Walk and NYHA Classification  assessment  
• Complete 2 questionnaires relating to your quality of life (MLHF Score, KCCQ) and  two 
questionnaires about how you feel (Fatigue Impact  Scales)  
• A Neurological test called the National Institute of Health Stroke Score (NIHSS)  and 
Modified Rankin will be done to assess your mental  state*  
 
3- Month Follow -up Visits  
• General physical examination (including blood  tests)  
• Documentation of  medications  
• Recording of weight, heart rate, blood pressure, respiratory  rate 
• Chest  X-Ray 
• (ECHO of your chest and  heart)  
• Complete NYHA Classification and Six Minute Walk -assessment to measure how far  you 
can walk in 6  minutes)  
• Complete 2 questionnaires rel ating to your quality of life (MLHF Score, KCCQ) and  two 
questionnaires about how you feel (Fatigue Impact  Scales)  
• A Neurological test (NIHSS) and Modified Rankin will be done to assess your  mental 
state 
 
6- Month Follow -up Visits  
• General physical examination (including blood  tests)  
• Documentation of  medications  
• Recording of weight, heart rate, blood pressure, respiratory  rate 
• CT Scan. This test is used to show by imaging in detail, sections of your aorta to 
determine if disease is present. This scan  will be performed in the hospital or out -patient 
image center. You will be asked to lie on a narrow table that slides into the center of the 
scanner while x -ray beams rotate around your chest. You will be asked to hold your 
breath during image capture. Yo u may need some medication to help you  relax  
• (ECHO of your chest and  heart)  
• Chest  X-Ray 
• A very fine tube (catheter) will be inserted into one of your blood vessel, either in your 
groin or neck, and passed into the right chamber of your heart to assess the pressures  in 
your heart (right heart  catheterization)  
• Complete NYHA Classification and Six Minute Walk -assessment to measure how far you 
can walk in 6  minutes)  
• Complete 2 questionnaires relating to your quality of life (MLHF Score, KCCQ) and  two 
questionnaires about how you feel (Fatigue Impact  Scales)  
• A Neurological test (NIHSS) will be done to assess your mental  state 
• A Neurological test called the Modified  Rankin  
• Walking test to measure your maximum limit for exercise (Peak O2  uptake)  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 94 of 150 
© Sunshine Heart  Confidential   
  
 
 
Long term Visits 12, 18 Month and Annual Visits (from implant date)  
• General physical examination (including blood  tests)  
• Documentation of  medications  
• Recording of weight, heart rate, blood pressure, respiratory  rate 
• (ECHO of your chest and  heart)  
• Complete NYHA Classification and Six Minute Walk -assessment to measure how far  you 
can walk in 6  minutes)  
• Complete 2 questionnaires relating to your quality of life (MLHF Score, KCCQ) and  two 
questionnaires about how you feel (Fatigue Impa ct Scales)  
 
*If at any time during the study you experience a neurological adverse event you will have the 
NIHSS and the Modified Rankin collected 30 and 60 days after your event.  
After 10 years of annual visits or the study is closed, your participation i n the study will be 
completed.  
 
Risks  
Screening Tests and Procedures  
There are some risks in going through the screening tests and procedures and are described below:  
• Drug reactions to any pre -medications you might receive before the CT scan or right heart 
catheterization such as drowsiness, low blood pressure, nausea or  vomiting.  
• For the right heart catheterization you may experience the  following;  
o Bruising around the area where the catheter was  inserted  
o Injury to the  vein 
o Puncture to the lung if the neck or chest veins are  used 
o rare complications could include cardiac arrhythmias, cardiac tamponade (pressure 
on your heart  due to fluid  build -up in the sac around  your heart),  low blood  pressure, 
infection, or embolism (blocking an artery)caused by blood  clots at the tip of the 
catheter.  
o Before the heart catheterization test, your doctor will review all the risks  associated 
with the  test 
• For the pulmonary testing, you may experience the  following;  
o Very dry throat as well as excessive  drooling  
o fatigue  
• Possible infection at the needle puncture site from the right heart catheterization or blood 
tests 
• Exposure to  x-ray 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 95 of 150 
© Sunshine Heart  Confidential   
  
 
Study Risks  
There are several risks associated with participating in this study listed below. Risks in this study 
may come from the surgical procedure itself, implantation procedure or the investigational device. 
Your study doctor will discuss them with you.  
General Anesthetic (1 -5%) 
• Drug  reactions  
• Low blood  pressure  
• Difficulty with maintaining adequate oxygen to the body  
 
Surgical procedure:  
• Bleeding, possibly requiring blood transfusions, surgical or medical  interventions  
• Infection possibly requiring surgical or medical intervention (e.g. intravenous  medication, 
antibiotics)  
• Stroke or other neurologic  event  
• Memor y and thinking  problems  
• Decrease or loss of kidney function, possibly requiring use of a machine to filter  your 
blood  
• Irregular  heartbeats  
• Fluid buildup around the  heart  
• Damage to the aortic wall that may cause the layers of the aorta to  separate  
• Device malfunction such as damage to the cuff, misplacement of the lead on the  heart  
• Blood  disorders  
• Abnormal liver function; digestion complications; fever or chills, organ failure  or 
dysfunction  
• High blood  pressure  
• Heart  attack  
• Separation of your  incision  
• Lack of sufficient oxygen to limbs or organs to support normal organ  function  
• Partial or full blockage of your veins or  arteries  
• Death  
 
C–Pulse® Heart Assist Device:  
• Lack of effect – the device may not provide relief from your heart failure symptoms if  they 
are severe  
• Device failure – failure of the device to provide adequate support to relieve the symptoms 
of heart  failure  
• Persistent leaking balloon may cause surgical emphysema (injury to the air sacs in 
the lung)  or pneumothorax  (abnormal  collection  of air in between  the lung and chest 
wall)  
• Leakage of non -sterile air may cause pneumothorax or chest  infection  
• Air emboli in the  aorta  
• Needle puncture in the  cuff 
• Failure  of the electronic  system  to detect  any system  failure  such as current  leakage, 
voltages, power supply or over inflation of the  cuff 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 96 of 150 
© Sunshine Heart  Confidential   
  
 
• Infection  – infection  from  the line that is tunneled  thru your skin to the outside  of your body 
may occur  
o Your doctor may perform additional testing that may expose you t o radiation  
• Emboli – due to the repeated inflations of the cuff, small particles in your blood may come 
loose from the aortic wall causing a  stroke  
• Aortic disruption - due to the repeated inflations of the cuff may cause a split in the aortic 
wall that may cause the layers of the aorta to  separate  
• Worsening  of heart  failure  symptoms -You may experience  symptoms  of heart  failure,  such 
as shortness of breath or  dizziness  
• Death  
There may be additional risks which are unknown. Your doctor has been chosen to participate as 
an investigator in this study because he or she has the skills and knowledge to perform the study 
procedures and this should minimize your risk.  
If your doctor suspects that you have an infection from the line that is tunneled thru  your skin to 
the outside  of your body,  additional  tests may be requested.  These  tests may include  blood  tests for 
infection, CT or PET scans, to determine if the tube should be removed to let the infection  heal.  
In the event  of your death  during  the study,  an autopsy  may be requested.  If an autopsy  is performed, 
small pieces of your aorta may be collected for examination under a microscope. This may be 
requested regardless of whether you have had the C -Pulse System implanted for the study. If you 
had a device  implanted,  that device  may be returned  to the Sponsor  for testing  as well,  if an autopsy 
is performed.  
If you are pregnant or plan to become pregnant or are nursing a baby, you cannot enter this study. 
There may be a risk of severe problems. Women may participate in this study only if they are past 
menopause,  have  had surgery  to make  them  sterile,  or are using  an acceptable  form  of birth  control 
throughout the course of the study. If you become pregnant during the trial, you must not ify your 
doctor  immediately.  
 
Benefits  
There is no guarantee that you will benefit from taking part in this study. The main benefit from 
participation in the study may be some improvement in your quality of life. It is not expected that 
there will be a com plete restoration to a quality of life that you had before heart failure.  
The information from this study may also benefit future patients who are in moderate to severe 
heart  failure.  
 
Alternatives  
The alternative  to using  this new device  includes  ongoing  medication  for alleviating  the symptoms 
of heart failure. If symptoms persist, cardiac transplantation or mechanical blood pumps may be an 
option in some patients. The C - Pulse device is intended as a treatment option in patients who are 
ambulatory , on optimal medical therapy but continue to have a poor quality of  life. 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 97 of 150 
© Sunshine Heart  Confidential   
  
 
Voluntary Participation  
Your  participation  in this study  is voluntary.  You may choose  whether  you wish  to be in this study 
and whether to remain in the study at all times after enrollment. If you withdraw from the study, 
you will not lose any benefits to which you are entitled. Your participation in the study may be 
stopped at any time by your doctor without your consent. If you withdraw or are withdrawn from 
the study for any reason, you may be asked to return to the clinic for a follow -up examination.  
You will be informed of any new information that may affect your decision to continue in the study.  
 
Termination  
This research project may stop for a variety of rea sons. These may include reasons such as: 
unacceptable side effects, the device being shown not to be effective or not need further 
investigation; and decisions made in the commercial interests of the Sponsor.  
 
New information arising during the study  
Durin g the study, new information about the risks and benefits of the device may become known 
to researchers and might alter your willingness to continue your participation in the study. If this 
occurs, you will be told about this new information. This new info rmation may mean that you can 
no longer  participate  in this research.  If this occurs,  the person(s)  supervising  the research  will stop 
your participation.  In all cases,  you will be offered  all available  care to suit your needs  and medical 
condition.  
 
Cost  
Routine costs are those costs normally incurred as a result of medical care associated with the 
treatment of your heart failure condition. These costs are generally the patient’s responsibility or, 
where  appropriate,  the responsibility  of your insurance  company.  You will not incur  any additional 
costs as a result of your participation in this  Study.  
 
Compensation  
You will not receive any compensation for participating in this study.  
 
Financial Arrangements with Sponsor  
As is usually  the case for clinical  trials  that are sponsored  by a manufacturing  company,  <Hospital> 
will receive  payment  from  the Sponsor  for each patient  enrolled  in this study.  These  payments  will 
be used to defray the costs of data collected for the study. No hospital staff member will receive 
private income as a result of your enrollment in this  study.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 98 of 150 
© Sunshine Heart  Confidential   
  
 
Injury  
In the event that physical or psychological injury occurs as a result of your participation in this 
research project, medical treatment w ill be available. This treatment, as well as other medical 
expenses, will be paid for by you or your health insurance in your usual manner. No  compensation 
or  reimbursement  is  available  from   (name of institution)  , or the Sponsor, Sunshine 
Heart, Inc. 
If you are injured you should report the injury by contacting:  
 
 
(Principal  Investigator)  (Telephone  number)  
 
Confidentiality  
If you agree to take part in this study, your medical records will be treated confidentially except  as 
required by law. Access to your medical records will be limited to the medical staff at the study 
center, some qualified representatives from the sponsor, the Institutional Review Board (IRB) 
reviewing the study, and the US Food and Drug Administration (FDA). Nothing about you, your 
illness  or treatment  will be made  public.  If the results  of this study  are published,  your identity  will 
remain  confidential.  
 
Study Questions  
If you have questions about the study, you may contact:  
 
 
(Principal  Investigator)  (Telephone  number)  
 
Subject Rights  
If you have questions regarding the conduct of this study or your rights as a research subject, you 
may contact:  
 
 
Chairperson of  the IRB (Telephone  number)  
 
Permission for Access to and Use of Health Info rmation  
If you decide to take part in the study, Sunshine Heart and others will see your health data. This 
section  governs  how your health  data will be used and shared  during  and after the study.  The health 
data that may be used and shared  includes  all data collected  during  the study  and any health  data in 
your medical records that is relevant to the  study.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 99 of 150 
© Sunshine Heart  Confidential   
  
 
Providers’ Disclosure of Health Information in Your Medical Records  
You agree to permit [hospital and/or clinic], your doctors, and y our other health care providers 
(“Providers”) to share health data in your medical records with [investigator(s)] and 
[his/her/their/its] staff (“Researchers”). You agree to permit Providers to share your health data:  
• With Sunshine Heart and its agents and  contractors  
• As required by  law 
• With  government  organizations  and review  boards  required  to watch  over the safety  and 
effectiveness of medical products and therapies and the conduct of  research  
• With other persons who are required to watch over the safety and effectiveness of 
medical products and therapies and the conduct of  research  
 
Researchers’ User and Disclosure of Your Health Information  
You agree to permit the Researchers to use and share your health data  
• Among themselves to conduct the  study  
• With other researchers in the  study  
• With Sunshine  Heart  
• With  government  organizations  and review  boards  required  to watch  over the safety  and 
effectiveness of medical products and therapies and the conduct of  research  
• With other persons who are required to watch over the safety and effectiveness of 
medical products and therapies and the conduct of  research  
Once Providers or Researchers have shared your health data with a third party, the data may be 
subject to further sharing by the third party. Federal privacy laws may no longer protect it from 
further sharing.  
While the study is in progress, you will not be allowed to see your health data that is created or 
collected for the study. After the study is done, you may see this data as in the [hospit al/clinical 
trial sits]’s Notice of Information practices.  
 
Sunshine Heart User and Disclosure of Your Health Information  
This section describes what Sunshine Heart will do with the study data. This includes your health 
data received during the study.  
Suns hine Heart  will keep  your health  data confidential  in keeping  with all applicable  laws.  Sunshine 
Heart may use your health data to conduct this study. Sunshine Heart may use your health data for 
other purposes, such  as: 
• Watch over and improve the device  performance  
• New medical  research  
• Plans for making new medical products or  procedures  
• Other business  purposes  
Any reports  about  the study  will not include  your name  or a description  of you. Data  received  during 
the study will not be used to market to you. Your name will not be placed on any mailing lists or 
sold to anyone for marketing  purposes.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 100 of 150 
© Sunshine Heart  Confidential   
  
 
Your Country’s regulations and other laws control Sunshine Heart’s work in making new devices. 
These laws help make certain the safety and qual ity of medical devices. Sunshine Heart may  share 
your health data with the United States Food and Drug Administration (FDA) or other US and 
foreign government authorities that are responsible for the safety of medical devices. Sunshine 
Heart may share your health data with institutional review boards and persons who watch over 
research and the safety and effectiveness of medical products and research. You agree to allow 
Sunshine Heart to use study data in these  ways.  
This consent does not have an ending  date. But you may change your mind and take back this 
consent  to use your health  data at any time.  To take back  this consent,  you must  write  to [name  and 
contact information]. If you take back this consent, you cannot take part in the study. Even after 
your part in the study ends, Sunshine Heart and Researchers may continue to use and share the 
health data they got during the study as described  here.  
 
Consent  
I have read the information in this consent form (or it has been read to me).  
I have  had an opport unity  to discuss  with my study  doctor  the purpose,  methods,  risks  and potential 
benefits of this research as well as available alternatives, and to ask questions regarding my 
participation in this research. My questions have been answered to my satisfaction.  
My participation  in this research  is voluntary.  I agree  to participate  in this research  study.  By signing 
this consent form, I have not given up any of my legal  rights.  
I will be given a copy of this informe d consent form.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 0 of 150 
© Sunshine Heart  Confidential   
  
 
Authorization  
I have been given the information about the use and disclosure of my health information for this 
research study. My questions have been answered.  
 
I authorize  the use and disclosure  of my health  information  to the parties  listed  in the authorization 
section of this consent for the purposes described  above.  
 
 
 
Signature  of Subject  Date/Time  
 
 
 
Print Name of Subject  
 
 
 
Subject’s Legal Representative Signature  (if applicable)  Date/Time  
 
 
 
Printed Name of Subject’s Legal Representative (if applicable)  
 
 
 
Investigator Signature  (or Designee)  Date/Time  
 
 
 
Printed Name of Investigator (or Designee)  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 1 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX I: REQUIRED TESTS  
 
 
 
Follow -up Requirements Baseline to 6 months Post Implant  
 Pre- 
Implant  Implant  Pre- 
Discharge7 1 mo  3 mo  6 mo  
A. PATIENT ELIGIBILITY  X      
B. GENERAL        
Demographic Data  X      
Medical History  X      
General Physical Examination  X X X X X X 
Concurrent Medications  X X X X X X 
Pregnancy test (if applicable)  X      
C. VITAL PARAMETERS        
Weight  X  X X X X 
Heart rate  
(ECG pre -implant)  X  X X X X 
Blood pressure  X  X X X X 
Respiratory rate  X  X X X X 
D. CARDIOPULMONARY        
CT aorta  X     X 
CXR  X    X X 
ECHO  X X2  X X X 
Right heart catheterization  
(CVP, PAP, CI, PCWP, SVR, PVR)  X     X 
Peak O2 uptake  X     X 
E. QUALITY OF LIFE        
NYHA Classification  X   X X X 
MLHF Score/ KCCQ  X   X X X 
Fatigue Impact Scales  X  X X X X 
Six Minute Walk  X   X X X 
F. HEMATOLOGY        
Hemoglobin  X  X X X X 
Hematocrit  X  X X X X 
Plasma free hemoglobin  X  X X X X 
Platelet count  X  X X X X 
White cell count  X  X X X X 
APTT  X  X X X X 
INR X  X X X X 
Fibrinogen  X  X X X X 
G. BIOCHEMISTRY        
Serum sodium  X  X X X X 
Serum potassium  X  X X X X 
Serum creatinine/ GFR3 X  X X X X 
BUN  X  X X X X 
Serum albumin  X  X X X X 
Serum bilirubin  X  X X X X 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 2 of 150 
© Sunshine Heart  Confidential   
  
 
Follow -up Requirements Baseline to 6 months Post Implant  
 Pre- 
Implant  Implant  Pre- 
Discharge7 1 mo  3 mo  6 mo  
Serum ALT  X  X X X X 
Serum AST  X  X X X X 
Serum BNP  X     X 
H. NEUROLOGICAL 
ASSESSMENT6       
Neurological testing (NIHSS)4 X  X X X X 
Modified Rankin 4 X  X X X X 
Head CT 5 X      
Neurological Consultation  X  X6    
I. IMPLANT DETAILS   X     
J. DEVICE LOG   X  X X X 
K. DISCHARGE 
CHECKLIST    X    
1 Annually  post-implant  
2 Epi-aortic Echo at  implant  
3 Estimated  GFR  at Baseline  and within one  week  post CT to evaluate  contrast  induced  nephropathy. 
4 Post Neurological Dysfunction AE – 30, 60 and 90 days post  event  
5 At Baseline only or as clinically indicated with any Neurological Dysfunction AE – Head CT should be completed only after clearance 
for implantation.  
6 Required at 5 -7 days post ICU discharge or at hospital discharge whichever occurs first and at the time of any suspected Neuro 
Dysfunction  AE 
7 At Discharge - (see Appendix  M) 
 
 
Long -term Post Implant Follow -Up Requirements  
 12 month  18 month  Annually  
Year  2-10 
A. PATIENT ELIGIBILITY     
B. GENERAL     
General Physical Examination  X X X 
Concurrent Medications  X X X 
Pregnancy test (if applicable)     
C. VITAL PARAMETERS     
Weight  X X X 
Heart rate  
(ECG pre -implant)  X X X 
Blood pressure  X X X 
Respiratory rate  X X X 
D. CARDIOPULMONARY     
ECHO  X X X 
E. QUALITY OF LIFE     
NYHA Classification  X X X 
MLHF Score/ KCCQ  X X X 
Fatigue Impact Scales  X X X 
Six Minute Walk  X X X 
F. HEMATOLOGY     
Hemoglobin  X X X 
Hematocrit  X X X 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 3 of 150 
© Sunshine Heart  Confidential   
  
 
Long -term Post Implant Follow -Up Requirements  
 12 month  18 month  Annually  
Year  2-10 
Plasma free hemoglobin  X X X 
Platelet count  X X X 
White cell count  X X X 
APTT  X X X 
INR X X X 
Fibrinogen  X X X 
G. BIOCHEMISTRY     
Serum sodium  X X X 
Serum potassium  X X X 
Serum creatinine/ GFR3 X X X 
BUN  X X X 
Serum albumin  X X X 
Serum bilirubin  X X X 
Serum ALT  X X X 
Serum AST  X X X 
I. IMPLANT DETAILS     
J. DEVICE LOG  X X X 
K. DISCHARGE CHECKLIST7     
1 Annually  post-implant  
2 Epi-aortic Echo at  implant  
3 Estimated GFR at Baseline  only 
4 Post Neurological Dysfunction AE – 30, 60 and 90 days post  event  
5 At Baseline only or as clinically indicated with any Neurological Dysfunction AE – Head CT should be completed 
only after clearance for  implantation.  
6 Required at 5 -7 days post ICU discharge or at hospital discharge whichever occurs first and at the time of any 
suspected Neuro Dysfunction  AE 
7 At Discharge (see Appendix  M) 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 4 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX J: CORE LABORATORIES  
 
Cardiopulmonary Exercise Testing  
Henry Ford Health System  
Clinical Exercise Physiology Core Lab 
6525 Second Ave  
Detroit, MI 48202  
 
Voice: (313) 972 -1920, FAX: (313) 972 -1921  
cepcorelab@hfhs.org  
 
 
Primary Contact: Clinton Brawner  
 
Echocardiography  
Cardiovascular Core Labs 
100 Irving Street, NW 
Suite EB -5123 
Washington, DC 20010  
 
Voice:  (202)877 -0223  
 
Primary Contact: Neil J Weissman, MD  
 
 
CT Scan  
Cardiovascular Core Labs 
100 Irving Street, NW 
Suite EB -5123 
Washington, DC 20010  
 
Voice: (202)877 6177  
 
Primary Contact: Wm Guy Weigold, MD  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 5 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX K: SAMPLE CASE REPORT FORMS  
 
Not related to this change – not resub mitted  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 6 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX L: NEUROLOGICAL TESTING  
 
NIH S TROKE SCALE  
 
 
The NIH Stroke Scale (NIHSS) must be administered at Pre –implant Baseline and each follow – 
up. Administer the stroke scale items in the order listed. Record performance in each category 
after each subscale exam. Do not go back and change scores. Follow directions provided for 
each exam technique. Scores should reflect what the patient does, not what the clinical thinks 
the patient can do. The clinician should record answers while administering the exam and work 
quickly. Except where indicated the patient should not be coached (i.e. repeated requests to 
patient to make a special effort).  
 
 
Instructions  Scale Definition  
1a. Level of Consciousness: The investigator must 
choose a response, even if a full evaluation is prevented 
by such obstacles as an endotracheal tube, language 
barrier, orotracheal trauma/bandages. A 3 is scored only 
if the patient makes no movement (other than reflexive 
posturing) in response to noxious stimulation  0 = Alert; keenly responsive.  
1 = Not alert, but arousable by minor stimulation to obey, answer, or 
respond.  
2 = Not alert, requires repeated stimulation to attend, or is obtunded 
and requires strong or painful stimulation to make movements (no t 
stereotyped).  
3 = Responds only with reflex motor or autonomic effects or totally 
unresponsive, flaccid, areflexic.  
1b. LOC Questions: The patient is asked the month 
and his/her age. The answer must be correct - there is 
no partial credit for being clos e. Aphasic and stuporous 
patients who do not comprehend the questions will 
score 2. Patients unable to speak because of 
endotracheal intubation, orotracheal trauma, severe 
dysarthria from any cause, language barrier or any other 
problem not secondary to ap hasia are given a 1. It is 
important that only the initial answer be graded and that 
the examiner not "help" the patient with verbal or non - 
verbal cues.  0 = Answers both questions correctly. 
1 = Answers one question correctly.  
2 = Answers neither question correctly.  
1c. LOC Commands: The patient is asked to open and 
close the eyes and then to grip and release the non - 
paretic hand. Substitute another one step command if 
the hands cannot be used. Credit is given if an 
unequivocal attempt is made bu t not completed due to 
weakness. If the patient does not respond to command, 
the task should be demonstrated to them (pantomime) 
and score the result (i.e., follows none, one or two 
commands). Patients with trauma, amputation, or other 
physical impediments  should be given suitable one -step 
commands. Only the first attempt is scored.  0 = Performs both tasks correctly 
1 = Performs one task correctly  
2 = Performs neither task correctly  
2. Best Gaze: Only horizontal eye movements will be 
tested. Voluntary or reflexive (oculocephalic) eye 
movements will be scored but caloric testing is not done. 
If the patient has a conjugate deviation of the eyes that 
can be overcome by voluntary or reflexive activity, the 
score will be 1. If a patient has an isol ated peripheral 
nerve paresis (CN III, IV or VI) score a 1. Gaze is 
testable in all aphasic patients. Patients with ocular 
trauma, bandages, pre -existing blindness or other 
disorder of visual acuity or fields should be tested with 
reflexive movements and a  choice made by the 
investigator. Establishing eye contact and then moving 
about the patient from side to side will occasionally 
clarify the presence of a partial gaze palsy.  0 = Normal  
1 = Partial gaze palsy. This score is given when gaze is abnormal in 
one or both eyes, but where forced deviation or total gaze paresis are 
not present.  
2 = Forced deviation, or total gaze paresis not overcome by the 
oculocephalic maneuver.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 7 of 150 
© Sunshine Heart  Confidential   
  
 
Instructions  Scale Definition  
3. Visual: Visual fields (upper and lower quadrants) are 
tested by confrontation, using finger counting or visual 
threat as appropriate. Patient must be encouraged, but if 
they look at the side of the moving fingers appropriately, 
this can be scored as normal. If there is unilateral 
blindness or enucleation, visual fields in the remaining 
eye are scored. Score 1 only if a clear -cut asymmetry, 
including quadrantanopia is found. If patient is blind from 
any cause score 3. Double simultaneous stimulation is 
performed at this point. If there is extinction patient 
receives a 1 and the results are used to answer question 
11. 0 = No visual loss  
1 = Partial hemianopia  
2 = Complete hemianopia  
3 = Bilateral hemianopia (blind including cortical blindness)  
4. Facial Palsy: Ask, or use pantomime to en courage 
the patient to show teeth or raise eyebrows and close 
eyes. Score symmetry of grimace in response to 
noxious stimuli in the poorly responsive or 
noncomprehending patient. If facial trauma/bandages, 
orotracheal tube, tape or other physical barrier o bscures 
the face, these should be removed to the extent 
possible.  0 = Normal symmetrical movement  
1 = Minor paralysis (flattened nasolabial fold, asymmetry on smiling) 
2 = Partial paralysis (total or near total paralysis of lower face)  
3 = Complete paralysis of one or both sides (absence of facial 
movement in the upper and lower face)  
5 & 6. Motor Arm and Leg: The limb is placed in the 
appropriate position: extend the arms (palms down) 90 
degrees (if sitting) or 45 degrees (if supine) and the leg 
30 degrees (always tested supine). Drift is scored if the 
arm falls before 10 seconds or the leg before 5 seconds. 
The aphasic patient is encouraged using urgency in the 
voice and pantomime but not noxious stimulation. Each 
limb is tested in turn, beginning with the non -paretic arm. 
Only in the case of amputation or joint fusion at the 
shoulder or hip may the score be "9" and the examiner 
must clearly write the explanation for scoring as a "9".   
5a. Left Arm 
5b. Right Arm  0 = No drift, limb holds 90 (or 45) degrees for full 10 seconds.  
1 = Drift, Limb holds 90 (or 45) degrees, but drifts down before full 10 
seconds; does not hit bed or other support.  
2 = Some effort against gravity, limb cannot get to or maintain (if cued) 
90 (or 45) degrees, drifts down to bed, but has some effort against 
gravity.  
3 = No effort against gravity, limb falls. 
4 = No movement  
9 = Amputation, joint fusion  
explain:    
6a. Left Leg 
6b. Right Leg  0 = No drift, leg holds 30 degrees position for full 5 seconds.  
1 = Drift, leg falls by the end of the 5 second period but does not hit 
bed. 
2 = Some effort against gravity; leg falls to bed by 5 seconds, but has 
some effort against gravity.  
3 = No effort against gravity, leg falls to bed immediately. 
4 = No movement  
9 = Amputation, joint fusion,  
explain:    
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 8 of 150 
© Sunshine Heart  Confidential   
  
 
Instructions  Scale Definition  
7. Limb Ataxia: This item is aimed at finding evidence 
of a unilateral cerebellar lesion. Test with eyes open. In 
case of visual defect, insure testing is done in intact 
visual field. The finger -nose -finger and heelshin tests 
are performed on both sides, and ataxia is scored only if 
present out of proportion to weakness. Ataxia is absent 
in the patient who cannot understand or is paralyzed. 
Only in the case of amput ation or joint fusion may the 
item be scored "9", and the examiner must clearly write 
the explanation for not scoring. In case of blindness test 
by touching nose from extended arm  position.  0 = Absent  
1 = Present in one limb 
2 = Present in two limbs  
If pre sent, is ataxia in Right arm 1 = Yes 2 = No  
9 = amputation or joint  fusion,  explain    
Left arm 1 = Yes 2 =  No 
9 = amputation or joint  fusion,  explain    
Right leg 1 = Yes 2 =  No 
9 = amputation or joint  fusion,  explain    
Left leg 1 = Yes 2 =  No 
9 = amputation or joint fusion,  explain    
7a. Right Arm : Ataxia present? 
7b. Left Arm : Ataxia present? 
7c. Right Leg : Ataxia present? 
7d. Left Leg : Ataxia present?  1 = Yes  
2 = No  
9 = amputation or joint fusion, 
explain    
8. Sensory: Sensation or grimace to pin prick when 
tested, or withdrawal from noxious stimulus in the 
obtunded or aphasic patient. Only sensory loss 
attributed to stroke is scored as abnormal and the 
examiner sho uld test as many body areas [arms (not 
hands), legs, trunk, face] as needed to accurately check 
for hemisensory loss. A score of 2, "severe or total," 
should only be given when a severe or total loss of 
sensation can be clearly demonstrated. Stuporous and 
aphasic patients will therefore probably score 1 or 0. 
The patient with brain stem stroke who has bilateral loss 
of sensation is scored 2. If the patient does not respond 
and is quadriplegic score 2. Patients in coma (item 
1a=3) are arbitrarily given a 2 o n this  item.  0 = Normal; no sensory loss.  
1 = Mild to moderate sensory loss; patient feels pinprick is less sharp or 
is dull on the affected side; or there is a loss of superficial pain with 
pinprick but patient is aware he/she is being touched.  
2 = Severe  to total sensory loss; patient is not aware of being touched 
in the face, arm, and leg.  
9. Best Language: A great deal of information about 
comprehension will be obtained during the preceding 
sections of the examination. The patient is asked to 
describe what is happening in the attached picture, to 
name the items on the attached naming sheet, and to 
read from the attached list of sentences. 
Comprehension is judged from responses here as well 
as to all of the commands in the preceding general 
neurological exam. If visual loss interferes with the tests, 
ask the patient to identify objects placed in the hand, 
repeat, and produce speech. The intubated patient 
should be asked to write. The patient in coma (question 
1a=3) will arbitrarily score 3 on this item. The examiner 
must choose a score in the patient with stupor or limited 
cooperation but a score of 3 should be  used only if the 
patient is mute and follows no one step  commands.  0 = No aphasia, normal  
1 = Mild to moderate aphasia; some obvious loss of fluency or facility of 
comprehension, without significant limitation on ideas expressed or 
form of expression. Reduction of speech and/or comprehension, 
however, makes conversation about provided material difficult or 
impossible. For example in conversation about provided materials 
examiner can identify picture or naming card from patient's  response.  
2 = Severe aphasia; all communication is through fragmentary 
expression; great need for inference, questioning, and guessing by the 
listener. Range of information that can be exchanged is limited; listener 
carries burden of communication. Examiner cannot ide ntify materials 
provided from patient response.  
3 = Mute, global aphasia; no usable speech or auditory comprehension.  
10. Dysarthria: If patient is thought to be normal an 
adequate sample of speech must be obtained by asking 
patient to read or repeat words from the attached list. If 
the patient has severe aphasia, the clarity of articulation 
of spontaneous speech can be rated. Only if the patient 
is intubated or has other physical barrier to producing 
speech, may the item be scored "9", and the examiner 
must clearly write an explanation for not scoring. Do not 
tell the patient why he/she is being tested.  0 = Normal  
1 = Mild to moderate; patient slurs at least some words and, at worst, 
can be understood with some difficulty.  
2 = Severe; patient's speech is so slurred as to be unintelligible in the 
absence of or out of proportion to any dysphasia, or is mute/anarthric.  
9 = Intubated or other physical barrier, 
explain    
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 9 of 150 
© Sunshine Heart  Confidential   
  
 
Instructions  Scale Definition  
11. Extinction and Inattention (formerly Neglect): 
Sufficient information to identify neglect may be obtained 
during the prior testing. If the patient has a severe visual 
loss preventing visual double simultaneous stimulation, 
and the cutaneous stimuli are  normal, the score is 
normal. If the patient has aphasia but does appear to 
attend to both sides, the score is normal. The presence 
of visual spatial neglect or anosagnosia may also be 
taken as evidence of abnormality. Since the abnormality 
is scored only if present, the item is never untestable.  0 = No abnormality.  
1 = Visual, tactile, auditory, spatial, or personal inattention or extinction 
to bilateral simultaneous stimulation in one of the sensory modalities.  
2 = Profound hemi -inattention or hemi -inattention to more than one 
modality. Does not recognize own hand or orients to only one side of 
space.  
 
MODIFIED RANKIN  
 
 
The Modified Ranking must be administered at Pre –implant Baseline and each follow –up. 
Administer the stroke scale items in the order listed. Score should reflect what the patient does, 
not what the clinical thinks the patient can do.  
The Modified Rankin is a score that is given according to the scale provided below: 
0 = No symptoms at all  
1 = No significant disability despite symptoms; able to carry out all usual duties and activities  
2 = Slight disability; unable to carry out all previous activities, but able to look after own affairs 
without assistance  
3 = Moderate disability; requiring some help, but able to walk wit hout assistance  
4 = Moderately severe disability; unable to walk without assistance and unable to attend to own 
bodily needs without assistance  
5 = Severe disability; bedridden, incontinent and requiring constant nursing care and attention 
6 = Dead  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 10 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX M: HOME DISCHARGE CHECKLIST  
 
 
Discharge Check List  
This checklist has been developed to be used as a guideline for the Discharge Criteria for each patient prior to 
going home.  
 Acceptable  Unacceptable  Comments  
Stable Medical Condition. (e.g. 
Healing wounds, no sign if 
infection or sepsis)     
Acceptable Oxygen Saturation 
on room air     
Sinus Rhythm or Atrial 
arrhythmia with Ventricular 
rates < 120 bpm     
Able to walk 30 meters with 
Device without stopping due to 
shortness of breath, muscle 
fatigue, unsteady gait, pain     
Care –giver demonstrates 
aseptic technique in changing 
exit site dressing     
Patient and caregiver 
independently demonstrate 
connection and disconnection 
of the drivers     
Patient and caregiver 
independently demonstrate 
changing and recharging 
batteries     
Patient and caregiver 
understand and respond to the 
Driver Alerts and Alarms     
Home Assessment Visit prior to 
discharge     
All protocol required testing is 
completed up to point of 
discharge     
Patient Handbook supplied to 
patient, with Emergency 
Contact details specified     
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 11 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX N: QUALITY OF LIFE QUESTIONNAIRES  
 
MINNESOTA LIVING WITH HEART FAILURE  QUESTIONNAIRE   
This questionnaire is to be completed by the patient, after receiving basic instruction from the 
Clinical Investigator or Research Nurse (Instructor). All attempts should be made to administer 
the questionnaire:  
• by the same person each time, in same  setting  
• before any other scheduled investigations or medical  reviews  
• in isolation from spouse and/or other persons who might affect the  answers  
Furthermore, the Instructor will not paraphrase the pertinent question if asked about the question, 
but just reiterate the pertinent instructions and the question itself, then ask the patient to respond 
according to what he or she thinks is appropriate  
Begin by showing the patient the questionnaire and asking that they answer a few questions.  
Tell the patient to read and think about each question carefully and telling them to make sure to 
answer all questions. Then go through the first question with him/her to make sure the 
instructions are clear – indicate that over the last month only.  
“If the answer is No then you circl e the zero (point to zero). If the answer is Yes, then how much 
did it stop you living as you wanted over the last month – how much did it prevent you doing 
things, or how bothersome was it?  
Circling 1 means little effect, and circling 5 means very much ef fect. The 2 –4 represent a range 
of effect in between little and very much.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 12 of 150 
© Sunshine Heart  Confidential   
  
 
Did your heart failure prevent you from living as you 
wanted during the last month by:  No 
0  Very Little 
1 2  
3 Very Much 
4 5 
1. causing swelling of your ankles, legs,  etc.? 0 1 2 3 4 5 
2. making you sit or lie down to rest during the  day?  0 1 2 3 4 5 
3. making your walking about or climbing stairs  difficult?  0 1 2 3 4 5 
4.  making your working around the house or  yard 
difficult?  0 1 2 3 4 5 
5. making your going places away from home  difficult?  0 1 2 3 4 5 
6. making your sleeping well at night  difficult?  0 1 2 3 4 5 
7.  making your relating to or doing things with your 
friends and family  difficult?  0 1 2 3 4 5 
8. making your working to earn a living  difficult?  0 1 2 3 4 5 
9.  making your recreational pastimes, sports, or hobbies 
difficult?  0 1 2 3 4 5 
10. making your sexual activities difficult?  0 1 2 3 4 5 
11. making you eat less of the food you like?  0 1 2 3 4 5 
12. making you short of breath?  0 1 2 3 4 5 
13. making you tired, fatigued, or low in energy?  0 1 2 3 4 5 
14. making you stay in a hospital?  0 1 2 3 4 5 
15. costing you money for medical care?  0 1 2 3 4 5 
16. giving you side –effects from medications?  0 1 2 3 4 5 
17. making you feel you are a burden to your family or 
friends?  0 1 2 3 4 5 
18. making you feel a loss of self –control in your life?  0 1 2 3 4 5 
19. making you worry?  0 1 2 3 4 5 
20. making it difficult for you to concentrate or remember 
things?  0 1 2 3 4 5 
21. making you feel depressed?  0 1 2 3 4 5 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 13 of 150 
© Sunshine Heart  Confidential   
  
 
KANSAS CITY CARDIAC QUALITY OF LIFE QUESTIONNAIRE  
 
 
Page intentionally left blank  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 14 of 150 
© Sunshine Heart  Confidential   
  
 
1. Heart failure affects different people in different ways. Some feel shortness of breath while 
others feel fatigue. Please indicate how much you were limited by heart failure (shortness of 
breath or fatigue) in your ability to do the following activities over the past 2  weeks . 
Place an X in one box on each line.  
 
 
 
 
Dressing yourself 
Showering/Bathing  
Walking 1 block on ground 
level  
Doing yardwork,  housework 
or carrying  groceries  
Climbing a flight of stairs 
without stopping  
Hurrying or jogging (as if to 
catch a bus)  Extremely 
Limited  
 
 
 
 
 
 
 
 Quite a 
bit 
Limited  
 
 
 
 
 
 
 Moderately 
Limited  
 
 
 
 
 
 
 
 Slightly  
Limited  
 
 
 
 
 
 
 
 Not at all 
Limited  
 
 
 
 
 
 
 
 Limited for 
other 
reasons or 
did not do 
the activity  
 
 
 
 
 
 
 
 
 
 
 
2. Compared with 2 weeks ago , have your symptoms of heart failure (shortness of  breath, 
fatigue or ankle swelling  changed?  
My symptoms of heart failure have become:  
Much Worse  Slightly  worse  Not Changed  Slightly  better  Much  better  I’ve had no  
symptoms over 
the last 2 weeks  
 
3. Over the past 2 weeks , how many times did you have swelling in your feet, ankles or legs when you 
woke up in the  morning?  
Every  morning  3 or more times a  week,  
but not every day  1-2 times  a week  Less than once  a 
week  Never over the past 2 
weeks  
 
     
 
4. Over the past 2 weeks , how much has swelling in your feet, ankles, or legs bothered  you? 
It has been:  
Extremely  
bothersome  Quite a  bit 
bothersome  Moderately  
bothersome  Slightly  
bothersome  Not at all  
bothersome  I’ve had no swelling  
 
      
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 15 of 150 
© Sunshine Heart  Confidential   
  
 
5. Over the past 2 weeks , on average, how many times has fatigue limited your ability to  do 
what you  want?  
All of  the time Several  times  
per day  At least once a 
day 3 or more 
times per 
week but not 
every day  1-2 times per 
week  Less than once 
a week  Never over the 
past 2 weeks  
 
       
 
6. Over the past 2 weeks , how much has your fatigue bothered  you? 
It has  been:  
Extremely  
bothersome  Quite a  bit 
bothersome  Moderately  
bothersome  Slightly  
bothersome  Not at all  
bothersome  I’ve had no fatigue  
 
      
 
7. Over the past 2 weeks , on average, how many times has shortness of breath limited  your 
ability to do what you  wanted?  
All of the time Several times  
per day  At least once 
a day  3 or more times 
per week but not 
every day  1-2 times 
per week  Less than 
once a week  Never over the 
past 2 weeks  
 
       
 
8. Over the past 2 weeks , how much has your shortness of breath bothered  you? 
It has  been:  
Extremely  
bothersome  Quite a  bit 
bothersome  Moderately  
bothersome  Slightly  
bothersome  Not at all  
bothersome  I’ve had no 
shortness of breath  
 
      
 
9. Over the past 2 weeks , on average how many times have you been forced to sleep sitting  up 
in a chair or with at least 3 pillows to prop you up because of shortness of  breath ? 
Every  night  3 or more times a  week,  
but not every day  1-2 times  per week  Less than once  a 
week  Never over the past 2 
weeks  
 
     
 
10. Heart failure symptoms can get worse for a number of reasons. How sure are you that you 
know what to do, or whom to call, if your heart failure gets worse?  
Not at  all sure Not very  sure Somewhat  sure Mostly  sure Completely  sure 
 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 16 of 150 
© Sunshine Heart  Confidential   
  
 
11. How well do you understand what things you are able to do to keep your heart  failure  
symptoms from getting worse (for example, weighing yourself, eating a low salt diet, etc.)?  
Do not understand  at all Do not  understand  
very we ll Somewhat 
understand  Mostly  understand  Completely 
understand  
 
     
 
12. Over the past 2 weeks  how much has your heart failure limited your enjoyment of  life? 
It has extremely limited 
my enjoyment of life  It has limited my 
enjoyment of life 
quite a bit  It has moderately 
limited my 
enjoyment of life  It has slightly limited 
my enjoyment of life  It has not limited my 
enjoyment of life  
 
     
 
13. If you had to spend the rest of your life with your heart failure the way it is right now , how 
would you feel about this?  
Not at  all satisfied  Mostly  dissatisfied  Somewhat  satisfied  Mostly  satisfied  Completely  satisfied  
 
 
14. Over the past 2 weeks , how often have you felt discouraged or down in the dumps  because 
of your heart  failure ? 
I felt that way all of  the 
time  I felt that way most 
of the time  I occasionally felt 
that way  I rarely felt that way I never felt that  way 
 
     
 
How much does your heart failure affect your lifestyle? Please indicate how your heart failure 
may have limited your participation in the following activities over the past 2 weeks . 
Please place an X in one box on each line.  
 
Activity  
 
Hobbies, 
recreational 
activities  
Working  or doing 
household chores  
Visiting family or 
friends out of your 
home  
Intimate 
relationships with 
loved ones   
 
Severely  
limited  
 
 
 
 
 
 
 
 
 
  
 
Limited  
quite a bit 
 
 
 
 
 
 
 
 
 
  
 
Moderately  
limited  
 
 
 
 
 
 
 
 
 
  
 
Slightly  
limited  
 
 
 
 
 
 
 
 
 
  
 
Did not  
limit at all 
 
 
 
 
 
 
 
 
 
 Does not 
apply or did 
not do for 
other 
reasons  
 
 
 
 
 
 
 
 
 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 17 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX O: HEART FAILURE ASSESSMENTS  
 
NYHA Classification  
In 1928, the New York Heart Association published a classification of patients with cardiac 
disease based on clinical severity and prognosis. This classification has been updated in seven 
subsequent editions of Nomenclature and Criteria for Diagnosis of Diseases of the Heart and 
Great Vessels (L ittle, Brown & Co.). The ninth edition, revised by the Criteria Committee of the 
American Heart Association, New York City Affiliate, was released March 4, 1994. These 
classifications are summarized below.  
 
Class I. Patients with cardiac disease but without resulting limitation of physical activity. 
Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or angina.  
Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They 
are comfortable a t rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or 
angina.  
Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They 
are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or 
angina.  
Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity 
without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at 
rest. If any physical activity is  undertaken, discomfort is increased.  
 
ACC/AHA Stages of Heart Failure  
In 2001, the ACC/AHA published an update subdividing clinical heart failure into four ‘stages’.  
The stages are listed below.  
 
Stage A. Patients at high risk for developing clinical HF (i.e. those with hypertension, diabetes, 
dyslipidaemia, and so on), but without detectable structural heart disease.  
Stage B. Patients with detectable structural heart disease (i.e. LVH, LV Dysfunction), but  no 
clinical signs or symptoms of HF.  
Stage C. Patients with current or past clinical HF.  
Stage D. Patients with end -stage refractory HF, who are candidates for extraordinary forms of 
therapy or for compassionate end -of-life care.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 18 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX P: SIX MINUTE HALL WALK  
 
The six minute walk test (6MWT) will be conducted as described by Guyatt et al.40 and as used 
by other investigators in heart failure clinical trials41 42. In a corridor, a 30.5 meter (100 feet) 
course (without elevations) will be marked and a chair will be placed at each end. The corridor 
should be long, flat, straight and one that is seldom travelled. The turnaround points should be 
marked with a cone (such as an orange traffic cone). A starting line, which marks the beginning 
and end of lap, should be marked on the floor using brightly colored tape.  
 
PATIENT PREPARATION  
• Comfortable clothing should be  worn.  
• Appropriate shoes for walking should be  worn.  
• Patients should use their usual walking aids during the test  (cane, walker, etc.).  
• The patient's usual medical regimen should be  continued.  
• A light meal is  acceptable  before  early  morning  or early  afternoon  tests.  
• Patients  should  not have  exercised  vigorously  within  2 hours  of beginning  the test. 
The patient should sit at rest in a chair, located near the starting position, for at least 10 minutes 
before the test starts. During this time, check for contraindications, measure pulse and blood 
pressure, and make sure that clothing and shoes are approp riate.  
Patients will be instructed to walk from end to end at their own pace while attempting to cover as 
much ground as possible in the allotted period of six minutes. A nurse coordinator will time the 
test, and encourage the patient every 30 seconds in a  standardized fashion (while facing the 
patient and using one of two phrases:  
“You’re doing well” or “Keep up the good work”). Patients will be allowed to stop and rest 
during the test, but will be instructed to resume walking as soon as they feel they are  able to do 
so. After six minutes, patients will be instructed to stop walking. The total distance walked will 
be measured to the nearest meter (and foot). Symptoms experienced by patients during the walk 
(e.g., angina, dyspnea, fatigue, dizziness) will be  recorded.  
The six –minute walk test will be performed at baseline, 1, 3, 6, 12, 18 month, and annually 
thereafter through study closure.  
 
 
 
 
 
 
 
 
 
40 [Guyatt]  
41 [Bittner 1993]  
42 [Riley 1992]  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 19 of 150 
© Sunshine Heart  Confidential   
  
 
Before the Baseline Six Minute Hall Walk test, a familiarization Six Minute Hall Walk test is 
required. The familiarization test should take place at least one hour before the Baseline test. If 
the patient had a test within 12 months of the Baseline test, that test will be considered a 
familiarization test. In addition, the Six Minute Hall Walk test should always be completed prior 
to the Cardiopulmonary testing with adequate time to rest before the CPX test (a minimum of 2 
hours is recommended).  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 20 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX Q: CARDIOPULMONARY EXERCISE TESTING 
OVERVIEW  
 
Cardiopulmonary exercise (CPX) testing will be performed at baseline and at the 6 –month 
follow –up visit to assess patients’ exercise tolerance.  
Overview of Exercise Protocol for Cardio pulmonary Exercise Test  
CPX tests will be performed at baseline and 6 months.  
For all CPX tests, patients will be exercised until they have reached a symptom –limited 
maximal effort. Note: The patient should continue until he/she has reached a symptom – 
limited maximal effort or other American College of Sports Medicine (ACSM) reasons to 
discontinue testing occur.43 
Exercise will be performed on a treadmill using a modified Naughton protocol. Exercise 
will be initiated at 1 mph (miles per hour)/0% grade and t he workload will be increased 
every two minutes to a symptomatic maximum (up to 3 mph/17.5% grade).  
Respiratory gases will be measured with a standard metabolic cart equipped with O2 and 
CO2 analyzers and a turbine volume transducer, which should be calibr ated within 1  hour 
of testing. Continuous 12 –lead ECG monitoring should be performed during the exercise 
test. The patient will then mount the treadmill and be exercised to his/her symptomatic 
maximum. Respiratory gas measurements will be made continuously  while the patient 
exercises. Symptoms experienced by the patient during exercise (e.g., angina, dyspnea, 
fatigue, dizziness) will be recorded. Following a test, the patient should be observed for 
at least 15 minutes, or longer as determined by the investi gator, before discharge from  the 
laboratory.  
Baseline Testing Logistics  
At the beginning of the study, two CPX tests are required: 1) a “familiarization” test to 
allow the patient to become familiar with walking on a treadmill and with the  breathing 
apparatus in his/her mouth, and 2) a baseline  test. 
During the familiarization test, the patient should exercise to his/her symptomatic 
maximum. If the patient reaches his/her symptomatic maximum, this test may be 
considered the baseline test. Th e CPX Core Lab will assess the outcome of the test for 
acceptability as a baseline.  
The first test should be conducted pre -implant. If a second test is required, it should be 
conducted 48 hours after the first test and also pre –implant. When working the pa tient 
into the study and scheduling tests, plan for a 48 hour window between these tests.  
Note: If a patient has a documented CPX test that was performed within 6 months of the 
implant date, this test will be considered the familiarization test. However, t he patient 
must still perform a baseline CPX test for the study, regardless of the previous CPX test.  
 
 
 
 
43 [Pollock  2000]  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 21 of 150 
© Sunshine Heart  Confidential   
  
 
 
Measured Exercise Variables  
Minute oxygen consumption (VO 2; ml/min), minute carbon dioxide production (VCO 2; 
ml/min), and minute ventilation (VE; L/min) will be measured using a breath -by-breath 
respiratory gas analyzer. The RER will be calculated as VCO 2/VO 2. Minute oxygen 
consumption will be normalized for body size by dividing the patient’s weight in kg (VO 2 
in ml/kg/min). Peak oxygen consumption will be that oxygen consumption at peak 
exercise with respiratory gas exchange ratio greater than 1.0. The oxygen consumption at 
anaerobic threshold will be determined by the V -slope method.44 This is the point during 
exercise at which the RER increases due to the generation of carbon dioxide. The 
anaerobic threshold divided by predicted maximum consumption for age and gender x 
100 will be calculated to assess for effort. The oxygen consumption divided by the 
predicted maximum x 100 will be calculated to normalize for age and gender. Watts and 
METS at peak exercise will be a measure of maximum workload, and exercise time will 
also be recorded.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 [Wasserman 1964]  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 22 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX R: STUDY SUMMARY  
 
 
TITLE  C-Pulse® Implantable Counterpulsation Pump (ICP) US Feasibility Study 
A Heart Assist Device  
  
SPONSOR  Sunshine Heart, Incorporated  
  
STUDY OBJECTIVES  Assess the safety and provide indications of performance of the C-Pulse® device. The study 
will include 20 patients enrolled at up 7 centers in the US and potentially some OUS centers. 
The study will be expanded to include a total of 40 patients enrolled at up to 9 centers. Patient 
data will be collected at baseline, 1 , 3, 6, 12, 18 months and annually to 10 years.  
  
BACKGROUND  The current need is for a heart assist device or a method that is effective enough to make its 
application appealing as a long -term therapy to a large number of patients and physicians to 
treat patients in moderate to severe heart failure who are refractory to drugs. It must be simple 
and safe, with a straight -forward implant procedure, and with long -term measurable patient 
benefits. Further, it would be advantageous for the d evice to be small, easy to insert, 
disconnectable, not in the bloodstream and allows for patient ambulation. Such a device may 
be more readily adopted by a wider group of cardiologists and surgeons, and be suitable for a 
wider group of people in ACC/AHA St age C, NHYA Class III/IV heart failure.  
Sunshine Heart, Inc. has proposed C -Pulse®, a novel ambulatory, non -obligatory, non -blood 
contacting extra -ascending aortic counterpulsation system. The C -Pulse® is designed to 
augment heart function in a safe manner  and to provide sustained relief from heart failure 
symptoms. It can be turned off safely, and similarly, in failure modes, is considered to have an 
associated low risk of death or disability, other than the recurrence of heart failure symptoms. 
The C -Pulse® is not an alternative to the heart, it is an augmentation device, and it does not 
preclude the use of other heart failure therapies such as valve surgery, heart transplantation or 
LVADs. It is important to point out that a counterpulsation device is aim ed to augment native 
heart function and is fundamentally different from total artificial hearts, left ventricular assist 
devices and heart transplants which are meant to be a total replacement or an alternative to the 
native heart. Thus, the C -Pulse® count erpulsation device is considered non -obligatory and not 
life-supporting.  
  
PURPOSE  The purpose of the study is to determine whether use of the C -Pulse® used as treatment for 
patients in moderate to severe heart failure is associated with reasonable assurance of safety and 
performance, such that the C -Pulse® merits FDA approval for continuation into a pivotal study 
to examine the safety and efficacy of the C -Pulse® for US market approval.  
  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 23 of 150 
© Sunshine Heart  Confidential   
 
 
 
DEVICE DESCRIPTION  The C -Pulse® utilizes an “extra -aortic” inflatable Cuff which is surgically implanted around the 
ascending aorta. The C -Pulse® ICP has been designed to have a simple, highly reliable 
implantable component (the Cuff) and external wearable compo nents (the Driver and Battery 
Carrier) which are connected by means of a Percutaneous Interface Lead. The Driver is 
programmable by a physician using a Programmer via infra -red (IR) connectivity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The modular design of the C -Pulse® is shown the figure above. Key features are outlined in 
Table 1. For the IDE study, the patient will be provided with two (2) each of the Driver and 
Battery Carrier. The Percutaneous Interface Lead is designed to facilitate simple surgical 
replacement of the external component, in the case of skin infections at the exit site or damage 
to the patient connector.  
Table 1: C -Pulse® System Components  
SHC implantable Cuff:  
• Simple, less invasive  surgery  
• No cardiopulmonary  bypass  
• 3 sizes to fit ascending aorta outside diameter 29 – 40 mm 
• Non-blood contacting 
SHC Percutaneous Interface  Lead:  
• 5 mm outside  diameter  
• Silicone with ECG wire  re-enforcements  
• Transmits air/ECG/heart  sounds  
• Patient connector (with water -tight cap) 
• Lead is  exchangeable  
• Home care package in cluding supplies for dressing  changes 
SHC wearable/portable Drive Unit and Battery Carrier  system:  
• Detachable, approx. 2.5 kg (total weight, split between Driver and Battery  Carrier) 
Ergonomic  design  
• wear in a vest or carry in a  bag 
• simple patient interface – on/off button and battery  indicator  
• visual and audible alarms  
• 4 hours battery life; single battery – recharge separately or in Battery  Carrier  
• 1.4m Driver cable with Isolation  Module  
• Physician  programmer  
• Infra -red functionality  
• Intuitive interf ace for setting counterpulsation  functions  
• Discrete “verification” button on Driver to accept Programmer  changes  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 24 of 150 
© Sunshine Heart  Confidential   
  
 
SYSTEM 
DEFINITION  Investigational Device:  
• C-Pulse® Cuff 
• Small  Cuff 
• Medium  Cuff 
• Large  Cuff 
• Percutaneous Interface  Lead  
• External Driver and Battery Carrier  
 Accessories:  
 • Battery  Charger  
• Programmer  
• Vest 
• Carry  bag 
• Home Care Kit (includes Percutaneous Lead Management  Kit) 
• Epicardial bipolar IS -1 pacemaker lead; Capsure Epi 35 cm, (Medtronic,  Inc., 
Minneapolis)  
  
PRIMARY 
OBJECTIVES  The primary objective of the C -Pulse feasibility study is to assess safety, while at the same time obtain 
performance data for evidence of efficacy to assist planning for a pivotal study. Refer to the section on 
Statistical Methods and Data Analysis for a detailed discussion of the definitions and methodology.  
The Clinical Investigation shall:  
1. Assess the risks with regard to the performance of the device as defined by  the serious adverse 
event rates, under normal conditions of  use. 
2. Assess the potential bene fits of C -Pulse as defined by improvements in Peak  VO2, 
hemodynamic measures, quality of life and HF  symptoms.  
  
SECONDARY 
OBJECTIVES  Secondary objectives are intended to provide additional information on patient response and device 
performance and to allow planning for the pivotal study. The secondary objectives are as follows:  
1. Further  assess  the potential  risks with  regard  to the performance  of the device  as defined  by the 
device failure rate, adverse event rates, adverse event attr ibution, re -hospitalization rates, 
duration of support, and length of time to hospital  discharge.  
2. Further assess the potential benefits of C -Pulse as defined by improvements in quality of  life, 
fatigue impact scales, hemodynamics, average distance walked in the 6 minute hall walk  test, 
and blood  tests.  
3. Assess the device  usage  
  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 25 of 150 
© Sunshine Heart  Confidential   
 
 
 
STUDY DESIGN  The study is designed to assess the safety and potential benefit of the C - Pulse™ System before 
initiating a wider randomized clinical trial to demonstrate efficacy. The effect of the C - Pulse™ system 
in relieving heart failure symptoms in patients with ACC/AHA Stage C; NYHA Class III – ambulatory 
Class IV heart failure will be documented with this study.  
This Feasibility Study is multi -center study in up to 7 centers in the US and potentially some OUS 
centers. The primary study population will include 20 subjects enrolled and implanted with the C - 
Pulse® System. The study will be expanded to include a total of 40 patients in up to 9 cente rs. The 
period of follow -up will be 6 months to assess the safety and performance before initiating the pivotal 
clinical trial. Patients will be followed for up to 5 years.  
 
 
Baseline  Long term  Follow -up 
Inclusion/Exclusion  Implant  1, 3, and 6  month  12 and 18 month  – 
Follow -up 
≤ 30 Days  annually  thereafter  
 
 
Figure 1.  Study Design  
Patients will be enrolled into the trial upon providing informed consent. Procedures related directly to 
the study must not be performed prior to informed consent. Data collection will be noted prior to 
implantation of the device and at one, three, and six months following implant and then annually post - 
implant for five years. Adverse events will be collected throughout the study until study closure and 
will be adjudicat ed by the CEC.  
Progress reports of the clinical outcomes will be prepared by the DSMB after enrollment of five (5) 
patients and twice per year thereafter, unless slow enrollment does not warrant this meeting frequency.  
Progression to the Pivotal study will  be based on the assessment for safety of the device and indicators 
of performance. Baseline and follow –up data will be used to assess any significant difference in quality 
of life and functional variables pre and post implant and to assess the effect of c ounterpulsation.  
Following successful completion of this Feasibility Study, a pivotal study will be conducted to examine 
the safety and efficacy of the C -Pulse® system in patients in moderate to severe heart failure. The 
pivotal trial is expected to measure the same variables as the Feasibility Study.  
  
SUBJECTS - 
CENTERS - 
DURATION - Up to 40 eligible patients will be implanted with the C - Pulse® 
Up to 9 US Centers  
The total duration of the Feasibility Study is expected to be approximately - 120 months.  
  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 26 of 150 
© Sunshine Heart  Confidential   
  
 
INCLUSION 
CRITERIA  Patients of both genders who satisfy all inclusion and exclusion criteria are eligible for this clinical 
study. Patients must meet the following criteria:  
1. Patient has ACC/AHA Stage C heart failure and remains in NYHA Class III - ambulatory 
Class IV despite optimal medical therapy. Patients must have stable, evidence –based optimal 
medical therapy for heart failure as defined  below:  
a. ACE inhibitor or ARB (Angiotensin Receptor Blocks) at l east 30 days  preceding 
implant or nitrate/hydralazine at the investigators  discretion  
b. Beta–blocker for at least 90 days and stable for 30 days preceding  implant  
Note: Stable is defined as no more than a 50% reduction or 100% increase in the medications 
listed above. Transition within a therapeutic class is allowed if the dose is equivalent  
2. Patient has left ventricular ejection fraction ≤  35% 
3. Patient has had Cardiac Resynchronization Therapy (CRT) for at least 90 days prior  to 
enrollment or is not indicated for a CRT  device  
4. Patient has had an implanted cardio –defibrillator (ICD) at least 30 days prior to enrollment  or 
is not indicated for ICD implantation  
5. Patient is at least 18 years of age and not older than 75  years  
6. Patient six minute hall walk assessment between 100 –350 meters  
7. Patient understands the nature of the procedure, is willing to comply with associated follow –up 
evaluations, and provide written informed consent prior to the  procedure  
  
EXCLUSION 
CRITERIA  Candidates must be excluded from the study if any of the following are met:  
1. Patient has any evidence of :  
a ascending aortic calcification on posterior –anterior or lateral chest x –ray at initial screening OR  
b. Atherosclerotic ascending aortic disease, specifically intima l thickening greater than 3mm or 
mobile atheroma (moderate) or mural calcification (severe) as detected by CT scan or 
echocardiography 45 (Echo)  
2. Patient has ascending aorto -coronary artery bypass grafts, history of aortic dissection,  Marfans 
disease or oth er connective tissue disorder or has had an aortic root  replacement  
3. Patient aorta not conforming to specified dimensional constraints defined by CT scan,  most 
specifically mid ascending aortic outside diameter less than 29mm or greater than  40mm  
4. Patient ha s severe mitral valve incompetence, grade 4  + 
5. Patient has moderate to severe aortic valve incompetence, grade  2–4+ 
6. Patient has systolic blood pressure less than 90 or greater than 140  mmHg  
7. Patient has a Serum Sodium less than 130  mEq/L  
8. Patient has a Estimated GFR less than 40 ml/min/1.73  m2 
9. Patient has any two of three of Bilirubin, AST, ALT greater than 3 times upper limit of  normal 
for each  institution  
 
 
45 [Davila –Roman 1999]  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 27 of 150 
© Sunshine Heart  Confidential   
  
 
EXCLUSION 
CRITERIA  
(continued)  10. Patient has a serum Albumin less than 3.0 g/dL  
11. Patient has BMI less than 18 or greater than 40  kg/m2  
12. Men with Peak VO 2 of greater than 18ml/kg/min or less than 10  ml/kg/min  
13. Women with Peak VO 2 of greater than 16 or less than 9  ml/kg/min  
14. Patient has any active  infection  
15. Patient has had a myocardial infarction, stroke, transient ischemic attack, cardiac or other  major 
surgery, in the 3 months prior to study  enrollment.  
16. Patient has severe COPD as evidenced by FEV1 less than or equal to 0.9  L/min  
17. Patient requires a concomitant surgical procedure (i.e. CABG, Valve  repair)  
18. Patient is supported with a left ventricular assist device or intra –aortic balloon  pump.  
19. Severe right heart dysfunction with systemic venous congestion evidenced by clinical 
signs/symptoms such as CV P ≥ 20 mmHg , Cardiac Index < 2.0 l/min/m2, elevated  liver 
function tests beyond three times the upper limit of normal with the presence of  ascites.  
20. Patient has reversible causes of heart failure that may be remedied by conventional surgery  or 
other interv ention  
21. Patient is pregnant. Note: Negative pregnancy test required in all women of child  bearing 
potential.  
22. Patient has any other condition that, in the opinion of the investigators, would disqualify  the 
patient for inclusion in the study, limits survival to less than one year, or not permit valid 
consideration  
23. Patient is currently enrolled or has participated in the last 30 days in another therapeutic or 
interventional clinical study that is likely to confound study results or affect study  outcome  
24. Patient has symptomatic Carotid artery disease or asymptomatic disease with a stenosis greater 
than 70% as determined by Carotid Doppler  Ultrasound.  
 
Data Collection Summary  
 
 
Follow -up Requirements Baseline to 6 months Post Implant  
 Pre-Implant  Implant  Pre-Discharge7 1 mo  3 mo  6 mo  
A. PATIENT ELIGIBILITY  X      
B. GENERAL        
Demographic Data  X      
Medical History  X      
General Physical Examination  X X X X X X 
Concurrent Medications  X X X X X X 
Pregnancy test (if applicable)  X      
C. VITAL PARAMETERS        
Weight  X  X X X X 
Heart rate  
(ECG pre -implant)  X  X X X X 
Blood pressure  X  X X X X 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 28 of 150 
© Sunshine Heart  Confidential   
  
 
Follow -up Requirements Baseline to 6 months Post Implant  
 Pre-Implant  Implant  Pre-Discharge7 1 mo  3 mo  6 mo 
Respiratory rate  X  X X X X 
D. CARDIOPULMONARY        
CT aorta  X     X 
CXR  X    X X 
ECHO  X X2  X X X 
Right heart catheterization  
(CVP, PAP, CI, PCWP, SVR, PVR)  X     X 
Peak O2 uptake  X     X 
E. QUALITY OF LIFE        
NYHA Classification  X   X X X 
MLHF Score/ KCCQ  X   X X X 
Fatigue Impact Scales  X  X X X X 
Six Minute Walk  X   X X X 
F. HEMATOLOGY        
Hemoglobin  X  X X X X 
Hematocrit  X  X X X X 
Plasma free hemoglobin  X  X X X X 
Platelet count  X  X X X X 
White cell count  X  X X X X 
APTT  X  X X X X 
INR X  X X X X 
Fibrinogen  X  X X X X 
G. BIOCHEMISTRY        
Serum sodium  X  X X X X 
Serum potassium  X  X X X X 
Serum creatinine/ GFR3 X  X X X X 
BUN  X  X X X X 
Serum albumin  X  X X X X 
Serum bilirubin  X  X X X X 
Serum ALT  X  X X X X 
Serum AST  X  X X X X 
Serum BNP  X     X 
H. NEUROLOGICAL ASSESSMENT6       
Neurological testing (NIHSS)4 X  X X X X 
Modified Rankin 4 X  X X X X 
Head CT 5 X      
Neurological Consultation  X  X6    
I. IMPLANT DETAILS   X     
J. DEVICE LOG   X  X X X 
K. DISCHARGE CHECKLIST    X    
1 Annually  post-implant  
2 Epi-aortic Echo at  implant  
3 Estimated  GFR  at Baseline  and within one  week  post CT to evaluate  contrast  induced  nephropathy. 
4 Post Neurological Dysfunction AE – 30, 60 and 90 days post  event  
5 At Baseline only or as clinically indicated with any Neurological Dysfunction AE – Head CT should be completed only after clearance 
for implantation.  
6 Required at 5 -7 days post ICU discharge or at hospital discharge whichever occurs first an d at the time of any suspected Neuro 
Dysfunction  AE 
7 At Discharge – within 36 hours prior to discharge and as close to discharge as possible (see Appendix  M) 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 29 of 150 
© Sunshine Heart  Confidential   
  
 
 
 
Long -term Post Implant Follow -Up Requirements  
 12 month  18 month  Annually  
Year  2-10 
A. PATIENT ELIGIBILITY     
B. GENERAL     
General Physical Examination  X X X 
Concurrent Medications  X X X 
Pregnancy test (if applicable)     
C. VITAL PARAMETERS     
Weight  X X X 
Heart rate  
(ECG pre -implant)  X X X 
Blood pressure  X X X 
Respiratory rate  X X X 
D. CARDIOPULMONARY     
ECHO  X X X 
E. QUALITY OF LIFE     
NYHA Classification  X X X 
MLHF Score/ KCCQ  X X X 
Fatigue Impact Scales  X X X 
Six Minute Walk  X X X 
F. HEMATOLOGY     
Hemoglobin  X X X 
Hematocrit  X X X 
Plasma free hemoglobin  X X X 
Platelet count  X X X 
White cell count  X X X 
APTT  X X X 
INR X X X 
Fibrinogen  X X X 
G. BIOCHEMISTRY     
Serum sodium  X X X 
Serum potassium  X X X 
Serum creatinine/ GFR3 X X X 
BUN  X X X 
Serum albumin  X X X 
Serum bilirubin  X X X 
Serum ALT  X X X 
Serum AST  X X X 
I. IMPLANT DETAILS     
J. DEVICE LOG  X X X 
K. DISCHARGE CHECKLIST7    
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 30 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX S:  BIBLIOGRAPHY  
 
Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, 
Clavell AL, Hayes DL, Ellestad M, and Messenger J for the MIRACLE Study Group. 
Cardiac Resynchronization in Chronic Heart Failure. N Engl J Med 2002;346:1845 –1853  
Ash, SR. Chronic peritoneal dialysis catheters: effects of catheter des ign, materials and location.  
Seminars in Dialysis 1990;3:39 –46. 3.  
Barnett MG, Fiore AC, Vaca KJ, Milligan TW, Barner HB. Tailoring aortoplasty for repair of 
fusiform ascending aortic aneurysms. Ann Thorac Surg 1995;59:497 –501 
Bauer M, Grauhan O, Hetzer R.Dislocated wrap after previous reduction aortoplasty causes 
erosion of the ascending aorta. Ann Thorac Surg. 2003;75:583 -4 
Bittner V, Weiner DH, Yusuf S, et al. “Prediction Of Mortality And Morbidity With A 6 –Minute 
Walk Test In Patients With Left  Ventricular Dysfunction”. JAMA 1993; 270:1702 –1707  
Carel T, von Segesser L, Jenni R, et al. Dealing with dilated ascending aorta during aortic valve 
replacement: advantages of a conservative surgical approach. Eur J Cardiothorac Surg 
1991;5:137 –43 
Cheung AT, Savino JS, Weiss SJ. Beat –to–beat augmentation of left ventricular function by 
intraaortic counterpulsation. Anesthesiology 1996;84:545 –54. 
Cochran RP, Starkey TD, Panos AL, et al. Ambulatory intraaortic balloon pump use as bridge to 
heart transplant. Ann Thorac Surg 2002;74:746 –52. 
Cohen M, Patel JJ, Dohad S, McBride R, Venkatesulu S, Boston BA, Chandrasekaran K. Pilot 
prospective evaluation of counterpulsation with different intra –aortic balloon volumes on 
cardiac performance in humans.Cathet Cardiova sc Diagn. 1995;36:82 –7 
Davies AN, Peters WS, Su T, Sullivan CE, Perkidides T, Milsom FP, White G. Extra –ascending 
aortic versus intra –descending aortic balloon counterpulsation – effect on coronary artery 
blood flow. Heart, Lung & Circulation 2004. In pres s 
Davis R, Ribner HS, Keung E, Sonnenblick EH, LeJemtel TH. Treatment of chronic congestive 
heart failure with captopril, an oral inhibitor of angiotensin -converting enzyme. N Engl J 
Med 1979;301:117 -21 
Davila –Roman V, Murphy S, Nickerson N, et al. Atheros clerosis of the ascending aorta is an 
independent predictor of long –term neurologic events and mortality. J Am Coll Cardiol 
1999;33:1308 –16. 
Demers P, Moffatt S, Oyer PE, Hunt SA, Reitz BA, Robbins RC. Long –term results of heart 
transplantation in patients  older than 60 years. J Thorac Cardiovasc Surg. 2003;126:224 – 
Furman S, Whitman R, Stewart J et al . Proximity to aortic valve and unidirectionality as prime 
factors in counterpulsation effectiveness. Trans Am Soc Artif Int Organs 1971; 17:153 – 
159 
Gitter R, Cate CM, Smart K, Jett GK.Influence of ascending versus descending balloon 
counterpulsation on bypass graft blood flow. Ann Thorac Surg. 1998;65:365 -70. 
Guyatt GH, Sullivan MJ, Thompson PH, et al. The 6 –Minute Walk: A New Measure Of Exercise  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 31 of 150 
© Sunshine Heart  Confidential   
  
 
Jeevanandam V, Jayakar D, Anderson AS, Martin S, Piccione W Jr, Heroux AL, Wynne J, 
Stephenson LW, Hsu J, Freed PS, Kantrowitz A. Circulatory assistance with a permanent 
implantable IABP: initial human experience. Circulation 2002;24(12 Su ppl 1):I183 –8 
Kofidis T, Fischer S, Leyh R, Mair H, Deckert M, Haberl R, Haverich A, Reichart B. Clinical 
relevance of intracranial high intensity transient signals in patients following prosthetic 
aortic valve replacement. Eur J Cardiothorac Surg 2002 Jan ;21(1):22 –6 
Laas J, Kseibi S, Perthel M, Klingbeil A, El –Ayoubi L, Alken A Impact of high intensity 
transient signals on the choice of mechanical aortic valve substitutes..Eur J Cardiothorac 
Surg 2003 Jan;23(1):93 –6 
Legget ME, Peters WS, Milsom FP, Clark J S, West TM, French RL, Merry AF. Extra –aortic 
balloon counterpulsation – an intra –operative feasibility study. Circulation 
2005;112[suppl I]:I –26−I –31 
Leuprecht A, Perktold K, Kozerke S, Boesiger P. Combined CFD and MRI study of blood flow 
in a human ascen ding aorta model. Biorheology 2002;39:425 –429 
Misfeld M, Scharfschwerdt M, Sievers HH.A novel, form -stable, anatomically curved vascular 
prosthesis for replacement of the thoracic aorta. Ann Thorac Surg. 2004;78:1060 -3 
Nabavi DG, Stockmann J, Schmid C, Sch neider M, Hammel D, Scheld HH, Ringelstein 
EB.Doppler microembolic load predicts risk of thromboembolic complications in 
Novacor patients. J Thorac Cardiovasc Surg 2003;126:160 –7 
Nadareishvili ZG, Beletsky V, Black SE, Fremes SE, Freedman M, Kurzman D, Lea ch L,  Norris 
JW. Is cerebral microembolism in mechanical prosthetic heart valves clinically relevant? 
J Neuroimaging 2002  Oct;12(4):310 –5 
Neaton JD, Normand SL, Gelijns A, Starling RC, Mann DL, Konstam MA.Designs for 
mechanical circulatory support device s tudies. J Card Fail. 2007;13:63 -74. 
Ootaki Y, Kamohara K, Akiyama M, Zahr F, Kopcak MW, Dessoffy R, Fukamachi K. Phasic 
coronary blood flow pattern during a continuous flow left ventricular assist support.  
EJCS  2005;28:711 —716 
Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart 
failure. N Engl J Med. 2001;344:1651 -8 
Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in 
the treatment of chronic heart failure. J Car d Fail. 2001 Jun;7(2):176 –82. 
Peters WS, Milsom FP. Relationship between ascending aortic anatomy and blood flow. Cardiac 
Society Australia/New Zealand, Canberra, Aug 2006: Heart, Lung & Circulation  
Pollock ML, Franklin BA, Balady GJ, et al. Resistance exe rcise in individuals with and without 
cardiovascular disease: benefits, rationale, safety, and prescription: An advisory from the 
Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, 
American Heart Association; Position pa per endorsed by the American College of Sports 
Medicine. Circulation. 2000;101:828 -33. 
Reichert CL, Koolen JJ, Visser CA. Transesophageal echocardiographic evaluation of left 
ventricular function during intraaortic balloon pump counterpulsation. J Am Soc 
Echocardiogr 1993;6:490 –5. 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 32 of 150 
© Sunshine Heart  Confidential   
  
 
Riley M, McParland J, Stanford CF, Nicholls DP. “Oxygen Consumption During Corridor Walk  
Testing In Chronic Cardiac Failure”. Eur Heart J. 1992; 13:789 –793. 
Rose EA, Gelijns AC, Moskowitz AJ, et al. Randomized Eval uation of Mechanical Assistance 
for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long –term 
mechanical left ventricular assistance for end –stage heart failure. N Engl J Med 2001; 
345: 1435 –43. 
Rubiscsek F, Thubrikar MJ. Conservative oper ation in the management of annular dilatation and 
ascending aortc aneurysm. Ann Thorac Surg 1994;57:1672 –4 
Takasu J, Takanashi K, Naito S, et al. Evaluation of morphological changes of the atherosclerotic 
aorta by enhanced computed tomography. Atherosclero sis. Dec 1992;97(2 –3):107 –121. 
Trainini J, Cabrera Fischer EI, Barisani J, et al. Dynamic aortomyoplasty in treating end –stage 
heart failure. J Heart Lung Transplant 2002; 21:1068 –73. 
Wasserman K, MvIlroy MB. “Detecting The Threshold Of Anaerobic Metabolis m In Cardiac 
Patients During Exercise”. Am J Cardiol. 1964; 14:844 –852. 
Wilhelm CR, Ristich J, Knepper LE, Holubkov R, Wisniewski SR, Kormos RL, Wagner 
WR.Measurement of hemostatic indexes in conjunction with transcranial doppler 
sonography in patients with ventricular assist devices. Stroke. 1999 Dec;30(12):2554 –61 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 33 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX T: CLINICAL STUDY AGREEMENT TEMPLATE  
 
Not related to this change – not resubmitted  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 34 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX U: INFECTION CONTROL GUIDELINES  
 
Overview  
Infection control encompasses many factors including nutrition, management of conditions such 
as diabetes, prophylactic treatments and exit site care.  
Prior to surgery it is recommended that the nutritional status of the patient be assessed and 
addressed i f the status is marginal. In addition, controlling blood sugar levels in the diabetic 
patients is also important.  
Pre-Operative Recommendations:  
• Nutritional status of the patient should be assessed prior to surgery. If nutritional  status 
of the patient is marginal, attempts should be made to improve the patient’s nutritional 
status prior to  surgery.  
• Diabetic patient’s glucose levels should be normalized on a stabile regimen prior  to 
surgery.  
• Percutaneous Interface Lead (PIL) exit site should be pre -selected  and marked prior to 
surgery. Pre -select an exit site for the Percutaneous Interface Lead that will facilitate PIL 
immobilization as well as patient selection for clothing, daily routine, etc. This should 
preferably be done while the patient is standing. P re-selection of the PIL exit site will 
help to facilitate effective PIL immobilization after implant. Pre -selection at the very 
least should take into account patient body habitus, patient’s dominant hand, as well as 
input from the patient concerning daily  routine and fit of  clothing.  
 
Prep for surgery:  
Pre-select an exit site for the Percutaneous Interface Lead that will facilitate the patient selection 
for clothing, daily routine, etc.  
Prepare and shave the patient: Pre -operative scrub with antiseptic (Septisol or Chlorhexidine)  on 
the night prior to surgery then again the morning of the surgery, and clip and shave the surgical 
area prior to transport to the operating  room.  
Antibiotic prophylaxis  recommendations:  
Administer prophylactic antis epsis coverage. Recommended prophylaxis:  
• Nasal Bactroban application day prior to  surgery  
• Vancomycin 15mg/kg IV one hour pre –op given over 30 minutes and with minimum 5 
minute interval blood pressure monitoring or arterial line monitoring – note that 
Vancomycin can cause hypotension in this patient population and should not be given 
unsupervised pre -operatively on the ward. Follow -up doses Q12 –24 hr post -operatively 
for 48 hrs, guided by serum Vancomycin trough  levels  
• Cephalexin 1g IV one hour pre –op then every 8 –12hr for 48  hrs 
• Rifampicin 600 mg PO 2hrs pre –op then daily for 2 days – stop if liver function tests 
become deranged greater than two times  baseline  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 35 of 150 
© Sunshine Heart  Confidential   
  
 
Peri-operative recommendations:  
• Observe Operating Room precautions – particularly, limit the number of people in  the 
room, and traffic in and out of the  room.  
• Recommend approach to skin  preparation:  
o antiseptic scrub (Septisol or  Chlorhexidine)  
• Drape patient with steri -drapes (e.g. Ioban), over exposed prepared  skin.  
• Delay  opening of the C -Pulse until necessary. Massage with antibiotic prior  to 
implantation.  
• Massage flocking and wrap with antibiotic soaked gauze (e.g. standard mix  doxycycline) 
prior to implantation. Keep the C -Pulse devices and driveline covered with antibi otic 
gauze while on OR prep  table.  
• The PIL should be inserted in such a manner that the flocking is not visible at the end  of 
surgery.  
• After implantation and before leaving the OR, close the exit site for good appositio n and 
leave sutures in place for 7 -10 days. Place a suture -tie on the PIL adjacent but separate 
(1-2 cm) from the exit site and leave in place for 4 -6 weeks. Secure the Percutaneous 
Interface Lead (PIL) Patient Connector and the Driver Lead connector with two points  of 
anchor using two separate adhesive catheter securement devices. Strict immobilization of 
the PIL at the skin exit site is crucial to getting effective flocking anchoring by fibrosis 
formation and preventing infection at the PIL exit site.  
Post-Implantation Recommendations:  
• Chest and other drains should be removed as soon as practical, at the discretion of  the 
surgeon, and typically within 48 hours, depending on  drainage.  
• Monitor patient’s nutritional status and intervene early if their status becomes  marginal.  
• An Insulin infusion should be established in patients with diabetes or other glucose 
intolerance until a regular diet and normal diabetic therapy can be re -introduce d. Early 
mobilization and graduated physical therapy should be conducted as tolerated from day  1. 
The Carry Bag Waist Strap and Driver Lead coiling Velcro strap should be used when 
ambulating. Ambulation should be started gradually and used with assistance  from 
physical therapy or other hospital  staff.  
• The C -Pulse Driver Lead should be attached to the patient’s clothing or 
secured with the coiling strap to establish a 3rd level of stress relief for  the 
driveline while the patient is out of  bed. 
• PIL dressing  changes should be performed strictly following dressing change protocol 
and should be limited to as few people as possible. Ongoing oral broad spectrum/gram 
negative antibiotics are recommended for or until chest drains are removed and the exit - 
site has dried sufficient for once daily dressing  only.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 36 of 150 
© Sunshine Heart  Confidential   
  
 
• Provide ongoing education to patient and caregivers on general hygiene, e.g. regular  hand 
washing and importance of PIL immobilization and care, to avoid pulling to treat 
percutaneous line gent ly and to avoid undue pulling, pushing or torque at the PIL exit 
site. 
• Schedule removal of the skin suture tie at the PIL exit site according to the  physician 
orders.  
.Exit Site Care:  
PIL Exit Site Dressing Change Key Points  
• Exit site dressing and lead stabilization should occur in the OR prior to the  patient 
transferring from the OR  table.  
• First 72 hours post -implant – dressing should remain unchanged as long as it remains 
dry.be changed as frequently as required post –operatively whilst ensuring that the 
percutaneous lead is immobilized. – this may be up to 2 –3 times per day in the first  1–2 
weeks if it is oozing. If wounds are healing well and there is no discharge, then go to 
daily or second -daily dry dressings.  
• If the dressing becomes soiled, it  should be changed  immediately  
• As post -operative drainage decreases, exit site dressing changes can be decreased to  once 
daily or once every other  day. 
• Strict immobilization of the PIL site should be observed at all times. The PIL  patient 
connector and dri ver lead connector should be stabilized using two adhesive  catheter 
securement devices - one for the PIL patient connector and one for the driver  lead.  
• The Driver should remain in the Carry Bag at all times when being used by the  patient, 
Careful attention  should be made to prevent the Driver from falling or being  dropped.  
• Limitation of personnel around patient should be exercised while performing PIL exit  site 
dressing changes to limit contamination of PIL exit  site. 
• Patient and/or Caregiver should be taug ht strict dressing change procedure and allowed  to 
take over dressing changes as soon as they are  competent.  
 
Dressing Change Procedure  
The following procedure is to be followed for all PIL exit site dressing changes.  
Equipment needed:  
• Driveline Management  Kit 
• One adhesive catheter securement device (in addition to that supplied in the  driveline 
management  kit). 
OR: 
• Masks  (2) 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 37 of 150 
© Sunshine Heart  Confidential   
  
 
• Disposable sterile drape or towel  (1) 
• Clean gloves (1  pair)  
• Sterile gloves (1 pair plus one unopened pair f or backup)  
• 2 Chlorhexidine surgical prep swab sticks (2% Chlorhexidine) or 2%  Chlorhexidine 
Solution  
• 4X4 drain sponge (1 packet of 2  sponges)  
• 4X4 gauze pad (1 packet of 2  pads)  
• Clear occlusive Dressing (i.e.  Tegaderm)  
• 2 adhesive catheter securement devices (i.e. a catheter anchor for the PIL patient 
connector and the Driver  Lead)  
Procedure Using Driveline Management Kit:  
1. Wash hands and arms thoroughly with water and antibacterial soap. Dry using a  clean 
disposable  towel.  
2. Place a mask over the nose and mouth of everyone in the room, including the patient  if 
possible.  
3. Put on clean  gloves.  
4. Open the dressing kit using sterile  technique.  
5. Remove open the sterile towel to create a sterile  field.  
6. Open and drop the chlorohexadine swab sticks in to the driveline management kit 
container. Open and drop the 4X4 gauze pad and drain sponge on the sterile  field.  
7. Remove and discard old  dressing.  
8. Examine the site for problems with PIL integrity and signs of infection (e.g.  purulent 
drainage, redness or t enderness to  palpation).  
9. If signs of infection are present, culture exit site drainage using a sterile  culturette.  
10. Examine the adhesive catheter securement devices. Remove if adhesive is coming  loose 
or if PIL immobilization requires revision. Be sure to allow as little movement as 
possible of the PIL at the exit  site. 
11. Remove dirty gloves and don sterile gloves. This must be done observing strict sterile 
technique.  
Note: It may be helpful to have another set of sterile gloves immediately available in the 
event contamination occurs.  
12. Clean the PIL exit site and the percutaneous lead with the Chlorahexadine swab  sticks.  
a.  Follow a circular pathway from the catheter outward. Use gentle pressure  moving 
from the exit site  outward.  
b. Discard each swab once lifted from the patient's  skin.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 38 of 150 
© Sunshine Heart  Confidential   
  
 
13. Allow solution to air dry for at least 2 minutes. DO NOT DRY THE SITE WITH A  4x4. 
14. Take a picture and upload it to the electronic data capture  system  
15. Apply the 4x4 drain sponge and the SorbaView Shield  Dressin g 
16. If not using Centurion supplies, apply a large clear occlusive dressing, or  tape 
reinforcement to entire site covering the drain sponge and  PIL. 
17. Ensure that the PIL is immobilized without twisting or tension by the two separate 
adhesive catheter secureme nt devices at two separate locations, one at the PIL patient 
connector and one at the driver lead connector. If either anchor is compromised replace  it 
immediately.  
Procedure Without Driveline Management Kit:  
1. Wash hands and arms thoroughly with water and antibacterial soap. Dry using a  clean 
disposable  towel.  
2. Place a mask over the nose and mouth of everyone in the room, including the patient  if 
possible.  
3. Put on clean  gloves.  
4. Open the disposable sterile towel to create a sterile  field.  
5. Open the 4x4 gauz e pads and 4x4 drain sponges and drop them on the sterile  field.  
6. Pour the Chlorhexidine cleansing solution (2%) onto the gauze pad or drop  the 
chlorhexadine swab sticks onto the sterile  field.  
7. Remove and discard old  dressing.  
8. Examine the site for problems with PIL integrity and signs of infection (e.g.  purulent 
drainage, redness or tenderness to  palpation).  
9. If signs of infection are present, culture exit site drainage using sterile  culturette.  
10. Examine the adhesive catheter securement devices. Remov e if adhesive is coming  loose 
or if PIL immobilization requires revision. Be sure to allow as little movement as 
possible of the PIL at the exit  site. 
11. Remove dirty gloves and don sterile gloves. This must be done observing strict  sterile 
technique.  
Note: I t may be helpful to have another set of sterile gloves immediately available in the 
event contamination occurs.  
12. Clean the PIL exit site and the percutaneous lead with the Chlorhexidine soaked gauze  or 
swabs.  
a. Follow a circular pathway from the catheter  outward.  
a. Discard each gauze pad or swab once lifted from the patient's  skin.  
b. If using Chlorhexidine solution on 4x4 gauze pads allow one pad to  remain 
wrapped around PIL for 2 minutes then remove and  discard  
13. Allow solution to air dry for at least 2 minutes. DO NOT DRY THE SITE WITH A  4x4. 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 39 of 150 
© Sunshine Heart  Confidential   
  
 
14. Take a picture and upload it to the electronic data capture  system  
15. Apply a 4X4 drain sponge around the  PIL. 
16. Apply large clear occlusive dressing (i.e. Tegaderm) or tape reinforcement to entir e site 
covering the drain sponge and  PIL. 
17. Ensure that PIL is held immobile without twisting or tension by the adhesive catheter 
securement devices at two separate locations, one at the PIL patient connector and one  at 
the driver lead connector. If either a nchor is compromised replace it  immediately.  
Additional Comments:  
- No ointment or cream should be use at any time on the percutaneous lead of the  C-Pulse 
unless directed to do so by the surgeon (no other  physician).  
- Inspect the Driver Carry Bag to be sure the integrity of the Velcro strap used to coil  the 
Driver Lead.  
- Take digital photos of the exit site to document the condition for future  reference.  
Infection Advisory Committee Recommendations:  
Due to the possible interaction of site infection leadin g to “Deep” infection or tissue swelling 
around the intrathoracic gas line and /or ascending aorta an infection procedure monitoring 
process is recommended. The following process is recommended to reduce risk of injury to the 
patient.  
Infection Monitoring  Process:  
In the presence of clinical signs (pain, redness, discharge, loss of driveline fixation) and /or 
microbiological evidence (positive wound culture) of infection (intermittent or chronic) over a 3  
month period despite  treatment . 
Decision Process:  
Are there clinical signs or microbiological evidence of infection over a 3 month period despite 
treatment?  
• No: Continue  therapy  
• Yes: Perform CT or PET  scan 
- If scan is positive  (i.e. shows  evidence  of DEEP  infection  or soft tissue  swelling  around 
the intrathoracic gas line and/or ascending aorta or presence of intrathoracic gas),  then 
REMOVE PIL AND  CUFF.  
- If scan is negative (i.e. shows no evidence of DEEP infection), REMOVE PIL  only.  
- If at the time of surgery there is clinical evidence of DEEP infection (i.e. pus or fluid 
around  the ‘Y’- connector,  positive  gram  stain,  and infected  tissue)  then REMOVE  the 
CUFF also.  
• If at the time of CT/PET scan or surgery there is no evidence of DEEP infection, then 
REPEAT SCAN at 3 months post -op and monitor f or clinical signs of infection, if none 
found then REPEAT SCAN  annually.  
• NOTE: If wound culture is positive for MRSA, MSSA or Pseudomonas, monitor more 
frequently with FOLLOW -UP CT -SCAN at 3  months.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 40 of 150 
© Sunshine Heart  Confidential   
  
 
Aortic Tissue Sampling Guideline  
In the e vent of a heart transplant, LVAD or patient death it is recommended that the C -Pulse 
system be removed. To ensure evaluation of the system and patient interaction the following 
process provides guidance on removal of the C -Pulse implanted components at the  time of 
explant, the observations to be recorded and for device return for analysis.  
• If possible, return the devices intact and connected. In the event of device  dissection, 
attempt to maintain the connections  intact.  
• For the Cuff, balloon integrity shoul d be maintained unless histopathological  analysis 
requires  dissection.  
• Depending upon the event (a heart transplant, LVAD or patient death) the  following 
three tissue samples of the aorta should be collected for analysis from patients 
implanted with the C -Pulse  system:  
- under the  cuff/balloon  
- proximal to the C -Pulse  Cuff 
- distal to the C -Pulse  Cuff 
- For control arm patient one tissue sample for the ascending aorta should  be 
collected for  analysis  
• The aorta samples should be sent to the local pathology lab for hematoxylin and  eosin 
stain histological studies. Microbial analysis should be undertaken at the time of 
explant.  
• Cultures should be obtained at the skin exit site, at the y -connector of the PIL and at  the 
balloon cuff and processed at the local labora tory for assessment of  organisms.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 41 of 150 
© Sunshine Heart  Confidential   
  
 
APPENDIX V: INVESTIGATIONAL PLAN REVISIONS  
 
The protocol amendments are listed below along with the justifications for change and the 
associated dates of the protocol revisions. Version 1 (PRO 02291 -A) was sent to IRBs for study 
preparation.  
 
Version 1  Justification for Change  Page(s)  
Initial Version – Date 7 June 
2007  Submission for IDE  All 
 
Version 2 (PRO 02291 -B) was created in response to FDA questions and incorporates the 
changes below. It was not delivered to IRBs for preparation of study documents.  
 
Version 1  Version 2  Justification for Change  Page(s)  
Randomized study 
design, 24 pts., 
blinded study.  Non-randomized study design, 20 
pts. Removed all references to old 
design and corrected study  design.   
To address FDA concern.  7, 15 -16, 21 -27, 54 - 
55, 108 -9 
Previous study 
population and 
eligibility criteria.  Updated eligibility criteria and 
associated references.   
To address FDA concern.   
15, 17 -19 
NA Added additional screening process.  To address FDA concern.  20-21 
 
NA Clarification and addition of 
required testing with associated data 
collection intervals.   
To address FDA concern.   
23-27,29, 93  
NA Clarification and addition of 
infection control guidelines.  To address FDA concern.  31-32, 119 -121 
 
NA Adverse events – clarified use of the  
Intermacs registry definitions. 
Rearranged AE section for 
clarification.   
To address FDA concern.   
34-41 
Previous study 
design.  Replaced Stat Section with updated 
analysis.  To address FDA concern.  42-44 
 
HF Composite  Removed the HF Composite due to 
removing randomization and to us 
individual assessment analysis in the 
feasibility.   
To address FDA concern.   
54 
DSMB and CEC 
paragraphs.  Relocated these paragraphs into the 
study safety section.  Clarification.  59-60 
Device usage 
statements  Clarified the usage to be greater than 
80% of the time.  To address FDA concern.  13,31  
NA Added Core Lab information sheet.  To address FDA concern.  94 
Study Summary  Updated with all relevant main 
protocol changes.  Clarification.  108-114 
NA Typos corrected.  Administrative  Throughout.  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 42 of 150 
© Sunshine Heart  Confidential   
  
 
 
Version 3 (PRO 02291 -C) was created in response to FDA questions and incorporates  the 
changes  below.  
 
Version 2  Version 3  Justification for Change  Page(s)  
 
Device usage 
statements  Deactivation time for the device 
limited to 15 minute intervals with a 
maximum acceptable 30 minute 
interval.   
To address FDA concern.   
13, 15, 32, 84  
 
Previous study 
population and 
eligibility criteria.  Updated eligibility criteria with 
expanded definition of right heart 
failure.  
Modified Peak VO 2 to be better 
suited for inclusion of women.   
 
To address FDA concern.   
 
18 
NA Expanded the neurological 
assessment data collection.  To address FDA concern.  26-27, 85  
 
NA Added Fatigue Impact Scales to the 
data collection and to case report 
forms.   
To address FDA concern.  23, 27, 45, 83, 85,  
86, Appendix K  
 
NA Adverse events – clarified 
unanticipated device effect (UADE) 
definition.   
Clarification   
41 
NA Typos and grammar correction. 
Updated names of CRF titles.  Administrative  Throughout  
NA Changes listed above incorporated 
into Study Summary.  Administrative  Appendix R  
 
Version 4 (PRO 02291 -D) was created in response to FDA questions and incorporates  the 
changes  below.  
 
Version 3  Version 4  Justification for Change  Page(s)  
 
Investigator 
Signature Page  Deleted this page. All Principle and 
Sub Investigators sign the Clinical 
Study Agreement that includes 
language requiring them to follow 
the protocol and GCP, etc.   
 
Clarification   
 
Formerly pg. 6  
 
 
Eligibility Criteria  Changed Albumin Exclusion level 
from 3.5 to 3.0 g/dL and changed 
upper BMI limit from 38 to 40.  
Clarified the clinical study exclusion 
to include studies that would 
confound the results of the C -Pulse 
study.  Investigator input from our 
last Investigator Meeting – 
the feedback indicated that 
the patient population for 
Class III would include 
patients with lower 
Albumin and larger BMI.   
 
18 
Investigational 
Center Information 
Section  Added that sites will send in lab 
normals for our clinical study files to 
help ensure all labs are collected 
within comparable normal limits.   
Clarification   
22 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 43 of 150 
© Sunshine Heart  Confidential   
  
 
 
 
 
Version 3  Version 4  Justification for Change  Page(s)  
 
 
Data Collection 
Summary Section  Expanded CT Scan language to 
include suggestions for minimizing 
renal insult due to the use of 
contrast.  
Included requirement to perform 
Head CT only after the patient is 
determined eligible for implantation.   
 
 
To address FDA concern.   
 
 
23 
 
Data Collection 
Overview Section  Expanded Neurological  Assessment 
to include the Modified  Rankin.  
Refine the section for clarity of 
neuro assessment  requirements.   
To address FDA concern.   
23 
Data Collection 
Overview Section  Added Six Minute Hall Walk at 1 
month timeframe to correspond with 
the NYHA and QoL assessments.  Additional data for 1 
month interval.   
23 
Hospital Discharge 
Section  Additional language added for 
clarification of data collection if 
readmitted and for discharge.   
Clarification   
36 
 
 
AE Section  Added definition of serious.  
Removed reference to children 
under 6 months from Neuro AE.  
Added Modified Rankin for data 
collection following Neuro AE.   
 
Clarification   
 
37 
Explant Handling 
Section  Added additional instruction.  Clarification  44 
Statistical Methods 
Section  Changed Peak VO 2 and Six Minute 
Hall Walk values to 1.2 ml/kg/min 
and 50 m, respectively.   
To address FDA concern.   
46 
Sample Informed 
Consent  Changes listed above incorporated 
into the sample informed consent as 
appropriate.   
Administrative   
82 
Appendices  Added the KCCQ, Modified Rankin 
and ACC/AHA Stages.  Administrative  100, 105, 110  
Appendix C  Updated Investigator for UAB .  Administrative  74 
 
Appendix K  Refined Sample Case Report Forms 
to incorporated changes listed 
above.   
Administrative   
99 
Appendix R  Changes listed above incorporated 
into Study Summary.  Administrative  114 
NA Typos and grammar correction.  Administrative  Throughout  
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 44 of 150 
© Sunshine Heart  Confidential   
  
 
Version 5 (PRO 02291 -E) was created in response to FDA questions and incorporates the 
changes below. This was sent to sites for IRB submission along with the Conditional FDA 
approval letter dated 10 Sept 2008.  
 
Version 4  Version 5  Justification for Change  Page(s)  
 
NA Addition of data requirement to 
monitor contrast induced 
nephropathy.  FDA Request #1 - 
Conditional Letter from 10 
Sept 2008  24, 27, 41,  
Appendix H – 
Informed Consent  
 
Indications for Use  Removed sentence stating “The C – 
Pulse® System is a therapy indicated 
for patients who can tolerate 
intermittent use.”  FDA Request #2 - 
Conditional Letter from 10 
Sept 2008   
12 
 
Appendix K  Modified the Enrollment Case 
Report Form to include the 
alternative therapy a patient could 
receive if C -Pulse wasn’t available.  FDA Request #3 – 
Conditional Letter from 10 
Sept 2008   
Appendix K – 
Enrollment Form  
 
 
 
 
 
 
Study Size and 
Duration section  All subjects must be consented prior 
to performing any study related 
procedures. A subject is considered 
enrolled upon signing the informed 
consent. To minimize the burden to 
the patient, data collected as 
standard of care and not for the 
specific reason for study eligibility 
may be used for the baseline data 
points as outlined in the informed 
consent. These tests will suffice for 
the respective portion of the  baseline 
dataset if collected within the pre - 
implant evaluation timeframe of 30 
days prior to implant.   
 
 
 
 
FDA Request #4a – 
Conditional Letter from 10 
Sept 2008   
 
 
 
 
 
6, 21  
 
 
Study Size and 
Duration section and 
Appendix K  Study Exit instruction included as 
follows: Study Exit of these  patients 
must be documented on the study 
exit form. The study exit form 
contains information on reason for 
study exit. Study Exit form 
modified to include  details.   
 
FDA Request #4b – 
Conditional Letter from 10 
Sept 2008   
 
21, 22, 30,  43 
Appendix K  – 
study exit form  
 
Design section and 
Screening and 
Patient Informed 
section  Any patient whom undergoes 
anesthesia for the purpose of C - 
Pulse implantation but does not 
receive the device will be monitored 
for adverse events as defined by the 
protocol for 30 days or discharge 
whichever occurs first.   
 
FDA Request #4c – 
Cond itional Letter from 10 
Sept 2008   
 
14, 21  
Screening and 
Patient Informed 
Consent section  A Screening Log is located in the 
site Regulatory Binder and must be 
completed for all patients screened 
for eligibility.  FDA Request #5 – 
Conditional Letter from 10 
Sept 2008   
21 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 45 of 150 
© Sunshine Heart  Confidential   
  
 
 
 
 
Version 4  Version 5  Justification for Change  Page(s)  
 
 
NA Additional data collection added to 
assess if a patient is required to use 
the C -Pulse due to symptoms during 
the time that they could be 
disconnected if symptoms were not 
present.   
FDA Request #6 – 
Conditional Letter from 10 
Sept 2008   
 
Appendix K – 
follow -up form  
Data Collection 
Overview section 
and Informed 
Consent (Appendix   
18 month follow -up visit added.  FDA Request #7 – 
Conditional Letter from 10 
Sept 2008   
14,22,24 -30, 
46,88,96,117,121  
Secondary 
Objectives  Added analysis of  Concomitant 
Medications from baseline to 6 
months.  FDA Request #8 – 
Conditional Letter from 10 
Sept 2008   
46 
 
Exclusion Criteria  Changed mild to moderate for aortic 
valve incompetence – Exclusion 
Criteria #5.  FDA Request #9 – 
Conditional Letter from 10 
Sept 2008  18, 119, Appendix 
K – Enrollment 
Form  
 
Follow -up Windows  6 month window extended to ±30  
days; 12, 18 and annual follow -ups 
extended to ± 60 days.  FDA Request #10 – 
Conditional Letter from 
10 Sept 2008   
22 
Neurologic 
Assessment  Changed the NIHSS limit: When a 
change of 2 or more is noted, a 
neuro assessment is required.  FDA Request #11 – 
Conditional Letter from 10 
Sept 2008   
27 
Major Bleeding 
Adverse Event 
Definition  Reduce the transfusion limit from 
greater than 2 units transfusion to 
any transfusion triggers an event.  FDA Request #12 – 
Conditional Letter from 10 
Sept 2008  37, Appendix K – 
Adverse Event 
form  
Efficacy 
Performance 
Requirement  Defined an analysis including 
responders, non responders and 
indeterminants.  FDA Request #13 – 
Conditional Letter from 10 
Sept 2008   
45 
NA Typos and grammar correction.  Administrative  Throughout  
 
Version 6 (PRO 02291 -F) was created in response to FDA questions and incorporates the 
changes below. This version will be sent to sites when Final FDA approval is received.  
 
Version 5  Version 6  Justification for Change  Page(s)  
Efficacy 
Performance 
Requirement  Further revised the analysis 
including responders, non 
responders and indeterminants  based 
on FDA  feedback.  FDA Request #13 – 
Conditional Letter from 10 
Sept 2008   
45 
 
Adverse Event 
Definitions  Removed reference to VAD, LVAD 
and blood contacting surfaces where 
appropriate as the C -Pulse does not 
have blood contacting surfaces and 
is more commonly a MCSD.   
Feedback from the CEC 
members and the need to 
provide clarification.   
 
38-41 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 46 of 150 
© Sunshine Heart  Confidential   
  
 
 
Version 7 (PRO 02291 -G) was created to add a seventh US site. In addition personnel and 
contact information was updates. During this review several clarification and typographical 
items were noted and corrected. This version will be sent to sites when Fina l FDA approval is 
received.  
 
Version 6  Version 7  Justification for Change  Page(s)  
 
 
6 US centers   
Up to 7 centers in the United States 
(US) and potentially some Outside 
the United States (OUS) centers.  Reference minutes from 
FDA Conference Call 
Requesting additional site 
and potential use of OUS 
data – Call 12/09/09   
6, 14, 19, 73,  
82, 114, 134  
Study duration \18 – 
24 months  24– 30 months  Slow enrollment.  6, 15, 117  
Sponsor Address  
CEO Name and 
Contact  Information  
Sponsor Clinical 
Contact Name and 
Contact  Information  
CRO Contact 
Information  Current  
Sponsor Address  
CEO Name and Contact 
Information  
Sponsor Clinical Contact Name and 
Contact Information  
CRO Contact Information   
 
 
Updated based on changes 
which have occurred  since 
last IP  update   
 
 
 
5, 60  
 
 
 
-- Table 3 – Added SVR under Right 
heart catheterization  
Removed Driver  
NYHA Class Assessment – made 
heading match text   
 
Clarifications and 
Typographical Errors   
 
23, 29, 36  
Appendix C – 
Participating 
Institutions  Appendix C  
Participating 
Institutions   
Updated to Current PIs 
and contact information   
73 
Appendix H – 
Sample Informed 
Consent  Appendix H – 
Sample Informed Consent  Updated to include current 
information in the IP   
81 
Appendix I – 
Required Tests  Appendix I – 
Required Tests  Updated to include current 
information in IP  94 
Appendix P – 
Six Minute Hall 
Walk  Appendix P – 
Six Minute Hall Walk  Updated to include current 
information in IP   
110 
Appendix R: Study 
Summary  Appendix R: Study Summary  Updated to include current 
information in IP  114 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 47 of 150 
© Sunshine Heart  Confidential   
  
 
Version 8 (PRO 02291 -H) was created as an expansion protocol to add twenty (20) additional 
patients and two (2) additional sites. In addition, contact information was updated and a 1 – 5 
year follow -up was revised to include an ECHO. During this review several clarification and 
typographical items were noted and corrected. This version will be sent to sites when Final FDA 
approval is received.  
 
Version 7  Version 8  Justification for Change  Page(s)  
 
7 US centers  Up to 9 centers in the United States 
(US) and potentially some Outside 
the United States (OUS) centers.   
Expansion protocol  6, 15, 20, 77,  
87, 121, 124  
20 patients implanted  
and 30 patients 
consented  40 patients implanted and 60 
patients consented   
Expansion protocol  6, 15, 87, 121,  
124 
24 – 30 months 
duration  36 months duration  Expansion protocol and 
slow enrollment  6, 16, 124  
Sponsor Address  
CEO Name and 
Contact  Information  
Sponsor Clinical 
Contact  Information  Current  
Sponsor Address and  contact 
information  
CEO Address and  Contact 
Information   
Updated based on changes 
which have occurred  since 
last IP  update   
 
5, 63  
No ECHO after 6 
mth follow -up ECHO added to 12, 18 months and 
2, 3, 4, and 5 year follow -u 
ps Updated to include 
Corelab ECHOs at all 
follow -ups 26, 28, 101,  
128 
Table 1  
“3 sizes to fit 
ascending aorta 
outside diameter  28– 
40 millimeter  (mm)”   
“3 sizes to fit ascending aorta 
outside diameter 29 –40 millimeter 
(mm)”  Typographical Error, 
changed to align with 
Inclusion/Exclusion 
Criteria   
 
12, 123  
Figure 1A 
Study Design   
Removed Number of Implants  Clarification for the 
purpose of the Figure to 
describe the process   
15, 124  
Hospital Discharge 
Criteria  “ventricular rates <10bpm” changed 
to read “ventricular rates <120bpm”  Typographical Correction  109 
Appendix C – 
Participating 
Institutions  Appendix C 
Participating  Institutions  Updated to Current PIs 
and contact information   
77 
Appendix D – IRB 
List Appendix D - 
IRB List  Updated to Current IRB 
List 78 
PRO 02291 –I Protocol C –Pulse Investigational Plan  Page 48 of 150 
© Sunshine Heart  Confidential   
  
 
Version 9 (PRO 02291 -I) was created to extend the follow up period from 5 to 10 years to 
accommodate follow up beyond 5 years. Appendix U of Version 9 was updated to reflect current 
infection control guidelines.  
 
Version 8  Version 9  Justification for Change  Page(s)  
   8 -9, 11, 13 - 15, 17 - 19, 21,  
   23, 25 – 27, 30 – 33, 35 - 45, 
   48, 53 – 60, 62 -64, 66, 70 -71, 
   74-76 
   Appendix D – Page 80  
 Adjust formatting, correct  Adjust pagination and  Appendix E – Page 81 - 83 
-- spelling and other 
grammatical edits  correct spelling and other 
minor edits.  Appendix H – Page 87 - 88, 
90 - 92, 96, 99  
   Appendix N – Page 114, 116  
   Appendix Q – Page 122 - 123 
   Appendix R – Page 124 - 125, 
   128 
   Appendix V – Page 150  
Trial Contact 
Information  Address and contact 
information  Update the Manufacturer 
address and study  contact 
information   
7, 65  
 
5 year follow up   
10 year follow up  Accommodate follow up 
of patients with full or 
partial C -Pulse system 
beyond 5 years  8, 17 -18, 25 -26, 28 - 29 
Appendix I – Page 103 - 104, 
Appendix R – Page 123, 126,  
130 
 
Appendix H  10 year follow up  
Additional surveillance 
imaging for suspected 
infection  Per guidance from 
Infection Advisory 
Committee   
Appendix H – Page 88, 94, 96  
 
Appendix U  Appendix U with revised 
infection control guidelines  Update infection control 
guidelines to align with 
current practice   
Appendix U – Page 136 - 144 
 